

Author Index for 1993

Abbruzzese, M. 48:191
Ackenheil, M. 48:201
Adami, H. 46:47
Adés, J. 46:203
Adler, L.E. 49:29
Alam, M.Y. 46:139
Alpert, M. 48:181
Altemus, M. 49:1
Amsterdam, J.D. 48:37
Anderson, G. 47:267
Apovian, M. 47:291
Apter, S. 46:151
Aronowitz, B. 48:257
Aronson, M. 47:175
Arora, R.C. 47:111
Ashleigh, E.A. 46:1
Axelson, D.A. 47:163
Baghai, T. 47:215
Bailly, D. 47:57
Ball, S. 48:145
Balon, R. 46:89
Barbato, G. 47:79
Barthélémy, C. 46:261
Bauer, L.O. 46:229, 47:69
Baumgartner, A. 48:153
Beals, J. 47:255
Bergeman, C.S. 48:229
Berger, M. 49:109
Berger, R. 46:89
Bernstein, D. 47:291
Beuscart, R. 47:57
Bierer, L.M. 49:211
Biggs, M.M. 46:269
Bissette, G. 46:1
Blackson, T. 46:9
Bliwise, D.L. 48:277
Boehnlein, J. 47:255
Bosmans, E. 49:11, 49:151
Botsis, A.J. 47:281
Boutros, N. 47:243
Bouvard, M. 49:63
Boyko, O.B. 47:163
Bräunig, P. 47:187
Bradshaw, S.L. 46:295
Breier, A. 47:47
Brewerton, T.D. 46:201
Brown, J. 46:29
Brown, S.-L. 47:281
Bruder, G. 49:167
Bruton, C.J. 48:145
Büchler, M. 46:261
Buchanan, A. 46:29
Buchanan, R.W. 47:47, 47:205
Buhari, A. 49:121
Bulbena, A. 46:59
Calabrese, J. 47:229, 49:11, 49:151
Campos-Barros, A. 48:153
Carosella, N.W. 49:41
Carpenter, W.T., Jr. 47:47
Carroll, B.T. 46:119
Carroll, J.S. 48:277
Carter, C.S. 48:17
Carter, J.L. 46:119
Cartwright, R.D. 46:165
Casanova, M.F. 49:41
Cassady, S. 46:47
Castillo, S. 46:1
Castle, D.J. 49:199
Chaderjian, M.C. 48:17
Chambers, M.J. 46:207
Chappell, P.B. 47:267
Charney, D.S. 48:119
Chase, G.A. 49:219
Cherpi, C. 46:261
Chudzik, J. 47:121
Cichon, S. 46:253
Clausnitzer, L. 47:297
Coccaro, E.F. 47:291, 48:219, 48:229
Cohen, D.J. 47:267
Cohen, J. 48:181
Cohen, L. 48:257
Cooper, T. 49:219
Cooreman, W. 47:229
Copolov, D.L. 48:79
Cosyns, P. 47:229, 49:11, 49:151
Cottraux, J. 49:63
Coursey, R.D. 47:87
Cowley, D.S. 47:151
Cromwell, R.L. 46:295
Crow, T. 48:27
d'Elia, G. 47:7, 47:23
Daffner-Bujia, C. 47:215
Danilenko, K.V. 47:99
Dannals, R.F. 49:219
Datiles, M. 47:87
Daveloose, D. 46:203
Davidson, M. 46:151
Davis, J.M. 48:57
Davis, K.L. 46:151, 49:211
Dawson-Hughes, B. 49:77
de Loof, C. 47:1
De Meester, I. 49:151
DeCaria, C. 48:257, 49:167
DeLisi, L.E. 48:27
Dement, W.C. 48:277
Demitrack, M.A. 49:1
Dietzel, M. 48:153
Dippold, C. 49:89
Docktor, B. 46:207
Doraiswamy, P.M. 47:163
Doran, A.R. 47:141
Duró, J.C. 46:59
Early, T.S. 49:183
Eckstein, R. 48:201
Ehlers, C.L. 49:121
El-Mallakh, R.S. 47:297
Ellinwood, E.H., Jr. 47:163
Endicott, J. 46:79
Faedda, G.L. 48:1
Faraone, S.V. 48:243
Farmer, A.E. 49:199
Fasiczka, A.L. 49:139
Fimmers, R. 46:253
Finkelstein, G. 47:281
Forsyth, C.S. 48:145
Frank, E. 49:121, 49:139
Freedman, R. 49:29
Frenkel, M. 48:257
Friedman, D. 49:167
Fritze, J. 46:253
Fung, K.P. 49:97
Gambini, O. 48:191
Ganguli, R. 48:69
Garamoni, G.L. 49:139
Garver, D.L. 48:93
Garvey, M.J. 47:129
Gehrts, T.L. 46:119
Gehrt, M.J. 47:87
George, M.S. 46:201, 49:257
Gietzen, D.W. 47:141
Giles, D.E. 46:269
Given, B.A. 49:239
Given, C.W. 49:239
Glitz, D. 46:89
Glod, C.A. 46:29
Goddard, A.W. 48:119
Gold, J.M. 49:41
Gold, P.W. 49:1
Golombok, S. 48:135
Goodman, W.K. 48:119

Goodwin, D.C. 48:1
 Gorman, J. 46:79
 Gräf, K.-J. 48:153
 Graw, P. 46:107
 Green, A.I. 46:139
 Greenblatt, D.J. 47:151
 Griez, E. 47:1, 47:295
 Griffith, J.M. 49:29
 Grochocinski, V.J. 49:121
 Gross, G. 47:187
 Gruzelier, J.H. 46:127
 Gullion, C.M. 48:9
 Gyulai, L. 48:37
 Haag, C. 47:215
 Halaris, A. 47:187
 Hale, J. 47:205
 Haller, J.W. 49:183
 Handelman, L. 47:175
 Harden, R.N. 46:201
 Hardin, M.T. 47:267
 Hardy, B.W. 48:9
 Haroutunian, V. 49:211
 Harris, S. 49:77
 Harrison, W. 46:79
 Hassett, A. 48:79
 Héroult, J. 46:261
 Helgason, T. 46:69
 Heninger, G.R. 48:119
 Hill, C. 48:79
 Hinz, A. 47:215
 Hirschowitz, J. 46:151
 Hirt, J. 48:79
 Hofschuster, E. 48:201
 Hollander, E. 48:257, 49:167
 Hommer, D.W. 47:151
 Horton, K. 48:145
 Horvath, T.B. 47:291
 Huber, G. 47:187
 Ivarsson, O. 46:69
 Jacobson, J. 47:175
 Jain, S.K. 46:295
 Janicak, P.G. 48:57
 Jarrett, R.B. 46:269
 Jennings, J.R. 49:139
 Joffe, R.T. 46:29
 Kågedal, B. 47:7
 Kahn, R.S. 46:151
 Kalaian, H.A. 49:239
 Kathol, R.G. 46:119
 Kavoussi, R.J. 48:219
 Keks, N.A. 48:79
 Kellner, R. 46:285
 Kelly, K.A. 47:87
 Kersteen-Tucker, Z. 46:175
 Keshavan, M.S. 49:89
 Ketter, T.A. 49:257
 Kinney, D.K. 48:47
 Kinzie, J.D. 47:255
 Kirkpatrick, B. 47:47
 Kirtland, A. 48:37
 Kjellman, B.F. 47:7, 47:23
 Kleinman, J.E. 49:41
 Knight, R.T. 46:175
 Knott, P. 46:151, 47:291
 Knott, P.J. 49:211
 Körner, J. 46:253
 Kotler, M. 47:281
 Kräuchi, K. 46:107
 Krahn, D.D. 49:1
 Krishnan, K.R.R. 47:163
 Kristbjarnarson, H. 46:69
 Kroft, C.D.L. 49:251
 Kürten, I. 48:153
 Kulkarni, J. 48:79
 Kupfer, D.J. 49:121, 49:139
 Laakmann, G. 47:215
 Lader, M. 48:135
 Lajonchere, C.M. 48:47
 Lam, R.W. 46:29
 Lanczik, M. 46:253
 Langohr, J.I. 46:1
 Lannfelt, L. 46:69, 46:253
 Lasko, N.B. 48:107
 Lauer, C.J. 49:109
 Lawrence, T. 47:291
 Lebegue, B. 46:29
 Leboyer, M. 46:261
 Leckman, J.F. 47:267
 Lee, J. 49:97
 Lee, K.A. 46:209, 48:277
 Leibenluft, E. 46:213
 Leite, P. 49:167
 Lejoyeux, M. 46:203
 Lelord, G. 46:261
 Leung, P. 47:255
 Levin, A. 48:257
 Levitt, A.J. 46:29
 Levy, D.L. 48:47
 Lewis, N. 46:1
 Liddle, P.F. 46:127
 Liebowitz, M.R. 48:257
 Lish, J.D. 48:37
 Loneragan, C. 47:37
 Losonczy, M. 47:175
 Lousberg, H. 47:295
 Lyons, M.J. 48:243
 Mackie, B. 48:79
 Maclin, E.L. 47:141
 Madden, P.A. 46:213
 Maes, M. 47:229, 49:11, 49:151
 Maglione, J.R. 47:141
 Mallet, J. 46:261
 Mallinger, A.G. 49:89
 Mannsmann, U. 48:153
 Manson, S.M. 47:255
 Marangell, L.B. 49:257
 Marin, D.B. 49:211
 Marks, I. 49:63
 Marks, R.C. 48:57
 Marler, M. 47:187
 Martín-Santos, R. 46:59
 Mateo, A. 46:59
 Mathalon, D.H. 46:175
 Matheson, B. 48:79
 Mathew, V.M. 46:127
 Maziére, J.-C. 46:203
 McClearn, G.E. 46:239, 48:229
 McCorkle, R. 49:239
 McDonald, W.M. 47:163
 McEachran, A.B. 49:121
 McGuffin, P. 49:199
 McKenzie, D.P. 48:79
 McLaughlin, M. 48:79
 Medoff, D. 48:47
 Meller, W.H. 46:119
 Meltzer, H.Y. 47:111, 47:229, 49:11, 49:151
 Mempel, W. 48:201
 Merril, C.R. 48:27
 Mezzich, A.C. 46:9
 Möller, H.-J. 46:253
 Moeller, F.G. 48:93
 Mohs, R.C. 49:211
 Moises, H.W. 46:69
 Molcho, A. 47:281
 Molina, L. 46:59
 Mollard, E. 49:63
 Moodley, P. 48:135
 Moran, M. 46:47
 Moss, H.B. 46:9, 46:29, 46:213, 47:79, 49:99
 Mühl, J.-P. 46:261

Müller, N. 48:201
 Murburg, M.M. 46:1
 Murdock, M.V. 48:9
 Murray, M.G. 46:29
 Nee, J. 46:79
 Nekich, J.C. 48:277
 Nelson, E. 49:183
 Nemerooff, C.B. 46:1, 47:163
 Neumann, C.S. 46:295
 Nöthen, M.M. 46:253
 Noel, M. 47:129
 Nofzinger, E.A. 49:139
 Nordahl, T.E. 48:17
 O'Shora-Celaya, L.J. 48:17
 Olson, A.M. 47:141
 Oreland, L. 46:239
 Oren, D.A. 46:29, 47:79,
 49:99
 Orhagen, T. 47:7
 Orr, S.P. 48:107
 Orsulak, P.J. 48:93
 Ozaki, N. 49:99
 Pandey, G.N. 48:57
 Pandey, S.C. 48:57
 Pappalardo, K.M. 46:139
 Park, S. 47:175
 Parquet, P.J. 47:57
 Pascualy, M. 46:1
 Pathak, D. 46:285
 Patterson, L.J. 47:163
 Pazzaglia, P.J. 49:257
 Peabody, C. 47:243
 Pearlson, G. 49:219
 Pedersen, N.L. 46:239
 Perl, D.P. 49:211
 Perrot, A. 46:261
 Peskind, E.R. 46:1
 Pettegrew, J.W. 49:89
 Petty, F. 48:9
 Pfefferbaum, A. 46:175
 Pigott, T.A. 49:1
 Pitman, R.K. 48:107
 Pitts, A.F. 46:119
 Plail, J.A. 46:9
 Plutchik, R. 47:281
 Pohl, R. 46:89
 Pols, H. 47:1, 47:295
 Polymeropoulos, M.H. 48:27
 Porta, M. 46:59
 Post, R.M. 49:257
 Pouget, E.R. 48:181
 Powers, R.E. 49:41
 Price, R.A. 48:37
 Propping, P. 46:253
 Purohit, D.P. 49:211
 Putilov, A.A. 47:99
 Putnam, F.W. 49:1
 Rabin, B.S. 48:69
 Racadot, N. 47:57
 Radford-Paregol, M. 48:47
 Raese, J.D. 48:93
 Ramesh, C. 46:89
 Rao, M.L. 47:187
 Raskind, M.A. 46:1
 Raus, J. 47:229
 Ravert, H.T. 49:219
 Reich, J. 48:267
 Reimann, D. 49:109
 Resnick, S.M. 48:37
 Reynolds, C. 46:239
 Reynolds, C.F., III 49:139
 Rietschel, M. 46:253
 Roberts, G.W. 48:145
 Roberts, L.A. 46:229
 Robertson, L.C. 48:17
 Roffwarg, H.P. 46:269
 Rosenthal, N.E. 46:19, 47:79,
 47:87, 49:99
 Roudier, M. 46:203
 Roy-Byrne, P.P. 47:151
 Royston, M.C. 48:145
 Rubinow, D.R. 49:1
 Rudorfer, M.V. 46:19
 Rush, A.J. 46:269, 48:9
 Rustin, T. 47:243
 Ryan, T.M. 49:211
 Sachdev, P. 47:37
 Saletu, B. 48:153
 Salzman, C. 46:139
 Samuelson, S.D. 46:119
 Sandberg, D. 46:79
 Saoud, J.B. 48:257
 Sapp, J. 49:219
 Sauvage, D. 46:261
 Scahill, L.D. 47:267
 Scarone, S. 48:191
 Scharpé, S. 47:229, 49:11,
 49:151
 Schatzberg, A.F. 46:139
 Schildkraut, J.J. 46:139
 Schmeidler, J.M. 49:211
 Schmidt, G.G. 46:41
 Schulz, R. 49:239
 Schwartz, J.-C. 46:69, 46:253
 Schwartz, P.J. 46:29, 46:213,
 47:79, 49:99
 Schwartz, R.M. 49:139
 Senkova, N.I. 37:99
 Servant, D. 47:57
 Sharma, R.P. 48:57
 Shaya, E.K. 49:219
 Shine, P. 48:135
 Sholomskas, D.E. 48:119
 Sibtain, N. 48:145
 Siever, L.J. 47:291
 Singh, B. 48:79
 Skwerer, R.G. 46:19
 Sobieraj, J.T. 46:139
 Sokoloff, P. 46:69, 46:253
 Somervell, P.D. 47:255
 Song, I.S. 47:175
 Srinivasan, K. 46:89
 Starcevic, V. 46:285
 Stein, D.J. 48:257
 Stein, M.B. 49:251
 Steinberg, J.L. 48:93
 Stern, R.G. 46:151
 Stoll, A.L. 48:1
 Stommel, M. 49:239
 Strakowski, S.M. 48:1
 Strauss, M. 49:219
 Strauss, M.E. 47:205
 Strelbel, B. 47:187
 Strijewski, A. 47:121
 Sullivan, E.V. 46:175
 Suy, E. 47:229, 49:11, 49:151
 Tang, S.W. 47:121
 Tarter, R.E. 46:9
 Teicher, M.H. 46:29
 Tenke, C. 49:167
 Thaker, G. 46:47
 Thase, M.E. 49:139
 Thorell, L.-H. 47:7, 47:23
 Tohen, M. 48:1
 Torrey, E.F. 48:27
 Towey, J. 49:167
 Trestman, R.L. 47:291
 Tsuang, M.T. 48:243
 Tuason, V.B. 47:141
 Tune, L.E. 49:219
 Tupler, L.A. 47:163
 Uhlenhuth, E.H. 46:285
 Uyttenbroeck, W. 47:229

Vallejo, J. 46:59
Vallescar, R. 46:59
van Aalst, V. 47:1
van Praag, H.M. 47:281
Vandervorst, C. 47:229
Vanyukov, M.M. 46:9
Veith, R.C. 46:1
Vignau, J. 47:57
Viret, J. 46:203
Voderholzer, U. 47:205
Wolf, N.V. 47:99
Wagner, H.N., Jr. 49:219
Waldo, M. 49:29
Walker, J.R. 49:251
Waller, D.A. 48:9
Warner, D. 47:243
Waternaux, C. 46:139
Waternaux, C.M. 48:243
Wehr, T.A. 46:213
Weinberg, P. 46:89
Weinberger, D.R. 49:41
Welkowitz, J. 48:181
Wessely, S. 49:199
Westbrook, F. 47:37
Whybrow, P.C. 48:37
Wiegand, M. 49:109
Wiener, J. 47:175
Wiese, C. 46:69
Williams, J. 49:199
Williams, R.J. 46:41
Wilson, A.A. 49:219
Wirz-Justice, A. 46:107
Wittmann, R. 47:215
Wolf, R. 48:153
Wong, D.F. 49:219
Wood, E. 46:165
Woods, S.W. 48:119
Xiao, H. 48:27
Yang, L. 46:69
Yeragani, V.K. 46:89
Yeung, A.S. 48:243
Young, T. 49:219
Yurgelun-Todd, D.A. 48:47
Zandbergen, J. 47:1, 47:295
Zigun, J.R. 47:297
Zipursky, R.B. 46:175
Zoega, T. 46:69
Zouridakis, G. 47:243

Subject Index for 1993

Adrenocorticotropic hormone

affective disorder, arginine vasopressin, 46:119
affective disorder, cortisol, 46:119
affective disorder, dexamethasone suppression test, 46:119
arginine vasopressin, affective disorder, 46:119
arginine vasopressin, cortisol, 46:119
arginine vasopressin, dexamethasone suppression test, 46:119
cortisol, affective disorder, 46:119
cortisol, arginine vasopressin, 46:119
cortisol, dexamethasone suppression test, 46:119
dexamethasone suppression test, affective disorder, 46:119
dexamethasone suppression test, arginine vasopressin, 46:119
dexamethasone suppression test, cortisol, 46:119
hypothalamic-pituitary-adrenal axis, affective disorder, 46:119

Affective disorder

adrenocorticotropic hormone, arginine vasopressin, 46:119
adrenocorticotropic hormone, cortisol, 46:119
adrenocorticotropic hormone, dexamethasone suppression test, 46:119
aging, tryptophan, 49:151
amino acids, haptoglobin, 49:151
amino acids, immune function, 49:151
amino acids, interleukin, 49:151
amino acids, serotonin, 49:151
amino acids, transferrin, 49:151
amino acids, tryptophan, 49:151
antidepressant medication, attention, 46:295
antidepressant medication, cortisol, 46:213
antidepressant medication, memory, 46:295
antidepressant medication, prolactin, 46:213
antidepressant medication, thyroid hormones, 46:213
antidepressant medication, treatment duration, 46:295
antidepressant medication, visual pattern integration, 46:295
arginine vasopressin, adrenocorticotropic hormone, 46:119
arginine vasopressin, cortisol, 46:119
arginine vasopressin, dexamethasone suppression test, 46:119

Affective disorder continued

attention, antidepressant medication, 46:295
attention, memory, 46:295
attention, treatment duration, 46:295
attention, visual pattern integration, 46:295
bipolar subtype, calcium channel blockers, 49:257
bipolar subtype, depressive symptoms, 47:129
bipolar subtype, dopamine D₃ receptor protein, 46:253
bipolar subtype, family history, 48:37, 48:47
bipolar subtype, first episode mania, 48:1
bipolar subtype, genetics, 46:253, 48:37, 48:47
bipolar subtype, *N*-acetyl-beta-glucosaminidase, 47:129
bipolar subtype, nimodipine, 49:257
bipolar subtype, obstetric complications, 48:47
bipolar subtype, outcome prediction, 48:1
bipolar subtype, rapid cycling, 48:37, 49:257
bipolar subtype, serine to glycine substitution on dopamine D₃, 46:253
bipolar subtype, serotonin, 47:129
bipolar subtype, substance abuse, 48:37
bipolar subtype, therapeutic response, 49:257
bipolar subtype, Tridimensional Personality Questionnaire, 48:1
calcium channel blockers, bipolar subtype, rapid cycling, 49:257
calcium channel blockers, nimodipine, 49:257
calcium channel blockers, therapeutic response, 49:257
carbohydrate craving, circadian rhythms, 46:107
carbohydrate craving, diet, 46:107
carbohydrate craving, eating sweets, 46:107
carbohydrate craving, phototherapy, 46:107
carbohydrate craving, seasonal depression, 46:107
Center for Epidemiologic Studies Depression Scale, American Indians, 47:255
Center for Epidemiologic Studies Depression Scale, cross-cultural diagnosis, 47:255
circadian rhythms, carbohydrate craving, 46:107
circadian rhythms, daytime affect, 49:139
circadian rhythms, diet, 46:107
circadian rhythms, eating sweets, 46:107

Affective disorder continued

- circadian rhythms, endogenous subtype, 47:215
- circadian rhythms, growth hormone, 47:215
- circadian rhythms, growth hormone releasing hormone, 47:215
- circadian rhythms, nocturnal penile tumescence, 49:139
- circadian rhythms, phototherapy, 46:107
- circadian rhythms, seasonal depression, 46:107
- circadian rhythms, sexual function, 49:139
- circadian rhythms, sleep, 47:215, 49:139
- circannual rhythm, light visor treatment, 46:29
- circannual rhythm, phototherapy, 46:29
- circannual rhythm, seasonal depression, 46:29
- circannual rhythms, eye blink rate, 47:79
- circannual rhythms, gender differences, 47:79
- circannual rhythms, phototherapy, 47:79
- circannual rhythms, prevalence in northern Canada, 46:41
- circannual rhythms, seasonal depression, 46:41, 47:79
- cortisol, adrenocorticotrophic hormone, 46:119
- cortisol, antidepressant medication, 46:213
- cortisol, arginine vasopressin, 46:119
- cortisol, dexamethasone suppression test, 46:119, 47:7, 47:23, 47:163, 49:11
- cortisol, dysthymic disorder, 47:7
- cortisol, electrodermal activity, 47:23
- cortisol, haptoglobin, 49:11
- cortisol, hippocampus, 47:163
- cortisol, immune function, 49:11
- cortisol, interleukins, 49:11
- cortisol, magnetic resonance imaging, 47:163
- cortisol, prolactin, 46:213
- cortisol, sleep deprivation, 46:213
- cortisol, thyroid stimulating hormone, 46:213, 47:7, 47:23
- cortisol, thyroxine, 47:7, 47:23
- cortisol, transferrin, 49:11
- cortisol, triiodothyronine, 46:213, 47:7, 47:23
- cross-cultural assessment, American Indians, 47:255
- cross-cultural assessment, Center for Epidemiologic Studies Depression Scale, 47:255
- cross-cultural assessment, diagnosis, 47:255
- cross-cultural assessment, epidemiology, 47:255
- Affective disorder** continued
- daytime affect, circadian rhythms, 49:139
- daytime affect, nocturnal penile tumescence, 49:139
- daytime affect, sexual function, 49:139
- daytime affect, sleep, 49:139
- depressed mood, naps, 49:109
- depressed mood, sleep, 49:109
- depressed mood, sleep deprivation, 49:109
- depressive symptoms, bipolar subtype, 47:129
- depressive symptoms, *N*-acetyl-beta-glucosaminidase, 47:129
- depressive symptoms, serotonin, 47:129
- dexamethasone suppression test, adrenocorticotrophic hormone, 46:119
- dexamethasone suppression test, arginine vasopressin, 46:119
- dexamethasone suppression test, cortisol, 46:119, 47:7, 47:23, 47:163, 49:11
- dexamethasone suppression test, dysthymic disorder, 47:7
- dexamethasone suppression test, electrodermal activity, 47:23
- dexamethasone suppression test, haptoglobin, 49:11
- dexamethasone suppression test, hippocampus, 47:163
- dexamethasone suppression test, immune function, 49:11
- dexamethasone suppression test, interleukins, 49:11
- dexamethasone suppression test, magnetic resonance imaging, 47:163
- dexamethasone suppression test, thyroid stimulating hormone, 47:7, 47:23
- dexamethasone suppression test, thyroxine, 47:7, 47:23
- dexamethasone suppression test, transferrin, 49:11
- dexamethasone suppression test, triiodothyronine, 47:7, 47:23
- diagnosis, cross-cultural assessment, American Indians, 47:255
- diagnosis, epidemiology, 47:255
- diet, carbohydrate craving, 46:107
- diet, circadian rhythms, 46:107
- diet, eating sweets, 46:107
- diet, phototherapy, 46:107
- diet, seasonal depression, 46:107
- divorce, dream masochism, 46:165

Affective disorder continued

- divorce, gender differences, 46:165
- divorce, personality, 46:165
- divorce, sex role identification, 46:165
- divorce, sleep, 46:165
- dopamine D₃ receptor protein, bipolar subtype, 46:253
- dopamine D₃ receptor protein, genetics, 46:253
- dopamine, serine to glycine substitution on dopamine D₃, 46:253
- dream masochism, divorce, 46:165
- dream masochism, gender differences, 46:165
- dream masochism, personality, 46:165
- dream masochism, sex role identification, 46:165
- dream masochism, sleep, 46:165
- dysthymic disorder, cortisol, 47:7
- dysthymic disorder, dexamethasone suppression test, 47:7
- dysthymic disorder, thyroid stimulating hormone, 47:7
- dysthymic disorder, thyroxine, 47:7
- dysthymic disorder, triiodothyronine, 47:7
- electrodermal activity, cortisol, 47:23
- electrodermal activity, dexamethasone suppression test, 47:23
- electrodermal activity, thyroid stimulating hormone, 47:23
- electrodermal activity, thyroxine, 47:23
- electrodermal activity, triiodothyronine, 47:23
- electrooculography, phototherapy, 49:99
- electrooculography, seasonal depression, 49:99
- endogenous subtype, circadian rhythms, 47:215
- endogenous subtype, growth hormone, growth hormone releasing hormone, 47:215
- endogenous subtype, sleep, 47:215
- epidemiology, cross-cultural assessment, American Indians, 47:255
- epidemiology, diagnosis, 47:255
- eye blink rate, circannual rhythms, 47:79
- eye blink rate, gender differences, 47:79
- eye blink rate, phototherapy, 47:79
- eye blink rate, seasonal depression, 47:79
- family history, bipolar subtype, 48:37, 48:47
- family history, human leukocyte antigen, 48:201
- family history, immune function, 48:201
- family history, lymphocytes, 48:201
- family history, obstetric complications, 48:47

Affective disorder continued

- family history of personality disorder, genetics, 48:243
- family history of personality disorder, schizophrenia, 48:243
- family history, schizophrenia, 48:201
- family history, substance abuse, 48:37
- first episode mania, bipolar subtype, 48:1
- first episode mania, outcome prediction, 48:1
- first episode mania, Tridimensional Personality Questionnaire, 48:1
- fluoxetine, sleep deprivation, 46:213
- gender differences, circannual rhythms, 47:79
- gender differences, divorce, 46:165
- gender differences, dream masochism, 46:165
- gender differences, eye blink rate, 47:79
- gender differences, immune function, 49:151
- gender differences, personality, 46:165
- gender differences, phototherapy, 47:79
- gender differences, seasonal depression, 47:79
- gender differences, sex role identification, 46:165
- gender differences, sleep, 46:165
- genetics, bipolar subtype, 46:253, 48:37, 48:47
- genetics, dopamine D₃ receptor protein, 46:253
- genetics, family history of personality disorder, 48:243
- genetics, human leukocyte antigen, 48:201
- genetics, immune function, 48:201
- genetics, lymphocytes, 48:201
- genetics, obstetric complications, 48:47
- genetics, schizophrenia, 48:201, 48:243
- genetics, serine to glycine substitution on dopamine D₃, 46:253
- genetics, substance abuse, 48:37
- growth hormone, circadian rhythms, 47:215
- growth hormone, endogenous subtype, 47:215
- growth hormone, sleep, 47:215
- growth hormone releasing hormone, circadian rhythms, 47:215
- growth hormone releasing hormone, endogenous subtype, 47:215
- growth hormone releasing hormone, sleep, 47:215
- haptoglobin, amino acids, 49:151
- haptoglobin, cortisol, 49:11
- haptoglobin, dexamethasone suppression test, 49:11
- haptoglobin, immune function, 47:229, 49:11, 49:151

Affective disorder continued

- haptoglobin, interleukin, 49:11, 49:151
- haptoglobin, serotonin, 49:151
- haptoglobin, sleep, 47:229
- haptoglobin, somatic symptoms, 47:229
- haptoglobin, transferrin, 49:11, 49:151
- haptoglobin, tryptophan, 49:151
- haptoglobin, weight and anorexia, 47:229
- hippocampus, cortisol, 47:163
- hippocampus, dexamethasone suppression test, 47:163
- hippocampus, magnetic resonance imaging, 47:163
- homovanillic acid, cerebrospinal fluid, 46:19
- homovanillic acid, 5-hydroxyindoleacetic acid, 46:19
- homovanillic acid, 3-methoxy-4-hydroxyphenylglycol, 46:19
- homovanillic acid, norepinephrine, 46:19
- homovanillic acid, orthostatic challenge, 46:19
- homovanillic acid, phototherapy, 46:19
- homovanillic acid, seasonal depression, 46:19
- human leukocyte antigen, family history, 48:201
- human leukocyte antigen, genetics, 48:201
- human leukocyte antigen, immune function, 48:201
- human leukocyte antigen, lymphocytes, 48:201
- human leukocyte antigen, schizophrenia, 48:201
- 5-hydroxyindoleacetic acid, cerebrospinal fluid, 46:19
- 5-hydroxyindoleacetic acid, homovanillic acid, 46:19
- 5-hydroxyindoleacetic acid, 3-methoxy-4-hydroxyphenylglycol, 46:19
- 5-hydroxyindoleacetic acid, norepinephrine, 46:19
- 5-hydroxyindoleacetic acid, orthostatic challenge, 46:19
- 5-hydroxyindoleacetic acid, phototherapy, 46:19
- 5-hydroxyindoleacetic acid, seasonal depression, 46:19
- immune function, amino acids, 49:151
- immune function, cortisol, 49:11
- immune function, dexamethasone suppression test, 49:11
- immune function, family history, 48:201
- immune function, gender differences, 49:151

Affective disorder continued

- immune function, genetics, 48:201
- immune function, haptoglobin, 47:229, 49:11, 49:151
- immune function, human leukocyte antigen, 48:201
- immune function, hypothalamic-pituitary-adrenal axis, 49:11
- immune function, interleukins, 49:11, 49:151
- immune function, lymphocytes, 48:201
- immune function, psychomotor retardation, 47:229
- immune function, schizophrenia, 48:201
- immune function, serotonin, 49:151
- immune function, sleep, 47:229
- immune function, somatic symptoms, 47:229
- immune function, transferrin, 49:11, 49:151
- immune function, tryptophan, 49:151
- immune function, weight and anorexia, 47:229
- interleukins, amino acids, 49:151
- interleukins, cortisol, 49:11
- interleukins, dexamethasone suppression test, 49:11
- interleukins, haptoglobin, 49:11, 49:151
- interleukins, immune function, 49:11, 49:151
- interleukin, serotonin, 49:151
- interleukins, transferrin, 49:11, 49:151
- interleukin, tryptophan, 49:151
- interpersonal psychotherapy, rapid eye movement latency, 49:121
- interpersonal psychotherapy, recovery, 49:121
- interpersonal psychotherapy, sleep, 49:121
- joint hypermobility syndrome, mitral valve prolapse, 46:59
- joint hypermobility syndrome, simple phobia, 46:59
- language, laterality, 47:99
- language, motor performance, 47:99
- language, phototherapy, 47:99
- language, seasonal depression, 47:99
- laterality, language, 47:99
- laterality, motor performance, 47:99
- laterality, phototherapy, 47:99
- laterality, seasonal depression, 47:99
- light visor treatment, circannual rhythm, 46:29
- light visor treatment, seasonal depression, 46:29
- lymphocytes, family history, 48:201
- lymphocytes, genetics, 48:201
- lymphocytes, human leukocyte antigen, 48:201
- lymphocytes, immune function, 48:201

Affective disorder continued

lymphocytes, schizophrenia, 48:201
 magnetic resonance imaging, cortisol, 47:163
 magnetic resonance imaging, dexamethasone suppression test, 47:163
 magnetic resonance imaging, hippocampus, 47:163
 memory, antidepressant medication, 46:295
 memory, attention, 46:295
 memory, treatment duration, 46:295
 memory, visual pattern integration, 46:295
 3-methoxy-4-hydroxyphenylglycol, cerebrospinal fluid, 46:19
 3-methoxy-4-hydroxyphenylglycol, homovanillic acid, 46:19
 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, 46:19
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 46:19
 3-methoxy-4-hydroxyphenylglycol, orthostatic challenge, 46:19
 3-methoxy-4-hydroxyphenylglycol, phototherapy, 46:19
 3-methoxy-4-hydroxyphenylglycol, seasonal depression, 46:19
 mitral valve prolapse, joint hypermobility syndrome, 46:59
 mitral valve prolapse, simple phobia, 46:59
 motor performance, language, 47:99
 motor performance, laterality, 47:99
 motor performance, phototherapy, 47:99
 motor performance, seasonal depression, 47:99
N-acetyl-beta-glucosaminidase, bipolar subtype, 47:129
N-acetyl-beta-glucosaminidase, depressive symptoms, 47:129
N-acetyl-beta-glucosaminidase, serotonin, 47:129
 naps, depressed mood, 49:109
 naps, sleep deprivation, 49:109
 nimodipine, bipolar subtype, rapid cycling, 49:257
 nimodipine, therapeutic response, 49:257
 nocturnal penile tumescence, circadian rhythms, 49:139
 nocturnal penile tumescence, daytime affect, 49:139
 nocturnal penile tumescence, sexual function, 49:139
 nocturnal penile tumescence, sleep, 49:139
 norepinephrine, cerebrospinal fluid, 46:19

Affective disorder continued

norepinephrine, homovanillic acid, 46:19
 norepinephrine, 5-hydroxyindoleacetic acid, 46:19
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 46:19
 norepinephrine, orthostatic challenge, 46:19, 47:291
 norepinephrine, phototherapy, 46:19
 norepinephrine, seasonal depression, 46:19
 obstetric complications, bipolar subtype, 48:47
 obstetric complications, family history, 48:47
 obstetric complications, genetics, 48:47
 orthostatic challenge, homovanillic acid, 46:19
 orthostatic challenge, 5-hydroxyindoleacetic acid, 46:19
 orthostatic challenge, 3-methoxy-4-hydroxyphenylglycol, 46:19
 orthostatic challenge, norepinephrine, 46:19, 47:291
 orthostatic challenge, phototherapy, 46:19
 orthostatic challenge, seasonal depression, 46:19
 outcome prediction, bipolar subtype, 48:1
 outcome prediction, first episode mania, 48:1
 outcome prediction, Tridimensional Personality Questionnaire, 48:1
 personality, divorce, 46:165
 personality, dream masochism, 46:165
 personality, gender differences, 46:165
 personality, sex role identification, 46:165
 personality, sleep, 46:165
 phototherapy, carbohydrate craving, 46:107
 phototherapy, circadian rhythms, 46:107
 phototherapy, circannual rhythms, 46:29, 47:79
 phototherapy, diet, 46:107
 phototherapy, eating sweets, 46:107
 phototherapy, electrooculography, 49:99
 phototherapy, eye blink rate, 47:79
 phototherapy, gender differences, 47:79
 phototherapy, homovanillic acid, 46:19
 phototherapy, 5-hydroxyindoleacetic acid, 46:19
 phototherapy, language, 47:99
 phototherapy, laterality, 47:99
 phototherapy, light visor treatment, 46:29
 phototherapy, 3-methoxy-4-hydroxyphenylglycol, 46:19
 phototherapy, motor performance, 47:99
 phototherapy, norepinephrine, 46:19

Affective disorder continued

phototherapy, orthostatic challenge, 46:19
 phototherapy, seasonal depression, 46:19, 46:29, 46:107, 47:79, 47:99, 49:99
 prevalence in northern Canada, circannual rhythms, 46:41
 prevalence in northern Canada, seasonal depression, 46:41
 prolactin, antidepressant medication, 46:213
 prolactin, cortisol, 46:213
 prolactin, sleep deprivation, 46:213
 prolactin, thyroid stimulating hormone, 46:213
 prolactin, triiodothyronine, 46:213
 psychomotor retardation, immune function, 47:229
 rapid cycling, bipolar subtype, 48:37, 49:257
 rapid cycling, calcium channel blockers, 49:257
 rapid cycling, family history, 48:37
 rapid cycling, genetics, 48:37
 rapid cycling, nimodipine, 49:257
 rapid cycling, substance abuse, 48:37
 rapid cycling, therapeutic response, 49:257
 rapid eye movement latency, interpersonal psychotherapy, 49:121
 rapid eye movement latency, recovery, 49:121
 rapid eye movement latency, remission, 46:269
 rapid eye movement latency, sleep, 46:269, 49:121
 recovery, interpersonal psychotherapy, 49:121
 recovery, rapid eye movement latency, 49:121
 recovery, sleep, 49:121
 remission, rapid eye movement latency, 46:269
 remission, sleep, 46:269
 schizophrenia, family history, 48:201
 schizophrenia, family history of personality disorder, 48:243
 schizophrenia, genetics, 48:201, 48:243
 schizophrenia, human leukocyte antigen, 48:201
 schizophrenia, immune function, 48:201
 schizophrenia, lymphocytes, 48:201
 seasonal depression, carbohydrate craving, 46:107
 seasonal depression, circadian rhythms, 46:107
 seasonal depression, circannual rhythms, 46:29, 46:41, 47:79
 seasonal depression, diet, 46:107
 seasonal depression, eating sweets, 46:107

Affective disorder continued

seasonal depression, electrooculography, 49:99
 seasonal depression, eye blink rate, 47:79
 seasonal depression, gender differences, 47:79
 seasonal depression, homovanillic acid, 46:19
 seasonal depression, 5-hydroxyindoleacetic acid, 46:19
 seasonal depression, language, 47:99
 seasonal depression, laterality, 47:99
 seasonal depression, light visor treatment, 46:29
 seasonal depression, 3-methoxy-4-hydroxyphenylglycol, 46:19
 seasonal depression, motor performance, 47:99
 seasonal depression, norepinephrine, 46:19
 seasonal depression, orthostatic challenge, 46:19
 seasonal depression, phototherapy, 46:19, 46:29, 46:107, 47:79, 47:99, 49:99
 seasonal depression, prevalence in northern Canada, 46:41
 serine to glycine substitution on dopamine D₃, bipolar subtype, 46:253
 serine to glycine substitution on dopamine D₃, genetics, 46:253
 serotonin, amino acids, 49:151
 serotonin, bipolar subtype, 47:129
 serotonin, depressive symptoms, 47:129
 serotonin, haptoglobin, 49:151
 serotonin, immune function, 49:151
 serotonin, interleukin, 49:151
 serotonin, N-acetyl-beta-glucosaminidase, 47:129
 serotonin, transferrin, 49:151
 serotonin, tryptophan, 49:151
 sex role identification, divorce, 46:165
 sex role identification, dream masochism, 46:165
 sex role identification, gender differences, 46:165
 sex role identification, personality, 46:165
 sex role identification, sleep, 46:165
 sexual function, circadian rhythms, 49:139
 sexual function, daytime affect, 49:139
 sexual function, nocturnal penile tumescence, 49:139
 sexual function, sleep, 49:139
 simple phobia, joint hypermobility syndrome, 46:59

Affective disorder continued

simple phobia, mitral valve prolapse, 46:59
 sleep, circadian rhythms, 47:215, 49:139
 sleep, daytime affect, 49:139
 sleep, depressed mood, 49:109
 sleep, divorce, 46:165
 sleep, dream masochism, 46:165
 sleep, endogenous subtype, 47:215
 sleep, gender differences, 46:165
 sleep, growth hormone, growth hormone releasing hormone, 47:215
 sleep, haptoglobin, 47:229
 sleep, immune function, 47:229
 sleep, interpersonal psychotherapy, 49:121
 sleep, nocturnal penile tumescence, 49:139
 sleep, personality, 46:165
 sleep, rapid eye movement latency, 46:269, 49:121
 sleep, recovery, 49:121
 sleep, remission, 46:269
 sleep, sex role identification, 46:165
 sleep, sexual function, 49:139
 sleep, somatic symptoms, 47:229
 sleep, weight and anorexia, 47:229
 sleep deprivation, antidepressant medication, 46:213
 sleep deprivation, cortisol, 46:213
 sleep deprivation, depressed mood, 49:109
 sleep deprivation, fluoxetine, 46:213
 sleep deprivation, naps, 49:109
 sleep deprivation, prolactin, 46:213
 sleep deprivation, sleep, 49:109
 sleep deprivation, thyroid stimulating hormone, 46:213
 sleep deprivation, triiodothyronine, 46:213
 somatic symptoms, haptoglobin, 47:229
 somatic symptoms, immune function, 47:229
 somatic symptoms, sleep, 47:229
 somatic symptoms, weight and anorexia, 47:229
 substance abuse, bipolar subtype, 48:37
 substance abuse, family history, 48:37
 substance abuse, genetics, 48:37
 substance abuse, rapid cycling, 48:37
 therapeutic response, bipolar subtype, 49:257
 therapeutic response, calcium channel blockers, 49:257
 therapeutic response, nimodipine, 49:257
 therapeutic response, rapid cycling, 49:257
 thyroid stimulating hormone, antidepressant medication, 46:213
 thyroid stimulating hormone, cortisol, 46:213, 47:7, 47:23

Affective disorder continued

thyroid stimulating hormone, dexamethasone suppression test, 47:7, 47:23
 thyroid stimulating hormone, dysthymic disorder, 47:7
 thyroid stimulating hormone, electrodermal activity, 47:23
 thyroid stimulating hormone, prolactin, 46:213
 thyroid stimulating hormone, sleep deprivation, 46:213
 thyroid stimulating hormone, thyroxine, 47:7, 47:23
 thyroid stimulating hormone, triiodothyronine, 46:213, 47:7, 47:23
 thyroxine, cortisol, 47:7, 47:23
 thyroxine, dexamethasone suppression test, 47:7, 47:23
 thyroxine, dysthymic disorder, 47:7
 thyroxine, electrodermal activity, 47:23
 thyroxine, thyroid stimulating hormone, 47:7, 47:23
 thyroxine, triiodothyronine, 47:7, 47:23
 transferrin, amino acids, 49:151
 transferrin, cortisol, 49:11
 transferrin, dexamethasone suppression test, 49:11
 transferrin, haptoglobin, 49:11, 49:151
 transferrin, immune function, 49:11, 49:151
 transferrin, interleukins, 49:11, 49:151
 transferrin, serotonin, 49:151
 transferrin, tryptophan, 49:151
 treatment duration, antidepressant medication, 46:295
 treatment duration, attention, 46:295
 treatment duration, memory, 46:295
 treatment duration, visual pattern integration, 46:295
 Tridimensional Personality Questionnaire, bipolar subtype, 48:1
 Tridimensional Personality Questionnaire, first episode mania, 48:1
 Tridimensional Personality Questionnaire, outcome prediction, 48:1
 triiodothyronine, antidepressant medication, 46:213
 triiodothyronine, cortisol, 46:213, 47:7, 47:23
 triiodothyronine, dexamethasone suppression test, 47:7, 47:23
 triiodothyronine, dysthymic disorder, 47:7
 triiodothyronine, electrodermal activity, 47:23
 triiodothyronine, prolactin, 46:213

Affective disorder continued

- triiodothyronine, sleep deprivation, 46:213
- triiodothyronine, thyroid stimulating hormone, 46:213, 47:7, 47:23
- triiodothyronine, thyroxine, 47:7, 47:23
- tryptophan, aging, 49:151
- tryptophan, amino acids, 49:151
- tryptophan, haptoglobin, 49:151
- tryptophan, immune function, 49:151
- tryptophan, interleukin, 49:151
- tryptophan, serotonin, 49:151
- tryptophan, transferrin, 49:151
- visual pattern integration, antidepressant medication, 46:295
- visual pattern integration, attention, 46:295
- visual pattern integration, memory, 46:295
- visual pattern integration, treatment duration, 46:295
- weight and anorexia, haptoglobin, 47:229
- weight and anorexia, immune function, 47:229
- weight and anorexia, sleep, 47:229
- weight and anorexia, somatic symptoms, 47:229

Aging

- affective disorder, tryptophan, 49:151
- agitation, circadian rhythms, 48:277
- agitation, circannual rhythms, 48:277
- agitation, dementia, 48:277
- agitation, sleep, 48:277
- agitation, sundowning, 48:277
- circadian rhythms, agitation, 48:277
- circadian rhythms, circannual rhythms, 48:277
- circadian rhythms, dementia, 48:277
- circadian rhythms, sleep, 48:277
- circadian rhythms, sundowning, 48:277
- circannual rhythms, agitation, 48:277
- circannual rhythms, circadian rhythms, 48:277
- circannual rhythms, dementia, 48:277
- circannual rhythms, sleep, 48:277
- circannual rhythms, sundowning, 48:277
- dementia, agitation, 48:277
- dementia, circadian rhythms, 48:277
- dementia, circannual rhythms, 48:277
- dementia, sleep, 48:277
- dementia, sundowning, 48:277
- depressed mood in elderly women, phototherapy, 47:87
- depressed mood in elderly women, sleep, 47:87

Aging continued

- dopamine D₂ receptor density, 49:219
- dopamine D₂ receptor density, gender differences, 49:219
- dopamine D₂ receptor density, illness duration, 49:219
- dopamine D₂ receptor density, methylspiperone, 49:219
- dopamine D₂ receptor density, positron emission tomography, 49:219
- dopamine D₂ receptor density, schizophrenia, 49:219
- dopamine D₂ receptor density, striatum, 49:219
- gender differences, dopamine D₂ receptor density, 49:219
- gender differences, positron emission tomography, 49:219
- gender differences, schizophrenia, 49:219
- illness duration, dopamine D₂ receptor density, 49:219
- illness duration, schizophrenia, 49:219
- methylspiperone, dopamine D₂ receptor density, 49:219
- methylspiperone, positron emission tomography, 49:219
- methylspiperone, schizophrenia, 49:219
- methylspiperone, striatum, 49:219
- phototherapy, depressed mood in elderly women, 47:87
- phototherapy, sleep, 47:87
- positron emission tomography, dopamine D₂ receptor density, 49:219
- positron emission tomography, schizophrenia, 49:219
- schizophrenia, dopamine D₂ receptor density, 49:219
- schizophrenia, positron emission tomography, 49:219
- sleep, agitation, 48:277
- sleep, circadian rhythms, 48:277
- sleep, circannual rhythms, 48:277
- sleep, dementia, 48:277
- sleep, depressed mood in elderly women, 47:87
- sleep, phototherapy, 47:87
- sleep, sundowning, 48:277
- striatum, dopamine D₂ receptor density, 49:219
- sundowning, agitation, 48:277
- sundowning, circadian rhythms, 48:277
- sundowning, circannual rhythms, 48:277
- sundowning, dementia, 48:277

Aging continued
 sundowning, sleep, 48:277
 tryptophan, affective disorder, 49:151

Akathisia
 animal models, neuroleptic-induced defecation in rats, 47:37
 neuroleptic-induced defecation in rats, animal models, 47:37

Alcohol abuse/dependence
 agoraphobia, anxiety disorder, 46:285
 agoraphobia, panic disorder, 46:285
 agoraphobia, substance abuse, 46:285
 anxiety disorder, agoraphobia, 46:285
 anxiety disorder, substance abuse, 46:285
 attention, cocaine, 46:202
 attention, reaction time, 46:202
 attention, substance abuse, 46:202
 attention, visual and auditory suppression tasks, 46:202
 attention, withdrawal, 46:202
 cocaine, attention, 46:202
 cocaine, motor performance, 47:69
 cocaine, reaction time, 46:202
 cocaine, substance abuse, 46:202
 cocaine, substance abuse, 47:69
 cocaine, tremor and body sway, 47:69
 cocaine, visual and auditory suppression tasks, 46:202
 cocaine, withdrawal, 46:202
 comorbidity, agoraphobia, 46:285
 comorbidity, anxiety disorder, 46:285
 comorbidity, panic disorder, 46:285
 comorbidity, substance abuse, 46:285
 depression, glutamyltransferase, 47:57
 depression, impulse control disorder, 47:57
 depression, serotonin, 47:57
 frontal lobe, memory, 46:175
 frontal lobe, neuropsychology, 46:175
 frontal lobe, schizophrenia, 46:175
 frontal lobe, Wisconsin Card Sorting Test, 46:175
 glutamyltransferase, depression, 47:57
 glutamyltransferase, impulse control disorder, 47:57
 glutamyltransferase, serotonin, 47:57
 impulse control disorder, depression, 47:57
 impulse control disorder, glutamyltransferase, 47:57
 impulse control disorder, serotonin, 47:57
 memory, frontal lobe, 46:175
 memory, neuropsychology, 46:175
 memory, schizophrenia, 46:175

Alcohol abuse/dependence continued
 memory, Wisconsin Card Sorting Test, 46:175
 motor performance, cocaine, 47:69
 motor performance, substance abuse, 47:69
 motor performance, tremor and body sway, 47:69
 neuropsychology, frontal lobe, 46:175
 neuropsychology, memory, 46:175
 neuropsychology, schizophrenia, 46:175
 neuropsychology, Wisconsin Card Sorting Test, 46:175
 panic disorder, agoraphobia, 46:285
 panic disorder, substance abuse, 46:285
 platelets, serotonin, 47:57
 reaction time, attention, 46:202
 reaction time, cocaine, 46:202
 reaction time, substance abuse, 46:202
 reaction time, visual and auditory suppression tasks, 46:202
 schizophrenia, frontal lobe, 46:175
 schizophrenia, memory, 46:175
 schizophrenia, neuropsychology, 46:175
 schizophrenia, Wisconsin Card Sorting Test, 46:175
 serotonin, depression, 47:57
 serotonin, glutamyltransferase, 47:57
 serotonin, impulse control disorder, 47:57
 serotonin, platelets, 47:57
 substance abuse, agoraphobia, 46:285
 substance abuse, anxiety disorder, 46:285
 substance abuse, attention, 46:202
 substance abuse, cocaine, 46:202, 47:69
 substance abuse, motor performance, 47:69
 substance abuse, panic disorder, 46:285
 substance abuse, reaction time, 46:202
 substance abuse, tremor and body sway, 47:69
 substance abuse, visual and auditory suppression tasks, 46:202
 substance abuse, withdrawal, 46:202
 tremor and body sway, cocaine, 47:69
 tremor and body sway, motor performance, 47:69
 tremor and body sway, substance abuse, 47:69
 visual and auditory suppression tasks, attention, 46:202
 visual and auditory suppression tasks, cocaine, 46:202
 visual and auditory suppression tasks, reaction time, 46:202
 visual and auditory suppression tasks, substance abuse, 46:202

Alcohol abuse/dependence continued
 visual and auditory suppression tasks, withdrawal, 46:202
 Wisconsin Card Sorting Test, frontal lobe, 46:175
 Wisconsin Card Sorting Test, memory, 46:175
 Wisconsin Card Sorting Test, neuropsychology, 46:175
 Wisconsin Card Sorting Test, schizophrenia, 46:175
 withdrawal, attention, 46:202
 withdrawal, cocaine, 46:202
 withdrawal, depression, 47:57
 withdrawal, reaction time, 46:202
 withdrawal, serotonin, 47:57
 withdrawal, visual and auditory suppression tasks, 46:202
Alzheimer's disease
 cognitive impairment, dihydroxyphenylacetic acid, 49:211
 cognitive impairment, dopamine, 49:211
 cognitive impairment, homovanillic acid, 49:211
 cognitive impairment, psychiatric symptoms, 49:211
 dihydroxyphenylacetic acid, cognitive impairment, 49:211
 dihydroxyphenylacetic acid, dopamine, 49:211
 dihydroxyphenylacetic acid, homovanillic acid, 49:211
 dihydroxyphenylacetic acid, post-mortem study, 49:211
 dihydroxyphenylacetic acid, psychiatric symptoms, 49:211
 dopamine, cognitive impairment, 49:211
 dopamine, dihydroxyphenylacetic acid, 49:211
 dopamine, homovanillic acid, 49:211
 dopamine, post-mortem study, 49:211
 dopamine, psychiatric symptoms, 49:211
 erythrocyte membrane, lipids, 46:203
 hippocampus, neurofibrillary tangles, 49:41
 hippocampus, post-mortem study, 49:41
 hippocampus, schizophrenia, 49:41
 hippocampus, senile plaques, 49:41
 homovanillic acid, cognitive impairment, 49:211
 homovanillic acid, dihydroxyphenylacetic acid, 49:211
 homovanillic acid, dopamine, 49:211
 homovanillic acid, post-mortem study, 49:211

Alcohol abuse/dependence continued
 homovanillic acid, psychiatric symptoms, 49:211
 lipids, erythrocyte membrane, 46:203
 neurofibrillary tangles, hippocampus, 49:41
 neurofibrillary tangles, post-mortem study, 49:41
 neurofibrillary tangles, schizophrenia, 49:41
 neurofibrillary tangles, senile plaques, 49:41
 psychiatric symptoms, cognitive impairment, 49:211
 psychiatric symptoms, dihydroxyphenylacetic acid, 49:211
 psychiatric symptoms, dopamine, 49:211
 psychiatric symptoms, homovanillic acid, 49:211
 schizophrenia, hippocampus, 49:41
 schizophrenia, neurofibrillary tangles, 49:41
 schizophrenia, post-mortem, 49:41
 schizophrenia, senile plaques, 49:41
 senile plaques, hippocampus, 49:41
 senile plaques, neurofibrillary tangles, 49:41
 senile plaques, post-mortem, 49:41
 senile plaques, schizophrenia, 49:41
Amino acids
 affective disorder, haptoglobin, 49:151
 affective disorder, immune function, 49:151
 affective disorder, interleukin, 49:151
 affective disorder, serotonin, 49:151
 affective disorder, transferrin, 49:151
 affective disorder, tryptophan, 49:151
 circadian rhythm, dopamine, 47:187
 circadian rhythm, neuroleptics, 47:187
 circadian rhythm, phenylalanine, 47:187
 circadian rhythm, schizophrenia, 47:187
 circadian rhythm, therapeutic response, 47:187
 dopamine, circadian rhythm, 47:187
 dopamine, neuroleptics, 47:187
 dopamine, phenylalanine, 47:187
 dopamine, schizophrenia, 47:187
 dopamine, therapeutic response, 47:187
 haptoglobin, affective disorder, 49:151
 haptoglobin, immune function, 49:151
 haptoglobin, interleukin, 49:151
 haptoglobin, serotonin, 49:151
 haptoglobin, transferrin, 49:151
 haptoglobin, tryptophan, 49:151
 immune function, affective disorder, 49:151
 immune function, haptoglobin, 49:151
 immune function, interleukin, 49:151
 immune function, serotonin, 49:151

Amino acids continued

immune function, transferrin, 49:151
 immune function, tryptophan, 49:151
 interleukin, affective disorder, 49:151
 interleukin, haptoglobin, 49:151
 interleukin, immune function, 49:151
 interleukin, serotonin, 49:151
 interleukin, transferrin, 49:151
 interleukin, tryptophan, 49:151
 neuroleptics, circadian rhythm, 47:187
 neuroleptics, dopamine, 47:187
 neuroleptics, phenylalanine, 47:187
 neuroleptics, schizophrenia, 47:187
 neuroleptics, therapeutic response, 47:187
 phenylalanine, circadian rhythm, 47:187
 phenylalanine, dopamine, 47:187
 phenylalanine, neuroleptics, 47:187
 phenylalanine, schizophrenia, 47:187
 phenylalanine, therapeutic response, 47:187
 schizophrenia, circadian rhythm, 47:187
 schizophrenia, dopamine, 47:187
 schizophrenia, neuroleptics, 47:187
 schizophrenia, phenylalanine, 47:187
 schizophrenia, therapeutic response, 47:187
 serotonin, affective disorder, 49:151
 serotonin, haptoglobin, 49:151
 serotonin, immune function, 49:151
 serotonin, interleukin, 49:151
 serotonin, transferrin, 49:151
 serotonin, tryptophan, 49:151
 therapeutic response, circadian rhythm, 47:187
 therapeutic response, dopamine, 47:187
 therapeutic response, neuroleptics, 47:187
 therapeutic response, phenylalanine, 47:187
 therapeutic response, schizophrenia, 47:187
 transferrin, affective disorder, 49:151
 transferrin, haptoglobin, 49:151
 transferrin, immune function, 49:151
 transferrin, interleukin, 49:151
 transferrin, serotonin, 49:151
 transferrin, tryptophan, 49:151
 tryptophan, affective disorder, 49:151
 tryptophan, haptoglobin, 49:151
 tryptophan, immune function, 49:151
 tryptophan, interleukin, 49:151
 tryptophan, serotonin, 49:151
 tryptophan, transferrin, 49:151

Amphetamine

affective lability, anxiety, 48:219
 affective lability, normal subjects, 48:219
 anxiety, affective lability, 48:219

Amphetamine continued

anxiety, normal subjects, 48:219
 normal subjects, affective lability, 48:219
 normal subjects, anxiety, 48:219

Animal models

domperidone, dysphoria, 47:37
 domperidone, haloperidol, 47:37
 domperidone, locomotor activity, 47:37
 domperidone, neuroleptic-induced defecation in rats, 47:37
 dysphoria, domperidone, 47:37
 dysphoria, haloperidol, 47:37
 dysphoria, locomotor activity, 47:37
 dysphoria, neuroleptic-induced defecation in rats, 47:37
 haloperidol, domperidone, 47:37
 haloperidol, dysphoria, 47:37
 haloperidol, locomotor activity, 47:37
 haloperidol, neuroleptic-induced defecation in rats, 47:37
 locomotor activity, domperidone, 47:37
 locomotor activity, dysphoria, 47:37
 locomotor activity, haloperidol, 47:37
 locomotor activity, neuroleptic-induced defecation in rats, 47:37
 neuroleptic-induced defecation in rats, domperidone, 47:37
 neuroleptic-induced defecation in rats, dysphoria, 47:37
 neuroleptic-induced defecation in rats, haloperidol, 47:37
 neuroleptic-induced defecation in rats, locomotor activity, 47:37
 neuroleptic-induced defecation in rats, neuroleptics, 47:37

Anorexia nervosa. See *Eating disorders*

Antidepressants

affective disorder, attention, 46:295
 affective disorder, cortisol, 46:213
 affective disorder, memory, 46:295
 affective disorder, prolactin, 46:213
 affective disorder, sleep deprivation, 46:213
 affective disorder, thyroid stimulating hormone, 46:213
 affective disorder, treatment duration, 46:295
 affective disorder, triiodothyronine, 46:213
 affective disorder, visual pattern integration, 46:295
 attention, affective disorder, 46:295
 attention, memory, 46:295
 attention, treatment duration, 46:295
 attention, visual pattern integration, 46:295

Antidepressants continued

- cortisol, affective disorder, 46:213
- cortisol, prolactin, 46:213
- cortisol, sleep deprivation, 46:213
- cortisol, thyroid stimulating hormone, 46:213
- cortisol, triiodothyronine, 46:213
- memory, affective disorder, 46:295
- memory, attention, 46:295
- memory, treatment duration, 46:295
- memory, visual pattern integration, 46:295
- prolactin, affective disorder, 46:213
- prolactin, cortisol, 46:213
- prolactin, sleep deprivation, 46:213
- prolactin, thyroid stimulating hormone, 46:213
- prolactin, triiodothyronine, 46:213
- sleep deprivation, affective disorder, 46:213
- sleep deprivation, cortisol, 46:213
- sleep deprivation, prolactin, 46:213
- sleep deprivation, thyroid stimulating hormone, 46:213
- sleep deprivation, triiodothyronine, 46:213
- thyroid stimulating hormone, affective disorder, 46:213
- thyroid stimulating hormone, cortisol, 46:213
- thyroid stimulating hormone, prolactin, 46:213
- thyroid stimulating hormone, sleep deprivation, 46:213
- thyroid stimulating hormone, triiodothyronine, 46:213
- treatment duration, affective disorder, 46:295
- treatment duration, attention, 46:295
- treatment duration, memory, 46:295
- treatment duration, visual pattern integration, 46:295
- triiodothyronine, affective disorder, 46:213
- triiodothyronine, cortisol, 46:213
- triiodothyronine, prolactin, 46:213
- triiodothyronine, sleep deprivation, 46:213
- triiodothyronine, thyroid stimulating hormone, 46:213
- visual pattern integration, affective disorder, 46:295
- visual pattern integration, attention, 46:295
- visual pattern integration, memory, 46:295
- visual pattern integration, treatment duration, 46:295

Antisocial personality

- children, conduct disorder, 46:9
- children, cortisol in saliva, 46:9
- children, genetics, 46:9

Antisocial personality continued

- children, substance abuse, 46:9
- conduct disorder, cortisol in saliva, 46:9
- conduct disorder, genetics, 46:9
- conduct disorder, substance abuse, 46:9
- cortisol in saliva, children, 46:9
- cortisol in saliva, conduct disorder, 46:9
- cortisol in saliva, substance abuse, 46:9
- genetics, conduct disorder, 46:9
- genetics, substance abuse, 46:9
- substance abuse, conduct disorder, 46:9
- substance abuse, cortisol in saliva, 46:9
- substance abuse, genetics, 46:9

Anxiety disorder

- agoraphobia, alcohol dependence, 46:285
- agoraphobia, comorbidity, 46:285
- agoraphobia, panic disorder, 46:285
- agoraphobia, substance abuse, 46:285
- alcohol intake, benzodiazepines, 48:135
- alcohol intake, computed tomography, 48:135
- alcohol intake, diazepam, 48:135
- alcohol intake, lorazepam, 48:135
- alcohol intake, ventricle-brain ratio, 48:135
- alcohol dependence, agoraphobia, 46:285
- alcohol dependence, comorbidity, 46:285
- alcohol dependence, panic disorder, 46:285
- alcohol dependence, substance abuse, 46:285
- attention, obsessive-compulsive disorder, 49:183
- attention, Posner task, 49:183
- attention, reaction time, 49:183
- attention, spatial-linguistic conflict task, 49:183
- auditory N200, event related potentials, 49:167
- auditory N200, laterality, 49:167
- auditory N200, neurological soft signs, 49:167
- auditory N200, obsessive-compulsive disorder, 49:167
- auditory N200, P3 component, 49:167
- autonomic nervous system, heart rate, 46:89
- autonomic nervous system, orthostatic challenge, 46:89
- autonomic nervous system, panic disorder, 46:89
- autonomic nervous system, power spectral analysis of heart rate, 46:89
- benzodiazepines, alcohol intake, 48:135
- benzodiazepines, computed tomography, 48:135

Anxiety disorder continued

benzodiazepines, diazepam, 48:135
 benzodiazepines, lorazepam, 48:135
 benzodiazepines, ventricle-brain ratio, 48:135
 carbon dioxide, clomipramine, 47:295
 carbon dioxide, panic disorder, 47:295
 carbon dioxide, ventilatory response, 47:295
 carbon dioxide, HCO_3 , 47:1
 carbon dioxide, hyperventilation, 47:1
 carbon dioxide, panic disorder, 47:1
 carbon dioxide, $p\text{CO}_2$, 47:1
 carbon dioxide, $p\text{H}$, 47:1
 carbon dioxide, $p\text{O}_2$, 47:1
 carbon dioxide, respiratory alkalosis, 47:1
 clomipramine, carbon dioxide, 47:295
 clomipramine, panic disorder, 47:295
 clomipramine, ventilatory response, 47:295
 comorbidity, agoraphobia, 46:285
 comorbidity, alcohol dependence, 46:285
 comorbidity, panic disorder, 46:285
 comorbidity, substance abuse, 46:285
 computed tomography, alcohol intake, 48:135
 computed tomography, benzodiazepines, 48:135
 computed tomography, diazepam, 48:135
 computed tomography, lorazepam, 48:135
 computed tomography, ventricle-brain ratio, 48:135
 cortisol, fluvoxamine, 48:119
 cortisol, 3-methoxy-4-hydroxyphenylglycol, 48:119
 cortisol, norepinephrine, 48:119
 cortisol, panic disorder, 48:119
 cortisol, reuptake inhibitor, 48:119
 cortisol, serotonin, 48:119
 cortisol, yohimbine, 48:119
 depressive mood, insomnia, 49:251
 depressive mood, phobia, 49:251
 depressive mood, quality of sleep, 49:251
 depressive mood, sleep, 49:251
 diazepam, alcohol intake, 48:135
 diazepam, benzodiazepines, 48:135
 diazepam, computed tomography, 48:135
 diazepam, lorazepam, 48:135
 diazepam response, eye movements, 47:151
 diazepam response, panic disorder, 47:151
 diazepam response, personality, 47:151
 diazepam response, saccadic eye movement velocity, 47:151
 diazepam response, Tridimensional Personality Questionnaire, 47:151

Anxiety disorder continued

diazepam, ventricle-brain ratio, 48:135
 event related potentials, auditory N200, 49:167
 event related potentials, laterality, 49:167
 event related potentials, neurological soft signs, 49:167
 event related potentials, obsessive-compulsive disorder, 49:167
 event related potentials, P3 component, 49:167
 eye movements, diazepam response, 47:151
 eye movements, panic disorder, 47:151
 eye movements, personality, 47:151
 eye movements, saccadic eye movement velocity, 47:151
 eye movements, Tridimensional Personality Questionnaire, 47:151
 fluvoxamine, cortisol, 48:119
 fluvoxamine, 3-methoxy-4-hydroxyphenylglycol, 48:119
 fluvoxamine, norepinephrine, 48:119
 fluvoxamine, panic disorder, 48:119
 fluvoxamine, reuptake inhibitor, 48:119
 fluvoxamine, serotonin, 48:119
 fluvoxamine, yohimbine, 48:119
 HCO_3 , carbon dioxide, 47:1
 HCO_3 , hyperventilation, 47:1
 HCO_3 , panic disorder, 47:1
 HCO_3 , $p\text{CO}_2$, 47:1
 HCO_3 , $p\text{H}$, 47:1
 HCO_3 , $p\text{O}_2$, 47:1
 HCO_3 , respiratory alkalosis, 47:1
 heart rate, autonomic nervous system, 46:89
 heart rate, orthostatic challenge, 46:89
 heart rate, panic disorder, 46:89
 heart rate, power spectral analysis of heart rate, 46:89
 hyperventilation, carbon dioxide, 47:1
 hyperventilation, HCO_3 , 47:1
 hyperventilation, panic disorder, 47:1
 hyperventilation, $p\text{CO}_2$, 47:1
 hyperventilation, $p\text{H}$, 47:1
 hyperventilation, $p\text{O}_2$, 47:1
 hyperventilation, respiratory alkalosis, 47:1
 insomnia, depressive mood, 49:251
 insomnia, phobia, 49:251
 insomnia, quality of sleep, 49:251
 insomnia, sleep, 49:251
 joint hypermobility syndrome, panic disorder, 46:59
 laterality, auditory N200, 49:167

Anxiety disorder continued

- lateryality, event related potentials, 49:167
- lateryality, neurological soft signs, 49:167
- lateryality, obsessive-compulsive disorder, 49:167
- lateryality, P3 component, 49:167
- lorazepam, alcohol intake, 48:135
- lorazepam, benzodiazepines, 48:135
- lorazepam, computed tomography, 48:135
- lorazepam, diazepam, 48:135
- lorazepam, ventricle-brain ratio, 48:135
- 3-methoxy-4-hydroxyphenylglycol, cortisol, 48:119
- 3-methoxy-4-hydroxyphenylglycol, fluvoxamine, 48:119
- 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 48:119
- 3-methoxy-4-hydroxyphenylglycol, panic disorder, 48:119
- 3-methoxy-4-hydroxyphenylglycol, reuptake inhibitor, 48:119
- 3-methoxy-4-hydroxyphenylglycol, serotonin, 48:119
- 3-methoxy-4-hydroxyphenylglycol, yohimbine, 48:119
- neurological soft signs, auditory N200, 49:167
- neurological soft signs, event related potentials, 49:167
- neurological soft signs, lateryality, 49:167
- neurological soft signs, obsessive-compulsive disorder, 49:167
- neurological soft signs, P3 component, 49:167
- norepinephrine, cortisol, 48:119
- norepinephrine, fluvoxamine, 48:119
- norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 48:119
- norepinephrine, panic disorder, 48:119
- norepinephrine, reuptake inhibitor, 48:119
- norepinephrine, serotonin, 48:119
- norepinephrine, yohimbine, 48:119
- obsessive-compulsive disorder, attention, 49:183
- obsessive-compulsive disorder, auditory N200, 49:167
- obsessive-compulsive disorder, event related potentials, 49:167
- obsessive-compulsive disorder, lateryality, 49:167
- obsessive-compulsive disorder, neurological soft signs, 49:167
- Anxiety disorder** continued
- obsessive-compulsive disorder, P3 component, 49:167
- obsessive-compulsive disorder, Posner task, 49:183
- obsessive-compulsive disorder, reaction time, 49:183
- obsessive-compulsive disorder, spatial-linguistic conflict task, 49:183
- orthostatic challenge, autonomic nervous system, 46:89
- orthostatic challenge, heart rate, 46:89
- orthostatic challenge, panic disorder, 46:89
- orthostatic challenge, power spectral analysis of heart rate, 46:89
- P3 component, auditory N200, 49:167
- P3 component, event related potentials, 49:167
- P3 component, lateryality, 49:167
- P3 component, neurological soft signs, 49:167
- P3 component, obsessive-compulsive disorder, 49:167
- panic disorder, agoraphobia, 46:285
- panic disorder, alcohol dependence, 46:285
- panic disorder, autonomic nervous system, 46:89
- panic disorder, carbon dioxide, 47:295
- panic disorder, carbon dioxide, 47:1
- panic disorder, clomipramine, 47:295
- panic disorder, comorbidity, 46:285
- panic disorder, cortisol, 48:119
- panic disorder, diazepam response, 47:151
- panic disorder, eye movements, 47:151
- panic disorder, fluvoxamine, 48:119
- panic disorder, HCO₃, 47:1
- panic disorder, heart rate, 46:89
- panic disorder, hyperventilation, 47:1
- panic disorder, joint hypermobility syndrome, 46:59
- panic disorder, 3-methoxy-4-hydroxyphenylglycol, 48:119
- panic disorder, norepinephrine, 48:119
- panic disorder, orthostatic challenge, 46:89
- panic disorder, pCO₂, 47:1
- panic disorder, personality, 47:151
- panic disorder, pH, 47:1
- panic disorder, pO₂, 47:1
- panic disorder, power spectral analysis of heart rate, 46:89
- panic disorder, respiratory alkalosis, 47:1
- panic disorder, reuptake inhibitor, 48:119

Anxiety disorder continued

panic disorder, saccadic eye movement velocity, 47:151
 panic disorder, serotonin, 48:119
 panic disorder, substance abuse, 46:285
 panic disorder, Tridimensional Personality Questionnaire, 47:151
 panic disorder, ventilatory response, 47:295
 panic disorder, yohimbine, 48:119
 $p\text{CO}_2$, HCO_3 , 47:1
 $p\text{CO}_2$, hyperventilation, 47:1
 $p\text{CO}_2$, panic disorder, 47:1
 $p\text{CO}_2$, pH , 47:1
 $p\text{CO}_2$, $p\text{O}_2$, 47:1
 $p\text{CO}_2$, respiratory alkalosis, 47:1
 personality, diazepam response, 47:151
 personality, eye movements, 47:151
 personality, panic disorder, 47:151
 personality, saccadic eye movement velocity, 47:151
 personality, Tridimensional Personality Questionnaire, 47:151
 pH , carbon dioxide, 47:1
 pH , HCO_3 , 47:1
 pH , hyperventilation, 47:1
 pH , panic disorder, 47:1
 pH , $p\text{CO}_2$, 47:1
 pH , $p\text{O}_2$, 47:1
 pH , respiratory alkalosis, 47:1
 phobia, depressive mood, 49:251
 phobia, insomnia, 49:251
 phobia, quality of sleep, 49:251
 phobia, sleep, 49:251
 $p\text{O}_2$, carbon dioxide, 47:1
 $p\text{O}_2$, HCO_3 , 47:1
 $p\text{O}_2$, hyperventilation, 47:1
 $p\text{O}_2$, panic disorder, 47:1
 $p\text{O}_2$, $p\text{CO}_2$, 47:1
 $p\text{CO}_2$, pH , 47:1
 $p\text{CO}_2$, respiratory alkalosis, 47:1
 Posner task, attention, 49:183
 Posner task, obsessive-compulsive disorder, 49:183
 Posner task, reaction time, 49:183
 Posner task, spatial-linguistic conflict task, 49:183
 power spectral analysis of heart rate, autonomic nervous system, 46:89
 power spectral analysis of heart rate, heart rate, 46:89
 power spectral analysis of heart rate, orthostatic challenge, 46:89

Anxiety disorder continued

power spectral analysis of heart rate, panic disorder, 46:89
 quality of sleep, depressive mood, 49:251
 quality of sleep, insomnia, 49:251
 quality of sleep, phobia, 49:251
 quality of sleep, sleep, 49:251
 reaction time, attention, 49:183
 reaction time, obsessive-compulsive disorder, 49:183
 reaction time, Posner task, 49:183
 reaction time, spatial-linguistic conflict task, 49:183
 respiratory alkalosis, carbon dioxide, 47:1
 respiratory alkalosis, HCO_3 , 47:1
 respiratory alkalosis, hyperventilation, 47:1
 respiratory alkalosis, panic disorder, 47:1
 respiratory alkalosis, $p\text{CO}_2$, 47:1
 respiratory alkalosis, pH , 47:1
 respiratory alkalosis, $p\text{CO}_2$, 47:1
 reuptake inhibitor, cortisol, 48:119
 reuptake inhibitor, fluvoxamine, 48:119
 reuptake inhibitor, 3-methoxy-4-hydroxyphenylglycol, 48:119
 reuptake inhibitor, norepinephrine, 48:119
 reuptake inhibitor, panic disorder, 48:119
 reuptake inhibitor, serotonin, 48:119
 reuptake inhibitor, yohimbine, 48:119
 saccadic eye movement velocity, diazepam response, 47:151
 saccadic eye movement velocity, eye movements, 47:151
 saccadic eye movement velocity, panic disorder, 47:151
 saccadic eye movement velocity, personality, 47:151
 saccadic eye movement velocity, Tridimensional Personality Questionnaire, 47:151
 serotonin, cortisol, 48:119
 serotonin, fluvoxamine, 48:119
 serotonin, 3-methoxy-4-hydroxyphenylglycol, 48:119
 serotonin, norepinephrine, 48:119
 serotonin, panic disorder, 48:119
 serotonin, reuptake inhibitor, 48:119
 serotonin, yohimbine, 48:119
 sleep, depressive mood, 49:251
 sleep, insomnia, 49:251
 sleep, phobia, 49:251
 sleep, quality of sleep, 49:251
 spatial-linguistic conflict task, attention, 49:183

Anxiety disorder continued

- spatial-linguistic conflict task, obsessive-compulsive disorder, 49:183
- spatial-linguistic conflict task, Posner task, 49:183
- spatial-linguistic conflict task, reaction time, 49:183
- substance abuse, agoraphobia, 46:285
- substance abuse, alcohol dependence, 46:285
- substance abuse, comorbidity, 46:285
- substance abuse, panic disorder, 46:285
- Tridimensional Personality Questionnaire, diazepam response, 47:151
- Tridimensional Personality Questionnaire, eye movements, 47:151
- Tridimensional Personality Questionnaire, panic disorder, 47:151
- Tridimensional Personality Questionnaire, personality, 47:151
- Tridimensional Personality Questionnaire, saccadic eye movement velocity, 47:151
- ventilatory response, carbon dioxide, 47:295
- ventilatory response, clomipramine, 47:295
- ventilatory response, panic disorder, 47:295
- ventricle-brain ratio, alcohol intake, 48:135
- ventricle-brain ratio, benzodiazepines, 48:135
- ventricle-brain ratio, computed tomography, 48:135
- ventricle-brain ratio, diazepam, 48:135
- ventricle-brain ratio, lorazepam, 48:135
- yohimbine, cortisol, 48:119
- yohimbine, fluvoxamine, 48:119
- yohimbine, 3-methoxy-4-hydroxyphenylglycol, 48:119
- yohimbine, norepinephrine, 48:119
- yohimbine, panic disorder, 48:119
- yohimbine, reuptake inhibitor, 48:119
- yohimbine, serotonin, 48:119

Arginine vasopressin

- adrenocorticotrophic hormone, affective disorder, 46:119
- adrenocorticotrophic hormone, cortisol, 46:119
- adrenocorticotrophic hormone, dexamethasone suppression test, 46:119
- adrenocorticotrophic hormone, hypothalamic-pituitary-adrenal axis, 46:119
- affective disorder, adrenocorticotrophic hormone, 46:119
- affective disorder, cortisol, 46:119
- affective disorder, dexamethasone suppression test, 46:119

Arginine vasopressin continued

- affective disorder, hypothalamic-pituitary-adrenal axis, 46:119
- cortisol, adrenocorticotrophic hormone, 46:119
- cortisol, affective disorder, 46:119
- cortisol, dexamethasone suppression test, 46:119
- cortisol, hypothalamic-pituitary-adrenal axis, 46:119
- dexamethasone suppression test, adrenocorticotrophic hormone, 46:119
- dexamethasone suppression test, affective disorder, 46:119
- dexamethasone suppression test, cortisol, 46:119
- dexamethasone suppression test, hypothalamic-pituitary-adrenal axis, 46:119
- electrodermal response, electromyography, 48:107
- electrodermal response, heart rate response, 48:107
- electrodermal response, oxytocin, 48:107
- electrodermal response, personal combat imagery, 48:107
- electrodermal response, posttraumatic stress syndrome, 48:107
- electrodermal response, Vietnam veterans, 48:107
- electromyography, electrodermal response, 48:107
- electromyography, heart rate response, 48:107
- electromyography, oxytocin, 48:107
- electromyography, personal combat imagery, 48:107
- electromyography, posttraumatic stress syndrome, 48:107
- electromyography, Vietnam veterans, 48:107
- heart rate response, electrodermal response, 48:107
- heart rate response, electromyography, 48:107
- heart rate response, oxytocin, 48:107
- heart rate response, personal combat imagery, 48:107
- heart rate response, posttraumatic stress syndrome, 48:107
- heart rate response, Vietnam veterans, 48:107
- hypothalamic-pituitary-adrenal axis, adrenocorticotrophic hormone, 46:119
- hypothalamic-pituitary-adrenal axis, affective disorder, 46:119

Arginine vasopressin continued

hypothalamic-pituitary-adrenal axis, cortisol, 46:119
 hypothalamic-pituitary-adrenal axis, dexamethasone suppression test, 46:119
 oxytocin, electrodermal response, 48:107
 oxytocin, electromyography, 48:107
 oxytocin, heart rate response, 48:107
 oxytocin, personal combat imagery, 48:107
 oxytocin, posttraumatic stress syndrome, 48:107
 oxytocin, Vietnam veterans, 48:107
 personal combat imagery, electrodermal response, 48:107
 personal combat imagery, electromyography, 48:107
 personal combat imagery, heart rate response, 48:107
 personal combat imagery, oxytocin, 48:107
 personal combat imagery, posttraumatic stress syndrome, 48:107
 personal combat imagery, Vietnam veterans, 48:107
 posttraumatic stress syndrome, electrodermal response, 48:107
 posttraumatic stress syndrome, electromyography, 48:107
 posttraumatic stress syndrome, heart rate response, 48:107
 posttraumatic stress syndrome, oxytocin, 48:107
 posttraumatic stress syndrome, personal combat imagery, 48:107
 posttraumatic stress syndrome, Vietnam veterans, 48:107
 Vietnam veterans, electrodermal response, 48:107
 Vietnam veterans, electromyography, 48:107
 Vietnam veterans, heart rate response, 48:107
 Vietnam veterans, oxytocin, 48:107
 Vietnam veterans, personal combat imagery, 48:107
 Vietnam veterans, posttraumatic stress syndrome, 48:107

Attention

affective disorder, antidepressant medication, 46:295
 affective disorder, memory, 46:295
 affective disorder, treatment duration, 46:295
 affective disorder, visual pattern integration, 46:295
 alcohol dependence, cocaine, 46:202

Attention continued

alcohol dependence, reaction time, 46:202
 alcohol dependence, substance abuse, 46:202
 alcohol dependence, visual and auditory suppression tasks, 46:202
 alcohol dependence, withdrawal, 46:202
 antidepressant medication, affective disorder, 46:295
 antidepressant medication, memory, 46:295
 antidepressant medication, treatment duration, 46:295
 antidepressant medication, visual pattern integration, 46:295
 anxiety disorder, obsessive-compulsive disorder, 49:183
 anxiety disorder, Posner task, 49:183
 anxiety disorder, reaction time, 49:183
 anxiety disorder, spatial-linguistic conflict task, 49:183
 cocaine, alcohol dependence, 46:202
 cocaine, reaction time, 46:202
 cocaine, substance abuse, 46:202
 cocaine, visual and auditory suppression tasks, 46:202
 cocaine, withdrawal, 46:202
 continuous performance test, positive and negative symptoms, 47:205
 continuous performance test, schizophrenia, 47:205
 continuous performance test, span of apprehension, 47:205
 continuous performance test, thought disorder, 47:205
 memory, affective disorder, 46:295
 memory, antidepressant medication, 46:295
 memory, treatment duration, 46:295
 memory, visual pattern integration, 46:295
 obsessive-compulsive disorder, anxiety disorder, 49:183
 obsessive-compulsive disorder, Posner task, 49:183
 obsessive-compulsive disorder, reaction time, 49:183
 obsessive-compulsive disorder, spatial-linguistic conflict task, 49:183
 paranoid subtype, schizophrenia, 48:17
 paranoid subtype, Stroop task, 48:17
 paranoid subtype, undifferentiated subtype, 48:17
 positive and negative symptoms, continuous performance test, 47:205

Attention continued
 positive and negative symptoms, schizophrenia, 47:205
 positive and negative symptoms, span of apprehension, 47:205
 positive and negative symptoms, thought disorder, 47:205
 Posner task, anxiety disorder, 49:183
 Posner task, obsessive-compulsive disorder, 49:183
 Posner task, reaction time, 49:183
 Posner task, spatial-linguistic conflict task, 49:183
 reaction time, alcohol dependence, 46:202
 reaction time, anxiety disorder, 49:183
 reaction time, cocaine, 46:202
 reaction time, obsessive-compulsive disorder, 49:183
 reaction time, Posner task, 49:183
 reaction time, spatial-linguistic conflict task, 49:183
 reaction time, substance abuse, 46:202
 reaction time, visual and auditory suppression tasks, 46:202
 reaction time, withdrawal, 46:202
 schizophrenia, continuous performance test, 47:205
 schizophrenia, paranoid subtype, 48:17
 schizophrenia, positive and negative symptoms, 47:205
 schizophrenia, span of apprehension, 47:205
 schizophrenia, Stroop task, 48:17
 schizophrenia, thought disorder, 47:205
 schizophrenia, undifferentiated subtype, 48:17
 span of apprehension, continuous performance test, 47:205
 span of apprehension, positive and negative symptoms, 47:205
 span of apprehension, schizophrenia, 47:205
 span of apprehension, thought disorder, 47:205
 spatial-linguistic conflict task, anxiety disorder, 49:183
 spatial-linguistic conflict task, obsessive-compulsive disorder, 49:183
 spatial-linguistic conflict task, Posner task, 49:183
 spatial-linguistic conflict task, reaction time, 49:183
 Stroop task, paranoid subtype, 48:17

Attention continued
 Stroop task, schizophrenia, 48:17
 Stroop task, undifferentiated subtype, 48:17
 substance abuse, alcohol dependence, 46:202
 substance abuse, cocaine, 46:202
 substance abuse, reaction time, 46:202
 substance abuse, visual and auditory suppression tasks, 46:202
 substance abuse, withdrawal, 46:202
 thought disorder, continuous performance test, 47:205
 thought disorder, positive and negative symptoms, 47:205
 thought disorder, schizophrenia, 47:205
 thought disorder, span of apprehension, 47:205
 treatment duration, affective disorder, 46:295
 treatment duration, antidepressant medication, 46:295
 treatment duration, memory, 46:295
 treatment duration, visual pattern integration, 46:295
 undifferentiated subtype, paranoid subtype, 48:17
 undifferentiated subtype, schizophrenia, 48:17
 undifferentiated subtype, Stroop task, 48:17
 visual and auditory suppression tasks, alcohol dependence, 46:202
 visual and auditory suppression tasks, cocaine, 46:202
 visual and auditory suppression tasks, reaction time, 46:202
 visual and auditory suppression tasks, substance abuse, 46:202
 visual and auditory suppression tasks, withdrawal, 46:202
 visual pattern integration, affective disorder, 46:295
 visual pattern integration, antidepressant medication, 46:295
 visual pattern integration, memory, 46:295
 visual pattern integration, treatment duration, 46:295
 withdrawal, alcohol dependence, 46:202
 withdrawal, cocaine, 46:202
 withdrawal, reaction time, 46:202
 withdrawal, substance abuse, 46:202
 withdrawal, visual and auditory suppression tasks, 46:202

Auditory acuity

asymmetry, schizophrenia, 46:127
 schizophrenia, asymmetry, 46:127

Autism

c-Harvey-Ras-1 marker, dopamine-beta-hydroxylase, 46:261
 c-Harvey-Ras-1 marker, genetics, 46:261
 c-Harvey-Ras-1 marker, restriction fragment length polymorphism, 46:261
 c-Harvey-Ras-1 marker, tryptophan hydroxylase, 46:261
 c-Harvey-Ras-1 marker, tyrosine hydroxylase, 46:261
 dopamine-beta-hydroxylase, c-Harvey-Ras-1 marker, 46:261
 dopamine-beta-hydroxylase, genetics, 46:261
 dopamine-beta-hydroxylase, restriction fragment length polymorphism, 46:261
 dopamine-beta-hydroxylase, tryptophan hydroxylase, 46:261
 dopamine-beta-hydroxylase, tyrosine hydroxylase, 46:261
 genetics, c-Harvey-Ras-1 marker, 46:261
 genetics, dopamine-beta-hydroxylase, 46:261
 genetics, restriction fragment length polymorphism, 46:261
 genetics, tryptophan hydroxylase, 46:261
 genetics, tyrosine hydroxylase, 46:261
 restriction fragment length polymorphism, c-Harvey-Ras-1 marker, 46:261
 restriction fragment length polymorphism, dopamine-beta-hydroxylase, 46:261
 restriction fragment length polymorphism, genetics, 46:261
 restriction fragment length polymorphism, tryptophan hydroxylase, 46:261
 restriction fragment length polymorphism, tyrosine hydroxylase, 46:261
 tryptophan hydroxylase, c-Harvey-Ras-1 marker, 46:261
 tryptophan hydroxylase, dopamine-beta-hydroxylase, 46:261
 tryptophan hydroxylase, genetics, 46:261
 tryptophan hydroxylase, restriction fragment length polymorphism, 46:261
 tryptophan hydroxylase, tyrosine hydroxylase, 46:261
 tyrosine hydroxylase, c-Harvey-Ras-1 marker, 46:261
 tyrosine hydroxylase, dopamine-beta-hydroxylase, 46:261
 tyrosine hydroxylase, genetics, 46:261

Autism continued

tyrosine hydroxylase, restriction fragment length polymorphism, 46:261
 tyrosine hydroxylase, tryptophan hydroxylase, 46:261

Autonomic nervous system

anxiety disorder, heart rate, 46:89
 anxiety disorder, orthostatic challenge, 46:89
 anxiety disorder, panic disorder, 46:89
 anxiety disorder, power spectral analysis of heart rate, 46:89
 heart rate, anxiety disorder, 46:89
 heart rate, orthostatic challenge, 46:89
 heart rate, panic disorder, 46:89
 heart rate, power spectral analysis of heart rate, 46:89
 orthostatic challenge, anxiety disorder, 46:89
 orthostatic challenge, heart rate, 46:89
 orthostatic challenge, panic disorder, 46:89
 orthostatic challenge, power spectral analysis of heart rate, 46:89
 panic disorder, anxiety disorder, 46:89
 panic disorder, heart rate, 46:89
 panic disorder, orthostatic challenge, 46:89
 panic disorder, power spectral analysis of heart rate, 46:89
 power spectral analysis of heart rate, anxiety disorder, 46:89
 power spectral analysis of heart rate, heart rate, 46:89
 power spectral analysis of heart rate, orthostatic challenge, 46:89
 power spectral analysis of heart rate, panic disorder, 46:89

Behavior therapy

fluvoxamine treatment, obsessive-compulsive disorder, 49:63
 obsessive-compulsive disorder, fluvoxamine treatment, 49:63

Benzodiazepines

alcohol intake, anxiety disorder, 48:135
 alcohol intake, computed tomography, 48:135
 alcohol intake, diazepam, 48:135
 alcohol intake, lorazepam, 48:135
 alcohol intake, ventricle-brain ratio, 48:135
 anxiety disorder, alcohol intake, 48:135
 anxiety disorder, computed tomography, 48:135
 anxiety disorder, diazepam, 48:135
 anxiety disorder, lorazepam, 48:135
 anxiety disorder, ventricle-brain ratio, 48:135

Benzodiazepines continued

- computed tomography, alcohol intake, 48:135
- computed tomography, anxiety disorder, 48:135
- computed tomography, diazepam, 48:135
- computed tomography, lorazepam, 48:135
- computed tomography, ventricle-brain ratio, 48:135
- diazepam, alcohol intake, 48:135
- diazepam, anxiety disorder, 48:135
- diazepam, computed tomography, 48:135
- diazepam, lorazepam, 48:135
- diazepam, ventricle-brain ratio, 48:135
- lorazepam, alcohol intake, 48:135
- lorazepam, anxiety disorder, 48:135
- lorazepam, computed tomography, 48:135
- lorazepam, diazepam, 48:135
- lorazepam, ventricle-brain ratio, 48:135
- ventricle-brain ratio, alcohol intake, 48:135
- ventricle-brain ratio, anxiety disorder, 48:135
- ventricle-brain ratio, computed tomography, 48:135
- ventricle-brain ratio, diazepam, 48:135
- ventricle-brain ratio, lorazepam, 48:135

Blood pressure

- desipramine, normal subjects, 46:1
- fluvoxamine, heart rate, 48:119
- fluvoxamine, panic disorder, 48:119
- fluvoxamine, yohimbine, 48:119
- heart rate, fluvoxamine, 48:119
- heart rate, panic disorder, 48:119
- heart rate, yohimbine, 48:119
- lactate infusion, menstrual cycle, 46:79
- lactate infusion, panic attacks, 46:79
- lactate infusion, premenstrual syndrome, 46:79
- menstrual cycle, lactate infusion, 46:79
- menstrual cycle, panic attacks, 46:79
- menstrual cycle, premenstrual syndrome, 46:79
- normal subjects, desipramine, 46:1
- panic disorder, fluvoxamine, 48:119
- panic disorder, heart rate, 48:119
- panic disorder, yohimbine, 48:119
- panic attacks, lactate infusion, 46:79
- panic attacks, menstrual cycle, 46:79
- panic attacks, premenstrual syndrome, 46:79
- premenstrual syndrome, lactate infusion, 46:79
- premenstrual syndrome, menstrual cycle, 46:79

Blood pressure continued

- premenstrual syndrome, panic attacks, 46:79
- yohimbine, fluvoxamine, 48:119
- yohimbine, heart rate, 48:119
- yohimbine, panic disorder, 48:119
- Bulima.** See *Eating disorders*
- Carbon dioxide**
- anxiety disorder, HCO_3 , 47:1
- anxiety disorder, hyperventilation, 47:1
- anxiety disorder, panic disorder, 47:1
- anxiety disorder, $p\text{CO}_2$, 47:1
- anxiety disorder, $p\text{H}$, 47:1
- anxiety disorder, $p\text{O}_2$, 47:1
- anxiety disorder, respiratory alkalosis, 47:1
- HCO_3 , anxiety disorder, 47:1
- HCO_3 , hyperventilation, 47:1
- HCO_3 , panic disorder, 47:1
- HCO_3 , $p\text{CO}_2$, 47:1
- HCO_3 , $p\text{H}$, 47:1
- HCO_3 , $p\text{O}_2$, 47:1
- HCO_3 , respiratory alkalosis, 47:1
- hyperventilation, anxiety disorder, 47:1
- hyperventilation, HCO_3 , 47:1
- hyperventilation, panic disorder, 47:1
- hyperventilation, $p\text{CO}_2$, 47:1
- hyperventilation, $p\text{H}$, 47:1
- hyperventilation, $p\text{O}_2$, 47:1
- hyperventilation, respiratory alkalosis, 47:1
- panic disorder, anxiety disorder, 47:1
- panic disorder, HCO_3 , 47:1
- panic disorder, hyperventilation, 47:1
- panic disorder, $p\text{CO}_2$, 47:1
- panic disorder, $p\text{H}$, 47:1
- panic disorder, $p\text{O}_2$, 47:1
- panic disorder, respiratory alkalosis, 47:1
- $p\text{CO}_2$, anxiety disorder, 47:1
- $p\text{CO}_2$, HCO_3 , 47:1
- $p\text{CO}_2$, hyperventilation, 47:1
- $p\text{CO}_2$, panic disorder, 47:1
- $p\text{CO}_2$, $p\text{H}$, 47:1
- $p\text{CO}_2$, $p\text{O}_2$, 47:1
- $p\text{CO}_2$, respiratory alkalosis, 47:1
- $p\text{H}$, anxiety disorder, 47:1
- $p\text{H}$, HCO_3 , 47:1
- $p\text{H}$, hyperventilation, 47:1
- $p\text{H}$, panic disorder, 47:1
- $p\text{H}$, $p\text{CO}_2$, 47:1
- $p\text{H}$, $p\text{O}_2$, 47:1
- $p\text{H}$, respiratory alkalosis, 47:1
- $p\text{O}_2$, anxiety disorder, 47:1
- $p\text{O}_2$, HCO_3 , 47:1
- $p\text{O}_2$, hyperventilation, 47:1

Carbon dioxide continued

pO₂, panic disorder, 47:1
pO₂, pCO₂, 47:1
pO₂, pH, 47:1
pO₂, respiratory alkalosis, 47:1
 respiratory alkalosis, anxiety disorder, 47:1
 respiratory alkalosis, HCO_3 , 47:1
 respiratory alkalosis, hyperventilation, 47:1
 respiratory alkalosis, panic disorder, 47:1
 respiratory alkalosis, *pCO₂*, 47:1
 respiratory alkalosis, *pH*, 47:1
 respiratory alkalosis, *pO₂*, 47:1

Center for Epidemiologic Studies Depression Scale
 cancer patients, caregivers of chronically ill, 49:239
 cancer patients, depressed mood, 49:239
 cancer patients, epidemiology, 49:239
 cancer patients, gender differences, 49:239
 caregivers of chronically ill, cancer patients, 49:239
 caregivers of chronically ill, depressed mood, 49:239
 caregivers of chronically ill, epidemiology, 49:239
 caregivers of chronically ill, gender differences, 49:239
 depressed mood, cancer patients, 49:239
 depressed mood, caregivers of chronically ill, 49:239
 depressed mood, epidemiology, 49:239
 depressed mood, gender differences, 49:239
 epidemiology, cancer patients, 49:239
 epidemiology, caregivers of chronically ill, 49:239
 epidemiology, depressed mood, 49:239
 epidemiology, gender differences, 49:239
 gender differences, cancer patients, 49:239
 gender differences, caregivers of chronically ill, 49:239
 gender differences, depressed mood, 49:239
 gender differences, epidemiology, 49:239

Cerebrospinal fluid

Cerebrospinal fluid

affective disorder, seasonal depression, 46:19
 corticotropin releasing factor, cortisol, 46:1
 corticotropin releasing factor, desipramine, 46:1
 corticotropin releasing factor, norepinephrine, 46:1
 cortisol, corticotropin releasing factor, 46:1
 cortisol, desipramine, 46:1
 cortisol, norepinephrine, 46:1
 desipramine, corticotropin releasing factor, 46:1
 desipramine, cortisol, 46:1
 desipramine, norepinephrine, 46:1
 dissociative phenomena, eating disorder, 49:1
 dissociative phenomena, endorphins, 49:1
 dissociative phenomena, homovanillic acid, 49:1
 dissociative phenomena, 5-hydroxyindoleacetic acid, 49:1
 dissociative phenomena, 3-methoxy-4-hydroxyphenylglycol, 49:1
 eating disorder, dissociative phenomena, 49:1
 eating disorder, endorphins, 49:1
 eating disorder, homovanillic acid, 49:1
 eating disorder, 5-hydroxyindoleacetic acid, 49:1
 eating disorder, 3-methoxy-4-hydroxyphenylglycol, 49:1
 endorphins, dissociative phenomena, 49:1
 endorphins, eating disorder, 49:1
 endorphins, homovanillic acid, 49:1
 endorphins, 5-hydroxyindoleacetic acid, 49:1
 endorphins, 3-methoxy-4-hydroxyphenylglycol, 49:1
 homovanillic acid, affective disorder, 46:19
 homovanillic acid, dissociative phenomena, 49:1
 homovanillic acid, eating disorder, 49:1
 homovanillic acid, endorphins, 49:1
 homovanillic acid, 5-hydroxyindoleacetic acid, 46:19, 49:1
 homovanillic acid, 3-methoxy-4-hydroxyphenylglycol, 46:19, 49:1
 homovanillic acid, norepinephrine, 46:19
 homovanillic acid, orthostatic challenge, 46:19
 homovanillic acid, phototherapy, 46:19
 homovanillic acid, seasonal depression, 46:19
 5-hydroxyindoleacetic acid, affective disorder, 46:19
 5-hydroxyindoleacetic acid, dissociative phenomena, 49:1
 5-hydroxyindoleacetic acid, eating disorder, 49:1

Cerebrospinal fluid continued

5-hydroxyindoleacetic acid, endorphins, 49:1
 5-hydroxyindoleacetic acid, homovanillic acid, 46:19, 49:1
 5-hydroxyindoleacetic acid, 3-methoxy-4-hydroxyphenylglycol, 46:19, 49:1
 5-hydroxyindoleacetic acid, norepinephrine, 46:19
 5-hydroxyindoleacetic acid, orthostatic challenge, 46:19
 5-hydroxyindoleacetic acid, phototherapy, 46:19
 5-hydroxyindoleacetic acid, seasonal depression, 46:19
 3-methoxy-4-hydroxyphenylglycol, affective disorder, 46:19
 3-methoxy-4-hydroxyphenylglycol, dissociative phenomena, 49:1
 3-methoxy-4-hydroxyphenylglycol, eating disorder, 49:1
 3-methoxy-4-hydroxyphenylglycol, endorphins, 49:1
 3-methoxy-4-hydroxyphenylglycol, homovanillic acid, 46:19, 49:1
 3-methoxy-4-hydroxyphenylglycol, hydroxyindoleacetic acid, 46:19, 49:1
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 46:19
 3-methoxy-4-hydroxyphenylglycol, orthostatic challenge, 46:19
 3-methoxy-4-hydroxyphenylglycol, phototherapy, 46:19
 3-methoxy-4-hydroxyphenylglycol, seasonal depression, 46:19
 norepinephrine, affective disorder, 46:19
 norepinephrine, corticotropin releasing factor, 46:1
 norepinephrine, cortisol, 46:1
 norepinephrine, desipramine, 46:1
 norepinephrine, homovanillic acid, 46:19
 norepinephrine, 5-hydroxyindoleacetic acid, 46:19
 norepinephrine, hypothalamic-pituitary-adrenal axis, 46:1
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 46:19
 norepinephrine, orthostatic challenge, 46:19
 norepinephrine, phototherapy, 46:19
 norepinephrine, seasonal depression, 46:19
 orthostatic challenge, affective disorder, 46:19
 orthostatic challenge, homovanillic acid, 46:19

Cerebrospinal fluid continued

orthostatic challenge, 5-hydroxyindoleacetic acid, 46:19
 orthostatic challenge, 3-methoxy-4-hydroxyphenylglycol, 46:19
 orthostatic challenge, norepinephrine, 46:19
 orthostatic challenge, phototherapy, 46:19
 orthostatic challenge, seasonal depression, 46:19
 phototherapy, affective disorder, 46:19
 phototherapy, homovanillic acid, 46:19
 phototherapy, 5-hydroxyindoleacetic acid, 46:19
 phototherapy, 3-methoxy-4-hydroxyphenylglycol, 46:19
 phototherapy, norepinephrine, 46:19
 phototherapy, orthostatic challenge, 46:19
 phototherapy, seasonal depression, 46:19
 seasonal depression, homovanillic acid, 46:19
 seasonal depression, 5-hydroxyindoleacetic acid, 46:19
 seasonal depression, 3-methoxy-4-hydroxyphenylglycol, 46:19
 seasonal depression, norepinephrine, 46:19
 seasonal depression, orthostatic challenge, 46:19
 seasonal depression, phototherapy, 46:19
c-Harvey-Ras marker
 autism, dopamine-beta-hydroxylase, 46:261
 autism, genetics, 46:261
 autism, restriction fragment length polymorphism, 46:261
 autism, tryptophan hydroxylase, 46:261
 autism, tyrosine hydroxylase, 46:261
 dopamine-beta-hydroxylase, autism, 46:261
 dopamine-beta-hydroxylase, genetics, 46:261
 dopamine-beta-hydroxylase, restriction fragment length polymorphism, 46:261
 dopamine-beta-hydroxylase, tryptophan hydroxylase, 46:261
 dopamine-beta-hydroxylase, tyrosine hydroxylase, 46:261
 genetics, autism, 46:261
 genetics, dopamine-beta-hydroxylase, 46:261
 genetics, restriction fragment length polymorphism, 46:261
 genetics, tryptophan hydroxylase, 46:261
 genetics, tyrosine hydroxylase, 46:261
 restriction fragment length polymorphism, autism, 46:261
 restriction fragment length polymorphism, dopamine-beta-hydroxylase, 46:261

c-Harvey Ras marker continued

restriction fragment length polymorphism, genetics, 46:261

restriction fragment length polymorphism, tryptophan hydroxylase, 46:261

restriction fragment length polymorphism, tyrosine hydroxylase, 46:261

tryptophan hydroxylase, autism, 46:261

tryptophan hydroxylase, dopamine-beta-hydroxylase, 46:261

tryptophan hydroxylase, genetics, 46:261

tryptophan hydroxylase, restriction fragment length polymorphism, 46:261

tryptophan hydroxylase, tyrosine hydroxylase, 46:261

tyrosine hydroxylase, autism, 46:261

tyrosine hydroxylase, dopamine-beta-hydroxylase, 46:261

tyrosine hydroxylase, genetics, 46:261

tyrosine hydroxylase, restriction fragment length polymorphism, 46:261

tyrosine hydroxylase, tryptophan hydroxylase, 46:261

Childhood disorders

antisocial personality disorder, conduct disorder, 46:9

antisocial personality disorder, cortisol in saliva, 46:9

antisocial personality disorder, genetics, 46:9

antisocial personality disorder, substance abuse, 46:9

conduct disorder, antisocial personality disorder, 46:9

conduct disorder, cortisol in saliva, 46:9

conduct disorder, genetics, 46:9

conduct disorder, substance abuse, 46:9

cortisol in saliva, antisocial personality disorder, 46:9

cortisol in saliva, conduct disorder, 46:9

cortisol in saliva, genetics, 46:9

cortisol in saliva, substance abuse, 46:9

genetics, antisocial personality disorder, 46:9

genetics, conduct disorder, 46:9

genetics, cortisol in saliva, 46:9

genetics, substance abuse, 46:9

substance abuse, antisocial personality disorder, 46:9

substance abuse, conduct disorder, 46:9

substance abuse, cortisol in saliva, 46:9

substance abuse, genetics, 46:9

Circadian rhythms

affective disorder, carbohydrate craving, 46:107

affective disorder, daytime affect, 49:139

affective disorder, diet, 46:107

affective disorder, eating sweets, 46:107

affective disorder, endogenous subtype, 47:215

affective disorder, growth hormone, 47:215

affective disorder, growth hormone releasing hormone, 47:215

affective disorder, nocturnal penile tumescence, 49:139

affective disorder, phototherapy, 46:107

affective disorder, seasonal depression, 46:107

affective disorder, sexual function, 49:139

affective disorder, sleep, 47:215

affective disorder, sleep, 49:139

aging, agitation, 48:277

aging, circannual rhythms, 48:277

aging, dementia, 48:277

aging, sleep, 48:277

aging, sundowning, 48:277

agitation, aging, 48:277

agitation, circannual rhythms, 48:277

agitation, dementia, 48:277

agitation, sleep, 48:277

agitation, sundowning, 48:277

amino acids, dopamine, 47:187

amino acids, neuroleptics, 47:187

amino acids, neutral serum amino acids, 47:187

amino acids, phenylalanine, 47:187

amino acids, schizophrenia, 47:187

amino acids, therapeutic response, 47:187

carbohydrate craving, affective disorder, 46:107

carbohydrate craving, diet, 46:107

carbohydrate craving, eating sweets, 46:107

carbohydrate craving, phototherapy, 46:107

carbohydrate craving, seasonal depression, 46:107

circannual rhythms, aging, 48:277

circannual rhythms, agitation, 48:277

circannual rhythms, dementia, 48:277

circannual rhythms, sleep, 48:277

circannual rhythms, sundowning, 48:277

daytime affect, affective disorder, 49:139

daytime affect, nocturnal penile tumescence, 49:139

daytime affect, sexual function, 49:139

Circadian rhythms continued
 daytime affect, sleep, 49:139
 dementia, aging, 48:277
 dementia, agitation, 48:277
 dementia, circannual rhythms, 48:277
 dementia, sleep, 48:277
 dementia, sundowning, 48:277
 diet, affective disorder, 46:107
 diet, carbohydrate craving, 46:107
 diet, eating sweets, 46:107
 diet, phototherapy, 46:107
 diet, seasonal depression, 46:107
 dopamine, amino acids, 47:187
 dopamine, haloperidol, 47:141
 dopamine, homovanillic acid, 47:141
 dopamine, neuroleptics, 47:187
 dopamine, neutral serum amino acids, 47:187
 dopamine, normal subjects, 47:141
 dopamine, phenylalanine, 47:187
 dopamine, schizophrenia, 47:187
 dopamine, therapeutic response, 47:187
 eating sweets, affective disorder, 46:107
 eating sweets, carbohydrate craving, 46:107
 eating sweets, diet, 46:107
 eating sweets, phototherapy, 46:107
 eating sweets, seasonal depression, 46:107
 endogenous subtype, affective disorder, 47:215
 endogenous subtype, growth hormone, 47:215
 endogenous subtype, growth hormone releasing hormone, 47:215
 endogenous subtype, sleep, 47:215
 growth hormone, affective disorder, 47:215
 growth hormone, endogenous subtype, 47:215
 growth hormone, growth hormone releasing hormone, 47:215
 growth hormone, sleep, 47:215
 growth hormone releasing hormone, affective disorder, 47:215
 growth hormone releasing hormone, endogenous subtype, 47:215
 growth hormone releasing hormone, growth hormone, 47:215
 growth hormone releasing hormone, sleep, 47:215
 haloperidol, dopamine, 47:141
 haloperidol, homovanillic acid, 47:141
 haloperidol, normal subjects, 47:141
 homovanillic acid, dopamine, 47:141
 homovanillic acid, haloperidol, 47:141

Circadian rhythms continued
 homovanillic acid, normal subjects, 47:141
 neuroleptics, amino acids, 47:187
 neuroleptics, dopamine, 47:187
 neuroleptics, neutral serum amino acids, 47:187
 neuroleptics, phenylalanine, 47:187
 neuroleptics, schizophrenia, 47:187
 neuroleptics, therapeutic response, 47:187
 neutral serum amino acids, amino acids, 47:187
 neutral serum amino acids, dopamine, 47:187
 neutral serum amino acids, neuroleptics, 47:187
 neutral serum amino acids, phenylalanine, 47:187
 neutral serum amino acids, schizophrenia, 47:187
 neutral serum amino acids, therapeutic response, 47:187
 nocturnal penile tumescence, affective disorder, 49:139
 nocturnal penile tumescence, daytime affect, 49:139
 nocturnal penile tumescence, sexual function, 49:139
 nocturnal penile tumescence, sleep, 49:139
 normal subjects, dopamine, 47:141
 normal subjects, haloperidol, 47:141
 normal subjects, homovanillic acid, 47:141
 phenylalanine, amino acids, 47:187
 phenylalanine, dopamine, 47:187
 phenylalanine, neuroleptics, 47:187
 phenylalanine, neutral serum amino acids, 47:187
 phenylalanine, schizophrenia, 47:187
 phenylalanine, therapeutic response, 47:187
 phototherapy, affective disorder, 46:107
 phototherapy, carbohydrate craving, 46:107
 phototherapy, diet, 46:107
 phototherapy, eating sweets, 46:107
 phototherapy, seasonal depression, 46:107
 prolactin, schizophrenia, 47:187
 prolactin, tyrosine, 47:187
 schizophrenia, amino acids, 47:187
 schizophrenia, dopamine, 47:187
 schizophrenia, neuroleptics, 47:187
 schizophrenia, neutral serum amino acids, 47:187
 schizophrenia, phenylalanine, 47:187
 schizophrenia, prolactin, 47:187
 schizophrenia, therapeutic response, 47:187

Circadian rhythms continued

schizophrenia, tyrosine, 47:187
 seasonal depression, affective disorder, 46:107
 seasonal depression, carbohydrate craving, 46:107
 seasonal depression, diet, 46:107
 seasonal depression, eating sweets, 46:107
 seasonal depression, phototherapy, 46:107
 sexual function, affective disorder, 49:139
 sexual function, daytime affect, 49:139
 sexual function, nocturnal penile tumescence, 49:139
 sexual function, sleep, 49:139
 sleep, affective disorder, 47:215
 sleep, affective disorder, 49:139
 sleep, aging, 48:277
 sleep, agitation, 48:277
 sleep, circadian rhythms, 48:277
 sleep, daytime affect, 49:139
 sleep, dementia, 48:277
 sleep, endogenous subtype, 47:215
 sleep, growth hormone, 47:215
 sleep, growth hormone releasing hormone, 47:215
 sleep, nocturnal penile tumescence, 49:139
 sleep, sexual function, 49:139
 sleep, sundowning, 48:277
 sundowning, aging, 48:277
 sundowning, agitation, 48:277
 sundowning, circadian rhythms, 48:277
 sundowning, dementia, 48:277
 sundowning, sleep, 48:277
 therapeutic response, amino acids, 47:187
 therapeutic response, dopamine, 47:187
 therapeutic response, neuroleptics, 47:187
 therapeutic response, neutral serum amino acids, 47:187
 therapeutic response, phenylalanine, 47:187
 therapeutic response, schizophrenia, 47:187
 tyrosine, prolactin, 47:187
 tyrosine, schizophrenia, 47:187

Circannual rhythms

affective disorder, eye blink rate, 47:79
 affective disorder, gender differences, 47:79
 affective disorder, light visor treatment, 46:29
 affective disorder, phototherapy, 46:29, 47:79
 affective disorder, prevalence in northern Canada, 46:41
 aging, agitation, 48:277
 aging, circadian rhythms, 48:277
 aging, dementia, 48:277

Circannual rhythms continued

aging, sleep, 48:277
 aging, sundowning, 48:277
 agitation, aging, 48:277
 agitation, circadian rhythms, 48:277
 agitation, dementia, 48:277
 agitation, sleep, 48:277
 agitation, sundowning, 48:277
 circadian rhythms, aging, 48:277
 circadian rhythms, agitation, 48:277
 circadian rhythms, dementia, 48:277
 circadian rhythms, sleep, 48:277
 circadian rhythms, sundowning, 48:277
 dementia, aging, 48:277
 dementia, agitation, 48:277
 dementia, circadian rhythms, 48:277
 dementia, sleep, 48:277
 dementia, sundowning, 48:277
 depressed mood, normal women, 49:77
 depressed mood, Profile of Mood States, 49:77
 depressed mood, thyroid stimulating hormone, 49:77
 depressed mood, thyroxine, 49:77
 depressed mood, triiodothyronine, 49:77
 depressed mood, Vitamin D, 49:77
 eye blink rate, affective disorder, 47:79
 eye blink rate, gender differences, 47:79
 eye blink rate, phototherapy, 47:79
 eye blink rate, seasonal depression, 47:79
 gender differences, affective disorder, 47:79
 gender differences, eye blink rate, 47:79
 gender differences, phototherapy, 47:79
 gender differences, seasonal depression, 47:79
 light visor treatment, affective disorder, 46:29
 light visor treatment, phototherapy, 46:29
 normal women, depressed mood, 49:77
 normal women, Profile of Mood States, 49:77
 normal women, thyroid stimulating hormone, 49:77
 normal women, thyroxine, 49:77
 normal women, triiodothyronine, 49:77
 normal women, Vitamin D, 49:77
 phototherapy, affective disorder, 46:29, 47:79
 phototherapy, eye blink rate, 47:79
 phototherapy, gender differences, 47:79
 phototherapy, light visor treatment, 46:29
 phototherapy, seasonal depression, 46:29, 47:79
 prevalence in northern Canada, affective disorder, 46:41
 prevalence in northern Canada, seasonal depression, 46:41

Circannual rhythms continued

Profile of Mood States, depressed mood, 49:77
 Profile of Mood States, normal women, 49:77
 Profile of Mood States, thyroid stimulating hormone, 49:77
 Profile of Mood States, thyroxine, 49:77
 Profile of Mood States, triiodothyronine, 49:77
 Profile of Mood States, Vitamin D, 49:77
 seasonal depression, eye blink rate, 47:79
 seasonal depression, gender differences, 47:79
 seasonal depression, light visor treatment, 46:29
 seasonal depression, phototherapy, 46:29, 47:79
 seasonal depression, prevalence in northern Canada, 46:41
 sleep, aging, 48:277
 sleep, agitation, 48:277
 sleep, circadian rhythms, 48:277
 sleep, dementia, 48:277
 sleep, sundowning, 48:277
 sundowning, aging, 48:277
 sundowning, agitation, 48:277
 sundowning, circadian rhythms, 48:277
 sundowning, dementia, 48:277
 sundowning, sleep, 48:277
 thyroid stimulating hormone, depressed mood, 49:77
 thyroid stimulating hormone, normal women, 49:77
 thyroid stimulating hormone, Profile of Mood States, 49:77
 thyroid stimulating hormone, thyroxine, 49:77
 thyroid stimulating hormone, triiodothyronine, 49:77
 thyroid stimulating hormone, Vitamin D, 49:77
 thyroxine, depressed mood, 49:77
 thyroxine, normal women, 49:77
 thyroxine, Profile of Mood States, 49:77
 thyroxine, thyroid stimulating hormone, 49:77
 thyroxine, triiodothyronine, 49:77
 thyroxine, Vitamin D, 49:77
 treatment, seasonal depression, 46:29
 triiodothyronine, depressed mood, 49:77
 triiodothyronine, normal women, 49:77
 triiodothyronine, Profile of Mood States, 49:77
 triiodothyronine, thyroid stimulating hormone, 49:77
 triiodothyronine, thyroxine, 49:77
 triiodothyronine, Vitamin D, 49:77
 Vitamin D, depressed mood, 49:77
 Vitamin D, normal women, 49:77
 Vitamin D, Profile of Mood States, 49:77

Circannual rhythms continued

Vitamin D, thyroid stimulating hormone, 49:77
 Vitamin D, thyroxine, 49:77
 Vitamin D, triiodothyronine, 49:77
Clomipramine
 anxiety disorder, carbon dioxide, 47:295
 anxiety disorder, panic disorder, 47:295
 anxiety disorder, ventilatory response, 47:295
 carbon dioxide, anxiety disorder, 47:295
 carbon dioxide, panic disorder, 47:295
 carbon dioxide, ventilatory response, 47:295
 panic disorder, anxiety disorder, 47:295
 panic disorder, carbon dioxide, 47:295
 panic disorder, ventilatory response, 47:295
 ventilatory response, anxiety disorder, 47:295
 ventilatory response, carbon dioxide, 47:295
 ventilatory response, panic disorder, 47:295
Clonidine
 diagnostic systems, growth hormone, 48:79
 diagnostic systems, schizophrenia, 48:79
 growth hormone, diagnostic systems, 48:79
 growth hormone, schizophrenia, 48:79
 schizophrenia, diagnostic systems, 48:79
 schizophrenia, growth hormone, 48:79
Clozapine
 dopamine, homovanillic acid, 46:139, 46:151
 dopamine, 3-methoxy-4-hydroxyphenylglycol, 46:139
 dopamine, norepinephrine, 46:139, 46:151
 dopamine, schizophrenia, 46:139, 46:151
 dopamine, therapeutic response, 46:139, 46:151
 homovanillic acid, dopamine, 46:139, 46:151
 homovanillic acid, 3-methoxy-4-hydroxyphenylglycol, 46:139
 homovanillic acid, norepinephrine, 46:139, 46:151
 homovanillic acid, schizophrenia, 46:139, 46:151
 homovanillic acid, therapeutic response, 46:139, 46:151
 3-methoxy-4-hydroxyphenylglycol, dopamine, 46:139
 3-methoxy-4-hydroxyphenylglycol, homovanillic acid, 46:139
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 46:139
 3-methoxy-4-hydroxyphenylglycol, schizophrenia, 46:139
 3-methoxy-4-hydroxyphenylglycol, therapeutic response, 46:139

Clozapine continued

norepinephrine, dopamine, 46:139, 46:151
 norepinephrine, homovanillic acid, 46:139,
 46:151
 norepinephrine, 3-methoxy-4-hydroxyphenyl-
 glycol, 46:139
 norepinephrine, schizophrenia, 46:139, 46:151
 norepinephrine, therapeutic response, 46:139,
 46:151
 schizophrenia, dopamine, 46:139, 46:151
 schizophrenia, homovanillic acid, 46:139,
 46:151
 schizophrenia, 3-methoxy-4-hydroxyphenyl-
 glycol, 46:139
 schizophrenia, norepinephrine, 46:139, 46:151
 schizophrenia, therapeutic response, 46:139,
 46:151
 therapeutic response, dopamine, 46:139, 46:151
 therapeutic response, homovanillic acid,
 46:139, 46:151
 therapeutic response, 3-methoxy-4-hydroxy-
 phenylglycol, 46:139
 therapeutic response, norepinephrine, 46:139,
 46:151
 therapeutic response, schizophrenia, 46:139,
 schizophrenia, 46:151

Cocaine

alcohol dependence, attention, 46:229
 alcohol dependence, motor performance,
 46:229
 alcohol dependence, reaction time, 46:229
 alcohol dependence, tremor and body sway, 47:69
 alcohol dependence, visual and auditory
 suppression tasks, 46:229
 alcohol dependence, withdrawal, 46:229
 attention, alcohol dependence, 46:229
 attention, reaction time, 46:229
 attention, visual and auditory suppression
 tasks, 46:229
 attention, withdrawal, 46:229
 auditory P50 component, event related
 potentials, 47:243
 auditory P50 component, paranoid subtype,
 47:243
 auditory P50 component, schizophrenia,
 47:243
 event related potentials, auditory P50
 component, 47:243
 event related potentials, paranoid subtype,
 47:243
 event related potentials, schizophrenia,
 47:243

Cocaine continued

motor performance, alcohol dependence,
 47:69
 motor performance, tremor and body sway,
 47:69
 paranoid subtype, auditory P50 component,
 47:243
 paranoid subtype, event related potentials,
 47:243
 paranoid subtype, schizophrenia, 47:243
 reaction time, alcohol dependence, 46:202
 reaction time, attention, 46:202
 reaction time, visual and auditory suppression
 tasks, 46:202
 reaction time, withdrawal, 46:202
 schizophrenia, auditory P50 component, 47:243
 schizophrenia, event related potentials,
 47:243
 schizophrenia, paranoid subtype, 47:243
 tremor and body sway, alcohol dependence,
 47:69
 tremor and body sway, motor performance,
 47:69
 visual and auditory suppression tasks,
 alcohol dependence, 46:202
 visual and auditory suppression tasks,
 attention, 46:202
 visual and auditory suppression tasks,
 reaction time, 46:202
 visual and auditory suppression tasks,
 withdrawal, 46:202
 withdrawal, alcohol dependence, 46:202
 withdrawal, attention, 46:202
 withdrawal, reaction time, 46:202
 withdrawal, visual and auditory suppression
 tasks, 46:202

Computed tomography

alcohol intake, anxiety disorder, 48:135
 alcohol intake, benzodiazepines, 48:135
 alcohol intake, diazepam, 48:135
 alcohol intake, lorazepam, 48:135
 alcohol intake, ventricle-brain ratio, 48:135
 anxiety disorder, alcohol intake, 48:135
 anxiety disorder, benzodiazepines, 48:135
 anxiety disorder, diazepam, 48:135
 anxiety disorder, lorazepam, 48:135
 anxiety disorder, ventricle-brain ratio, 48:135
 benzodiazepines, alcohol intake, 48:135
 benzodiazepines, anxiety disorder, 48:135
 benzodiazepines, diazepam, 48:135
 benzodiazepines, lorazepam, 48:135
 benzodiazepines, ventricle-brain ratio, 48:135

Computed tomography continued
 diazepam, alcohol intake, 48:135
 diazepam, anxiety disorder, 48:135
 diazepam, benzodiazepines, 48:135
 diazepam, lorazepam, 48:135
 diazepam, ventricle-brain ratio, 48:135
 lorazepam, alcohol intake, 48:135
 lorazepam, anxiety disorder, 48:135
 lorazepam, benzodiazepines, 48:135
 lorazepam, diazepam, 48:135
 lorazepam, ventricle-brain ratio, 48:135
 ventricle-brain ratio, alcohol intake, 48:135
 ventricle-brain ratio, anxiety disorder, 48:135
 ventricle-brain ratio, benzodiazepines, 48:135
 ventricle-brain ratio, diazepam, 48:135
 ventricle-brain ratio, lorazepam, 48:135
Conduct disorder
 antisocial personality disorder, cortisol in saliva, 46:9
 antisocial personality disorder, genetics, 46:9
 antisocial personality disorder, substance abuse, 46:9
 cortisol in saliva, antisocial personality disorder, 46:9
 cortisol in saliva, substance abuse, 46:9
 genetics, antisocial personality disorder, 46:9
 genetics, substance abuse, 46:9
 substance abuse, antisocial personality disorder, 46:9
 substance abuse, cortisol in saliva, 46:9
 substance abuse, genetics, 46:9
Corticotropin releasing hormone
 cerebrospinal fluid, norepinephrine, 46:1
 cortisol, desipramine, 46:1
 cortisol, norepinephrine, 46:1
 desipramine, cortisol, 46:1
 desipramine, norepinephrine, 46:1
 norepinephrine, cerebrospinal fluid, 46:1
 norepinephrine, cortisol, 46:1
 norepinephrine, desipramine, 46:1
Cortisol
 adrenocorticotrophic hormone, affective disorder, 46:119
 adrenocorticotrophic hormone, arginine vasopressin, 46:119
 adrenocorticotrophic hormone, dexamethasone suppression test, 46:119
 affective disorder, adrenocorticotrophic hormone, 46:119
 affective disorder, antidepressant medication, 46:213
 affective disorder, arginine vasopressin, 46:119

Cortisol continued
 affective disorder, dexamethasone suppression test, 46:119, 47:7, 47:23, 47:163, 49:11
 affective disorder, dysthymic disorder, 47:7
 affective disorder, electrodermal activity, 47:23
 affective disorder, haptoglobin, 49:11
 affective disorder, hippocampus, 47:163
 affective disorder, immune function, 49:11
 affective disorder, interleukins, 49:11
 affective disorder, magnetic resonance imaging, 47:163
 affective disorder, prolactin, 46:213
 affective disorder, sleep deprivation, 46:213
 affective disorder, thyroid stimulating hormone, 46:213
 affective disorder, thyroid stimulating hormone, 47:7, 47:23
 affective disorder, thyroxine, 47:7, 47:23
 affective disorder, transferrin, 49:11
 affective disorder, triiodothyronine, 46:213, 47:7, 47:23
 antidepressant medication, affective disorder, 46:213
 antidepressant medication, prolactin, 46:213
 antidepressant medication, sleep deprivation, 46:213
 antidepressant medication, thyroid stimulating hormone, 46:213
 antidepressant medication, triiodothyronine, 46:213
 antisocial personality disorder, conduct disorder, 46:9
 antisocial personality disorder, genetics, 46:9
 antisocial personality disorder, substance abuse, 46:9
 anxiety disorder, fluvoxamine, 48:119
 anxiety disorder, 3-methoxy-4-hydroxyphenylglycol, 48:119
 anxiety disorder, norepinephrine, 48:119
 anxiety disorder, panic disorder, 48:119
 anxiety disorder, reuptake inhibitor, 48:119
 anxiety disorder, serotonin, 48:119
 anxiety disorder, yohimbine, 48:119
 arginine vasopressin, adrenocorticotrophic hormone, 46:119
 arginine vasopressin, affective disorder, 46:119
 arginine vasopressin, dexamethasone suppression test, 46:119
 cerebrospinal fluid, norepinephrine, 46:1
 conduct disorder, antisocial personality disorder, 46:9

Cortisol continued

conduct disorder, genetics, 46:9
 conduct disorder, substance abuse, 46:9
 corticotropin releasing factor, desipramine, 46:1
 corticotropin releasing factor, norepinephrine, 46:1
 desipramine, corticotropin releasing factor, 46:1
 desipramine, norepinephrine, 46:1
 dexamethasone suppression test, adrenocorticotrophic hormone, 46:119
 dexamethasone suppression test, affective disorder, 46:119, 47:23, 47:7, 47:163, 49:11
 dexamethasone suppression test, arginine vasopressin, 46:119
 dexamethasone suppression test, dysthymic disorder, 47:7
 dexamethasone suppression test, electrodermal activity, 47:23
 dexamethasone suppression test, haptoglobin, 49:11
 dexamethasone suppression test, hippocampus, 47:163
 dexamethasone suppression test, immune function, 49:11
 dexamethasone suppression test, interleukins, 49:11
 dexamethasone suppression test, magnetic resonance imaging, 47:163
 dexamethasone suppression test, thyroid stimulating hormone, 47:7, 47:23
 dexamethasone suppression test, thyroxine, 47:7, 47:23
 dexamethasone suppression test, transferrin, 49:11
 dexamethasone suppression test, triiodothyronine, 47:7, 47:23
 dysthymic disorder, affective disorder, 47:7
 dysthymic disorder, dexamethasone suppression test, 47:7
 dysthymic disorder, thyroid stimulating hormone, 47:7
 dysthymic disorder, thyroxine, 47:7
 dysthymic disorder, triiodothyronine, 47:7
 electrodermal activity, affective disorder, 47:23
 electrodermal activity, dexamethasone suppression test, 47:23
 electrodermal activity, thyroid stimulating hormone, 47:23
 electrodermal activity, thyroxine, 47:23

Cortisol continued

electrodermal activity, triiodothyronine, 47:23
 fluvoxamine, anxiety disorder, 48:119
 fluvoxamine, 3-methoxy-4-hydroxy-phenylglycol, 48:119
 fluvoxamine, norepinephrine, 48:119
 fluvoxamine, panic disorder, 48:119
 fluvoxamine, reuptake inhibitor, 48:119
 fluvoxamine, serotonin, 48:119
 fluvoxamine, yohimbine, 48:119
 genetics, antisocial personality disorder, 46:9
 genetics, conduct disorder, 46:9
 genetics, substance abuse, 46:9
 haptoglobin, affective disorder, 49:11
 haptoglobin, dexamethasone suppression test, 49:11
 haptoglobin, immune function, 49:11
 haptoglobin, interleukins, 49:11
 haptoglobin, transferrin, 49:11
 hippocampus, affective disorder, 47:163
 hippocampus, dexamethasone suppression test, 47:163
 hippocampus, magnetic resonance imaging, 47:163
 immune function, affective disorder, 49:11
 immune function, dexamethasone suppression test, 49:11
 immune function, haptoglobin, 49:11
 immune function, interleukins, 49:11
 immune function, transferrin, 49:11
 interleukins, affective disorder, 49:11
 interleukins, dexamethasone suppression test, 49:11
 interleukins, haptoglobin, 49:11
 interleukins, hypothalamic-pituitary-adrenal axis, 49:11
 interleukins, immune function, 49:11
 interleukins, transferrin, 49:11
 magnetic resonance imaging, affective disorder, 47:163
 magnetic resonance imaging, dexamethasone suppression test, 47:163
 magnetic resonance imaging, hippocampus, 47:163
 3-methoxy-4-hydroxyphenylglycol, anxiety disorder, 48:119
 3-methoxy-4-hydroxyphenylglycol, fluvoxamine, 48:119
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 48:119
 3-methoxy-4-hydroxyphenylglycol, panic disorder, 48:119

Cortisol continued

3-methoxy-4-hydroxyphenylglycol, reuptake inhibitor, 48:119
 3-methoxy-4-hydroxyphenylglycol, serotonin, 48:119
 3-methoxy-4-hydroxyphenylglycol, yohimbine, 48:119
 norepinephrine, anxiety disorder, 48:119
 norepinephrine, cerebrospinal fluid, 46:1
 norepinephrine, corticotropin releasing factor, 46:1
 norepinephrine, desipramine, 46:1
 norepinephrine, fluvoxamine, 48:119
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 48:119
 norepinephrine, panic disorder, 48:119
 norepinephrine, serotonin, 48:119
 norepinephrine, yohimbine, 48:119
 panic disorder, fluvoxamine, 48:119
 panic disorder, 3-methoxy-4-hydroxyphenylglycol, 48:119
 panic disorder, norepinephrine, 48:119
 panic disorder, reuptake inhibitor, 48:119
 panic disorder, serotonin, 48:119
 panic disorder, yohimbine, 48:119
 prolactin, affective disorder, 46:213
 prolactin, antidepressant medication, 46:213
 prolactin, sleep deprivation, 46:213
 prolactin, thyroid stimulating hormone, 46:213
 prolactin, triiodothyronine, 46:213
 reuptake inhibitor, anxiety disorder, 48:119
 reuptake inhibitor, fluvoxamine, 48:119
 reuptake inhibitor, norepinephrine, 48:119
 reuptake inhibitor, panic disorder, 48:119
 reuptake inhibitor, serotonin, 48:119
 reuptake inhibitor, yohimbine, 48:119
 serotonin, anxiety disorder, 48:119
 serotonin, fluvoxamine, 48:119
 serotonin, 3-methoxy-4-hydroxyphenylglycol, 48:119
 serotonin, norepinephrine, 48:119
 serotonin, panic disorder, 48:119
 serotonin, reuptake inhibitor, 48:119
 serotonin, yohimbine, 48:119
 sleep deprivation, affective disorder, 46:213
 sleep deprivation, antidepressant medication, 46:213
 sleep deprivation, prolactin, 46:213
 sleep deprivation, thyroid stimulating hormone, 46:213
 sleep deprivation, triiodothyronine, 46:213

Cortisol continued

substance abuse, antisocial personality disorder, 46:9
 substance abuse, conduct disorder, 46:9
 substance abuse, genetics, 46:9
 thyroid stimulating hormone, affective disorder, 46:213, 47:7, 47:23
 thyroid stimulating hormone, antidepressant medication, 46:213
 thyroid stimulating hormone, dexamethasone suppression test, 47:7, 47:23
 thyroid stimulating hormone, dysthymic disorder, 47:7
 thyroid stimulating hormone, electrodermal activity, 47:23
 thyroid stimulating hormone, prolactin, 46:213
 thyroid stimulating hormone, sleep deprivation, 46:213
 thyroid stimulating hormone, thyroxine, 47:7, 47:23
 thyroid stimulating hormone, triiodothyronine, 46:213, 47:7, 47:23
 thyroxine, affective disorder, 47:7, 47:23
 thyroxine, dexamethasone suppression test, 47:7, 47:23
 thyroxine, dysthymic disorder, 47:7
 thyroxine, electrodermal activity, 47:23
 thyroxine, thyroid stimulating hormone, 47:7, 47:23
 thyroxine, triiodothyronine, 47:7, 47:23
 transferrin, affective disorder, 49:11
 transferrin, dexamethasone suppression test, 49:11
 transferrin, haptoglobin, 49:11
 transferrin, immune function, 49:11
 transferrin, interleukins, 49:11
 triiodothyronine, affective disorder, 46:213, 47:7, 47:23
 triiodothyronine, antidepressant medication, 46:213
 triiodothyronine, dexamethasone suppression test, 47:7, 47:23
 triiodothyronine, dysthymic disorder, 47:7
 triiodothyronine, electrodermal activity, 47:23
 triiodothyronine, prolactin, 46:213
 triiodothyronine, sleep deprivation, 46:213
 triiodothyronine, thyroid stimulating hormone, 46:213, 47:7, 47:23
 triiodothyronine, thyroxine, 47:7, 47:23
 yohimbine, anxiety disorder, 48:119
 yohimbine, fluvoxamine, 48:119

Cortisol continued

yohimbine, 3-methoxy-4-hydroxyphenylglycol, 48:119
 yohimbine, norepinephrine, 48:119
 yohimbine, panic disorder, 48:119
 yohimbine, serotonin, 48:119
Dementia. See also Alzheimer's disease
 aging, agitation, 48:277
 aging, circadian rhythms, 48:277
 aging, circannual rhythms, 48:277
 aging, sleep, 48:277
 aging, sundowning, 48:277
 agitation, aging, 48:277
 agitation, circadian rhythms, 48:277
 agitation, circannual rhythms, 48:277
 agitation, sleep, 48:277
 agitation, sundowning, 48:277
 circadian rhythms, aging, 48:277
 circadian rhythms, agitation, 48:277
 circadian rhythms, sleep, 48:277
 circadian rhythms, sundowning, 48:277
 circannual rhythms, aging, 48:277
 circannual rhythms, agitation, 48:277
 circannual rhythms, sleep, 48:277
 circannual rhythms, sundowning, 48:277
 sleep, aging, 48:277
 sleep, agitation, 48:277
 sleep, circadian rhythms, 48:277
 sleep, circannual rhythms, 48:277
 sleep, sundowning, 48:277
 sundowning, aging, 48:277
 sundowning, agitation, 48:277
 sundowning, circadian rhythms, 48:277
 sundowning, circannual rhythms, 48:277
 sundowning, sleep, 48:277

Depression. See Affective disorder.**Desipramine**

blood pressure, normal subjects, 46:1
 corticotropin releasing factor, cortisol, 46:1
 corticotropin releasing factor, norepinephrine, 46:1
 cortisol, corticotropin releasing factor, 46:1
 cortisol, norepinephrine, 46:1
 heart rate, normal subjects, 46:1
 norepinephrine, corticotropin releasing factor, 46:1
 norepinephrine, cortisol, 46:1
 normal subjects, blood pressure, 46:1
 normal subjects, heart rate, 46:1
Dexamethasone suppression test. See Cortisol.

Diazepam

alcohol intake, anxiety disorder, 48:135
 alcohol intake, computed tomography, 48:135
 alcohol intake, ventricle-brain ratio, 48:135
 anxiety disorder, alcohol intake, 48:135
 anxiety disorder, computed tomography, 48:135
 anxiety disorder, panic disorder, 47:151
 anxiety disorder, personality, 47:151
 anxiety disorder, saccadic eye movement velocity, 47:151
 anxiety disorder, Tridimensional Personality Questionnaire, 47:151
 anxiety disorder, ventricle-brain ratio, 48:135
 computed tomography, alcohol intake, 48:135
 computed tomography, anxiety disorder, 48:135
 computed tomography, ventricle-brain ratio, 48:135
 eye movements, anxiety disorder, 47:151
 eye movements, panic disorder, 47:151
 eye movements, personality, 47:151
 eye movements, saccadic eye movement velocity, 47:151
 eye movements, Tridimensional Personality Questionnaire, 47:151
 lorazepam, alcohol intake, 48:135
 lorazepam, anxiety disorder, 48:135
 lorazepam, computed tomography, 48:135
 lorazepam, ventricle-brain ratio, 48:135
 panic disorder, personality, 47:151
 panic disorder, saccadic eye movement velocity, 47:151
 panic disorder, Tridimensional Personality Questionnaire, 47:151
 personality, anxiety disorder, 47:151
 personality, panic disorder, 47:151
 personality, saccadic eye movement velocity, 47:151
 personality, Tridimensional Personality Questionnaire, 47:151
 saccadic eye movement velocity, anxiety disorder, 47:151
 saccadic eye movement velocity, panic disorder, 47:151
 saccadic eye movement velocity, personality, 47:151
 saccadic eye movement velocity, Tridimensional Personality Questionnaire, 47:151
 Tridimensional Personality Questionnaire, anxiety disorder, 47:151
 Tridimensional Personality Questionnaire, panic disorder, 47:151

Diazepam continued
 Tridimensional Personality Questionnaire, personality, 47:151
 Tridimensional Personality Questionnaire, saccadic eye movement velocity, 47:151
 ventricle-brain ratio, alcohol intake, 48:135
 ventricle-brain ratio, anxiety disorder, 48:135
 ventricle-brain ratio, computed tomography, 48:135

Diet
 affective disorder, carbohydrate craving, 46:107
 affective disorder, circadian rhythms, 46:107
 affective disorder, eating sweets, 46:107
 affective disorder, phototherapy, 46:107
 affective disorder, seasonal depression, 46:107
 carbohydrate craving, affective disorder, 46:107
 carbohydrate craving, circadian rhythms, 46:107
 carbohydrate craving, eating sweets, 46:107
 carbohydrate craving, phototherapy, 46:107
 carbohydrate craving, seasonal depression, 46:107
 circadian rhythms, affective disorder, 46:107
 circadian rhythms, carbohydrate craving, 46:107
 circadian rhythms, eating sweets, 46:107
 circadian rhythms, phototherapy, 46:107
 circadian rhythms, seasonal depression, 46:107
 eating sweets, affective disorder, 46:107
 eating sweets, carbohydrate craving, 46:107
 eating sweets, circadian rhythms, 46:107
 eating sweets, phototherapy, 46:107
 eating sweets, seasonal depression, 46:107
 phototherapy, affective disorder, 46:107
 phototherapy, carbohydrate craving, 46:107
 phototherapy, circadian rhythms, 46:107
 phototherapy, eating sweets, 46:107
 phototherapy, seasonal depression, 46:107
 seasonal depression, carbohydrate craving, 46:107
 seasonal depression, circadian rhythms, 46:107
 seasonal depression, eating sweets, 46:107
 seasonal depression, phototherapy, 46:107

Dihydroxyphenylacetic acid
 Alzheimer's disease, cognitive impairment, 49:211
 Alzheimer's disease, dopamine, 49:211
 Alzheimer's disease, homovanillic acid, 49:211
 Alzheimer's disease, post-mortem study, 49:211

Dihydroxyphenylacetic acid continued
 Alzheimer's disease, psychiatric symptoms, 49:211
 cognitive impairment, Alzheimer's disease, 49:211
 cognitive impairment, dopamine, 49:211
 cognitive impairment, homovanillic acid, 49:211
 cognitive impairment, psychiatric symptoms, 49:211
 dopamine, Alzheimer's disease, 49:211
 dopamine, cognitive impairment, 49:211
 dopamine, homovanillic acid, 49:211
 dopamine, post-mortem study, 49:211
 dopamine, psychiatric symptoms, 49:211
 homovanillic acid, Alzheimer's disease, 49:211
 homovanillic acid, cognitive impairment, 49:211
 homovanillic acid, dopamine, 49:211
 homovanillic acid, post-mortem study, 49:211
 homovanillic acid, psychiatric symptoms, 49:211
 psychiatric symptoms, Alzheimer's disease, 49:211
 psychiatric symptoms, cognitive impairment, 49:211
 psychiatric symptoms, dopamine, 49:211
 psychiatric symptoms, homovanillic acid, 49:211

Diurnal rhythms. See *Circadian rhythms*.

Domperidone
 animal models, dysphoria, 47:37
 animal models, haloperidol, 47:37
 animal models, locomotor activity, 47:37
 animal models, neuroleptic-induced defecation in rats, 47:37
 dysphoria, animal models, 47:37
 dysphoria, haloperidol, 47:37
 dysphoria, locomotor activity, 47:37
 dysphoria, neuroleptic-induced defecation in rats, 47:37
 haloperidol, animal models, 47:37
 haloperidol, dysphoria, 47:37
 haloperidol, locomotor activity, 47:37
 haloperidol, neuroleptic-induced defecation in rats, 47:37
 locomotor activity, animal models, 47:37
 locomotor activity, dysphoria, 47:37
 locomotor activity, haloperidol, 47:37
 locomotor activity, neuroleptic-induced defecation in rats, 47:37
 neuroleptic-induced defecation in rats, animal models, 47:37
 neuroleptic-induced defecation in rats, dysphoria, 47:37
 neuroleptic-induced defecation in rats, haloperidol, 47:37

Domperidone continued

neuroleptic-induced defecation in rats, locomotor activity, 47:37
 neuroleptics, animal models, 47:37
 neuroleptics, defecation in rats, 47:37
 neuroleptics, dysphoria, 47:37
 neuroleptics, haloperidol, 47:37
 neuroleptics, locomotor activity, 47:37

Dopamine
 affective disorder, bipolar subtype, 46:253
 affective disorder, D_3 receptor protein, 46:253
 affective disorder, genetics, 46:253
 affective disorder, serine to glycine substitution on D_3 , 46:253
 age of onset, homovanillic acid, 48:93
 age of onset, positive and negative symptoms, 48:93
 age of onset, schizophrenia, 48:93
 aging, D_2 receptor density, 49:219
 aging, gender differences, 49:219
 aging, illness duration, 49:219
 aging, methylspiperone, 49:219
 aging, positron emission tomography, 49:219
 aging, schizophrenia, 49:219
 aging, striatum, 49:219
 Alzheimer's disease, cognitive impairment, 49:211
 Alzheimer's disease, dihydroxyphenylacetic acid, 49:211
 Alzheimer's disease, homovanillic acid, 49:211
 Alzheimer's disease, post-mortem study, 49:211
 Alzheimer's disease, psychiatric symptoms, 49:211
 amino acids, circadian rhythm, 47:187
 amino acids, neuroleptics, 47:187
 amino acids, neutral serum amino acids, 47:187
 amino acids, phenylalanine, 47:187
 amino acids, schizophrenia, 47:187
 amino acids, therapeutic response, 47:187
 bipolar subtype, affective disorder, 46:253
 bipolar subtype, dopamine D_3 receptor protein, 46:253
 bipolar subtype, genetics, 46:253
 bipolar subtype, serine to glycine substitution on D_3 , 46:253
 circadian rhythms, amino acids, 47:187
 circadian rhythms, haloperidol, 47:141
 circadian rhythms, homovanillic acid, 47:141

Dopamine continued

circadian rhythms, neuroleptics, 47:141, 47:187
 circadian rhythms, neutral serum amino acids, 47:187
 circadian rhythms, normal subjects, 47:141
 circadian rhythms, phenylalanine, 47:187
 circadian rhythms, schizophrenia, 47:187
 circadian rhythms, therapeutic response, 47:187
 clozapine, homovanillic acid, 46:139, 46:151
 clozapine, 3-methoxy-4-hydroxyphenylglycol, 46:139
 clozapine, norepinephrine, 46:139, 46:151
 clozapine, schizophrenia, 46:139, 46:151
 clozapine, therapeutic response, 46:139, 46:151
 cognitive impairment, Alzheimer's disease, 49:211
 cognitive impairment, dihydroxyphenylacetic acid, 49:211
 cognitive impairment, homovanillic acid, 49:211
 cognitive impairment, psychiatric symptoms, 49:211
 D_2 receptor density, aging, 49:219
 D_2 receptor density, gender differences, 49:219
 D_2 receptor density, illness duration, 49:219
 D_2 receptor density, positron emission tomography, 49:219
 D_2 receptor density, schizophrenia, 49:219
 D_2 receptor density, striatum, 49:219
 D_2 receptor gene linkage, Icelandic pedigrees, 46:69
 D_3 receptor gene linkage, schizophrenia, 46:69
 D_3 receptor protein, affective disorder, 46:253
 D_3 receptor protein, bipolar subtype, 46:253
 D_3 receptor protein, genetics, 46:253
 dihydroxyphenylacetic acid, Alzheimer's disease, 49:211
 dihydroxyphenylacetic acid, cognitive impairment, 49:211
 dihydroxyphenylacetic acid, homovanillic acid, 49:211
 dihydroxyphenylacetic acid, post-mortem study, 49:211
 dihydroxyphenylacetic acid, psychiatric symptoms, 49:211
 gender differences, aging, 49:219

Dopamine continued

gender differences, D_2 receptor density, 49:219
 gender differences, illness duration, 49:219
 gender differences, methylspiperone, 49:219
 gender differences, positron emission tomography, 49:219
 gender differences, schizophrenia, 49:219
 gender differences, striatum, 49:219
 genetics, affective disorder, 46:253
 genetics, bipolar subtype, 46:253
 genetics, D_3 receptor gene linkage, 46:69
 genetics, D_3 receptor protein, 46:253
 genetics, Icelandic pedigrees, 46:69
 genetics, linkage of D_3 receptor gene, 46:69
 genetics, schizophrenia, 46:69
 genetics, serine to glycine substitution on D_3 , 46:253
 haloperidol, circadian rhythms, 47:141
 haloperidol, homovanillic acid, 47:141
 haloperidol, normal subjects, 47:141
 homovanillic acid, age of onset, 48:93
 homovanillic acid, Alzheimer's disease, 49:211
 homovanillic acid, circadian rhythms, 47:141
 homovanillic acid, clozapine, 46:139, 46:151
 homovanillic acid, cognitive impairment, 49:211
 homovanillic acid, dihydroxyphenylacetic acid, 49:211
 homovanillic acid, haloperidol, 47:141
 homovanillic acid, 3-methoxy-4-hydroxy phenylglycol, 46:139
 homovanillic acid, norepinephrine, 46:139, 46:151
 homovanillic acid, normal subjects, 47:141
 homovanillic acid, positive and negative symptoms, 48:93
 homovanillic acid, post-mortem study, 49:211
 homovanillic acid, psychiatric symptoms, 49:211
 homovanillic acid, schizophrenia, 46:139, 46:151, 48:93
 homovanillic acid, therapeutic response, 46:139, 46:151
 illness duration, aging, 49:219
 illness duration, D_2 receptor density, 49:219
 illness duration, gender differences, 49:219
 illness duration, methylspiperone, 49:219
 illness duration, positron emission tomography, 49:219
 illness duration, schizophrenia, 49:219

Dopamine continued

illness duration, striatum, 49:219
 linkage of D_3 receptor gene, Icelandic pedigrees, 46:69
 linkage of D_3 receptor gene, schizophrenia, 46:69
 3-methoxy-4-hydroxyphenylglycol, clozapine, 46:139
 3-methoxy-4-hydroxyphenylglycol, homovanillic acid, 46:139
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 46:139
 3-methoxy-4-hydroxyphenylglycol, schizophrenia, 46:139
 3-methoxy-4-hydroxyphenylglycol, therapeutic response, 46:139
 methylspiperone, aging, 49:219
 methylspiperone, D_2 receptor density, 49:219
 methylspiperone, gender differences, 49:219
 methylspiperone, illness duration, 49:219
 methylspiperone, positron emission tomography, 49:219
 methylspiperone, schizophrenia, 49:219
 methylspiperone, striatum, 49:219
 neuroleptics, amino acids, 47:187
 neuroleptics, circadian rhythm, 47:187
 neuroleptics, neutral serum amino acids, 47:187
 neuroleptics, phenylalanine, 47:187
 neuroleptics, schizophrenia, 47:187
 neuroleptics, therapeutic response, 47:187
 neutral serum amino acids, circadian rhythms, 47:187
 neutral serum amino acids, neuroleptics, 47:187
 neutral serum amino acids, phenylalanine, 47:187
 neutral serum amino acids, schizophrenia, 47:187
 neutral serum amino acids, therapeutic response, 47:187
 norepinephrine, clozapine, 46:139, 46:151
 norepinephrine, homovanillic acid, 46:139, 46:151
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 46:139
 norepinephrine, schizophrenia, 46:139, 46:151
 norepinephrine, therapeutic response, 46:139, 46:151
 normal subjects, circadian rhythms, 47:141
 normal subjects, haloperidol, 47:141
 normal subjects, homovanillic acid, 47:141

Dopamine continued

phenylalanine, amino acids, 47:187
 phenylalanine, circadian rhythms, 47:187
 phenylalanine, neuroleptics, 47:187
 phenylalanine, neutral serum amino acids, 47:187
 phenylalanine, schizophrenia, 47:187
 phenylalanine, therapeutic response, 47:187
 positive and negative symptoms, age of onset, 48:93
 positive and negative symptoms, homovanillic acid, 48:93
 positive and negative symptoms, schizophrenia, 48:93
 positron emission tomography, aging, 49:219
 positron emission tomography, D_2 receptor density, 49:219
 positron emission tomography, gender differences, 49:219
 positron emission tomography, illness duration, 49:219
 positron emission tomography, methylspiperone, 49:219
 positron emission tomography, schizophrenia, 49:219
 positron emission tomography, striatum, 49:219
 post-mortem study, Alzheimer's disease, 49:211
 post-mortem study, cognitive impairment, 49:211
 post-mortem study, dihydroxyphenylacetic acid, 49:211
 post-mortem study, homovanillic acid, 49:211
 psychiatric symptoms, Alzheimer's disease, 49:211
 psychiatric symptoms, cognitive impairment, 49:211
 psychiatric symptoms, dihydroxyphenylacetic acid, 49:211
 psychiatric symptoms, homovanillic acid, 49:211
 schizophrenia, age of onset, 48:93
 schizophrenia, aging, 49:219
 schizophrenia, amino acids, 47:187
 schizophrenia, circadian rhythms, 47:187
 schizophrenia, clozapine, 46:139, 46:151
 schizophrenia, D_2 receptor density, 49:219
 schizophrenia, D_3 receptor gene linkage, 46:69
 schizophrenia, gender differences, 49:219
 schizophrenia, genetics, 46:69

Dopamine continued

schizophrenia, homovanillic acid, 46:139, 46:151, 48:93
 schizophrenia, Icelandic pedigrees, 46:69
 schizophrenia, illness duration, 49:219
 schizophrenia, linkage of D_3 receptor gene, 46:69
 schizophrenia, 3-methoxy-4-hydroxyphenylglycol, 46:139
 schizophrenia, methylspiperone, 49:219
 schizophrenia, neuroleptics, 47:187
 schizophrenia, neutral serum amino acids, 47:187
 schizophrenia, norepinephrine, 46:139, 46:151
 schizophrenia, phenylalanine, 47:187
 schizophrenia, positive and negative symptoms, 48:93
 schizophrenia, positron emission tomography, 49:219
 schizophrenia, striatum, 49:219
 schizophrenia, therapeutic response, 46:139, 46:151, 47:187
 serine to glycine substitution on D_3 , affective disorder, 46:253
 serine to glycine substitution on D_3 , bipolar subtype, 46:253
 serine to glycine substitution on D_3 , genetics, 46:253
 striatum, aging, 49:219
 striatum, D_2 receptor density, 49:219
 striatum, gender differences, 49:219
 striatum, illness duration, 49:219
 striatum, methylspiperone, 49:219
 striatum, positron emission tomography, 49:219
 striatum, schizophrenia, 49:219
 therapeutic response, amino acids, 47:187
 therapeutic response, circadian rhythms, 47:187
 therapeutic response, clozapine, 46:139, 46:151
 therapeutic response, homovanillic acid, 46:139, 46:151
 therapeutic response, 3-methoxy-4-hydroxyphenylglycol, 46:139
 therapeutic response, neuroleptics, 47:187
 therapeutic response, neutral serum amino acids, 47:187
 therapeutic response, norepinephrine, 46:139, 46:151
 therapeutic response, phenylalanine, 47:187
 therapeutic response, schizophrenia, 46:139, 46:151, 47:187

Dopamine-beta-hydroxylase

- autism, c-Harvey-Ras-1 marker, 46:261
- autism, genetics, 46:261
- autism, restriction fragment length polymorphism, 46:261
- autism, tryptophan hydroxylase, 46:261
- autism, tyrosine hydroxylase, 46:261
- c-Harvey-Ras-1 marker, autism, 46:261
- c-Harvey-Ras-1 marker, genetics, 46:261
- c-Harvey-Ras-1 marker, restriction fragment length polymorphism, 46:261
- c-Harvey-Ras-1 marker, tryptophan hydroxylase, 46:261
- c-Harvey-Ras-1 marker, tyrosine hydroxylase, 46:261
- genetics, autism, 46:261
- genetics, c-Harvey-Ras-1 marker, 46:261
- genetics, restriction fragment length polymorphism, 46:261
- genetics, tryptophan hydroxylase, 46:261
- genetics, tyrosine hydroxylase, 46:261
- restriction fragment length polymorphism, autism, 46:261
- restriction fragment length polymorphism, c-Harvey-Ras-1 marker, 46:261
- restriction fragment length polymorphism, genetics, 46:261
- restriction fragment length polymorphism, tryptophan hydroxylase, 46:261
- restriction fragment length polymorphism, tyrosine hydroxylase, 46:261
- tryptophan hydroxylase, autism, 46:261
- tryptophan hydroxylase, c-Harvey-Ras-1 marker, 46:261
- tryptophan hydroxylase, genetics, 46:261
- tryptophan hydroxylase, restriction fragment length polymorphism, 46:261
- tryptophan hydroxylase, tyrosine hydroxylase, 46:261
- tyrosine hydroxylase, autism, 46:261
- tyrosine hydroxylase, c-Harvey-Ras-1 marker, 46:261
- tyrosine hydroxylase, genetics, 46:261
- tyrosine hydroxylase, restriction fragment length polymorphism, 46:261
- tyrosine hydroxylase, tryptophan hydroxylase, 46:261

Drug abuse. See Cocaine**Eating disorders**

- bulimia nervosa, migraine, 46:201
- bulimia, novelty seeking, 48:9
- bulimia, serotonin, 48:9

Eating disorders continued

- bulimia, Tridimensional Personality Questionnaire, 48:9
- bulimia, whole blood serotonin levels, 48:9
- dissociative phenomena, endorphins, 49:1
- dissociative phenomena, homovanillic acid, 49:1
- dissociative phenomena, 5-hydroxyindoleacetic acid, 49:1
- dissociative phenomena, 3-methoxy-4-hydroxyphenylglycol, 49:1
- endorphins, cerebrospinal fluid, 49:1
- endorphins, dissociative phenomena, 49:1
- endorphins, homovanillic acid, 49:1
- endorphins, 5-hydroxyindoleacetic acid, 49:1
- endorphins, 3-methoxy-4-hydroxyphenylglycol, 49:1
- homovanillic acid, cerebrospinal fluid, 49:1
- homovanillic acid, dissociative phenomena, 49:1
- homovanillic acid, endorphins, 49:1
- homovanillic acid, 5-hydroxyindoleacetic acid, 49:1
- homovanillic acid, 3-methoxy-4-hydroxyphenylglycol, 49:1
- 5-hydroxyindoleacetic acid, cerebrospinal fluid, 49:1
- 5-hydroxyindoleacetic acid, dissociative phenomena, 49:1
- 5-hydroxyindoleacetic acid, endorphins, 49:1
- 5-hydroxyindoleacetic acid, homovanillic acid, 49:1
- 5-hydroxyindoleacetic acid, 3-methoxy-4-hydroxyphenylglycol, 49:1
- 3-methoxy-4-hydroxyphenylglycol, cerebrospinal fluid, 49:1
- 3-methoxy-4-hydroxyphenylglycol, dissociative phenomena, 49:1
- 3-methoxy-4-hydroxyphenylglycol, endorphins, 49:1
- 3-methoxy-4-hydroxyphenylglycol, homovanillic acid, 49:1
- 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, 49:1
- migraine, bulimia nervosa, 46:201
- novelty seeking, bulimia, 48:9
- novelty seeking, serotonin, 48:9
- novelty seeking, Tridimensional Personality Questionnaire, 48:9
- serotonin, bulimia, 48:9
- serotonin, novelty seeking, 48:9

Eating disorders continued

serotonin, Tridimensional Personality Questionnaire, 48:9
 serotonin, whole blood levels, 48:9
 Tridimensional Personality Questionnaire, bulimia, 48:9
 Tridimensional Personality Questionnaire, novelty seeking, 48:9
 Tridimensional Personality Questionnaire, serotonin, 48:9

Electrodermal activity

affective disorder, cortisol, 47:23
 affective disorder, dexamethasone suppression test, 47:23
 affective disorder, thyroid stimulating hormone, 47:23
 affective disorder, thyroxine, 47:23
 affective disorder, triiodothyronine, 47:23
 arginine vasopressin, electromyography, 48:107
 arginine vasopressin, heart rate response, 48:107
 arginine vasopressin, oxytocin, 48:107
 arginine vasopressin, personal combat imagery, 48:107
 arginine vasopressin, posttraumatic stress syndrome, 48:107
 cortisol, affective disorder, 47:23
 cortisol, dexamethasone suppression test, 47:23
 cortisol, thyroid stimulating hormone, 47:23
 cortisol, thyroxine, 47:23
 cortisol, triiodothyronine, 47:23
 dexamethasone suppression test, affective disorder, 47:23
 dexamethasone suppression test, cortisol, 47:23
 dexamethasone suppression test, thyroid stimulating hormone, 47:23
 dexamethasone suppression test, thyroxine, 47:23
 dexamethasone suppression test, triiodothyronine, 47:23
 electromyography, arginine vasopressin, 48:107
 electromyography, heart rate response, 48:107
 electromyography, oxytocin, 48:107
 electromyography, personal combat imagery, 48:107
 electromyography, posttraumatic stress syndrome, 48:107

Electrodermal activity continued

heart rate response, arginine vasopressin, 48:107
 heart rate response, electromyography, 48:107
 heart rate response, oxytocin, 48:107
 heart rate response, personal combat imagery, 48:107
 heart rate response, posttraumatic stress syndrome, 48:107
 oxytocin, arginine vasopressin, 48:107
 oxytocin, electromyography, 48:107
 oxytocin, heart rate response, 48:107
 oxytocin, personal combat imagery, 48:107
 oxytocin, posttraumatic stress syndrome, 48:107
 personal combat imagery, arginine vasopressin, 48:107
 personal combat imagery, electromyography, 48:107
 personal combat imagery, heart rate response, 48:107
 personal combat imagery, oxytocin, 48:107
 personal combat imagery, posttraumatic stress syndrome, 48:107
 posttraumatic stress syndrome, arginine vasopressin, 48:107
 posttraumatic stress syndrome, electromyography, 48:107
 posttraumatic stress syndrome, heart rate response, 48:107
 posttraumatic stress syndrome, oxytocin, 48:107
 posttraumatic stress syndrome, personal combat imagery, 48:107
 posttraumatic stress syndrome, Vietnam veterans, 48:107
 thyroid stimulating hormone, affective disorder, 47:23
 thyroid stimulating hormone, cortisol, 47:23
 thyroid stimulating hormone, dexamethasone suppression test, 47:23
 thyroid stimulating hormone, thyroxine, 47:23
 thyroid stimulating hormone, triiodothyronine, 47:23
 thyroxine, affective disorder, 47:23
 thyroxine, cortisol, 47:23
 thyroxine, dexamethasone suppression test, 47:23
 thyroxine, thyroid stimulating hormone, 47:23
 thyroxine, triiodothyronine, 47:23

Electrodermal activity continued
 triiodothyronine, affective disorder, 47:23
 triiodothyronine, cortisol, 47:23
 triiodothyronine, dexamethasone suppression test, 47:23
 triiodothyronine, thyroxine, 47:23
Electroencephalography. See Event related potentials
Electromyography
 arginine vasopressin, electrodermal response, 48:107
 arginine vasopressin, heart rate response, 48:107
 arginine vasopressin, oxytocin, 48:107
 arginine vasopressin, personal combat imagery, 48:107
 arginine vasopressin, posttraumatic stress syndrome, 48:107
 electrodermal response, arginine vasopressin, 48:107
 electrodermal response, heart rate response, 48:107
 electrodermal response, oxytocin, 48:107
 electrodermal response, personal combat imagery, 48:107
 electrodermal response, posttraumatic stress syndrome, 48:107
 heart rate response, arginine vasopressin, 48:107
 heart rate response, electrodermal response, 48:107
 heart rate response, oxytocin, 48:107
 heart rate response, personal combat imagery, 48:107
 heart rate response, posttraumatic stress syndrome, 48:107
 oxytocin, arginine vasopressin, 48:107
 oxytocin, electrodermal response, 48:107
 oxytocin, heart rate response, 48:107
 oxytocin, personal combat imagery, 48:107
 oxytocin, posttraumatic stress syndrome, 48:107
 personal combat imagery, arginine vasopressin, 48:107
 personal combat imagery, electrodermal response, 48:107
 personal combat imagery, heart rate response, 48:107
 personal combat imagery, oxytocin, 48:107
 personal combat imagery, posttraumatic stress syndrome, 48:107

Electromyography continued
 posttraumatic stress syndrome, arginine vasopressin, 48:107
 posttraumatic stress syndrome, electrodermal response, 48:107
 posttraumatic stress syndrome, heart rate response, 48:107
 posttraumatic stress syndrome, oxytocin, 48:107
 posttraumatic stress syndrome, personal combat imagery, 48:107
 posttraumatic stress syndrome, Vietnam veterans, 48:107
Electrooculography. See also Eye movements
 affective disorder, phototherapy, 49:99
 affective disorder, seasonal depression, 49:99
 phototherapy, affective disorder, 49:99
 phototherapy, seasonal depression, 49:99
 seasonal depression, phototherapy, 49:99
Endorphins
 dissociative phenomena, eating disorder, 49:1
 dissociative phenomena, homovanillic acid, 49:1
 dissociative phenomena, 5-hydroxyindoleacetic acid, 49:1
 dissociative phenomena, 3-methoxy-4-hydroxyphenylglycol, 49:1
 eating disorder, dissociative phenomena, 49:1
 eating disorder, homovanillic acid, 49:1
 eating disorder, 5-hydroxyindoleacetic acid, 49:1
 eating disorder, 3-methoxy-4-hydroxyphenylglycol, 49:1
 homovanillic acid, cerebrospinal fluid, 49:1
 homovanillic acid, dissociative phenomena, 49:1
 homovanillic acid, eating disorder, 49:1
 homovanillic acid, 5-hydroxyindoleacetic acid, 49:1
 homovanillic acid, 3-methoxy-4-hydroxyphenylglycol, 49:1
 5-hydroxyindoleacetic acid, cerebrospinal fluid, 49:1
 5-hydroxyindoleacetic acid, dissociative phenomena, 49:1
 5-hydroxyindoleacetic acid, eating disorder, 49:1
 5-hydroxyindoleacetic acid, homovanillic acid, 49:1
 5-hydroxyindoleacetic acid, 3-methoxy-4-hydroxyphenylglycol, 49:1
 3-methoxy-4-hydroxyphenylglycol, cerebrospinal fluid, 49:1

Endorphins continued

- 3-methoxy-4-hydroxyphenylglycol, dissociative phenomena, 49:1
- 3-methoxy-4-hydroxyphenylglycol, eating disorder, 49:1
- 3-methoxy-4-hydroxyphenylglycol, homovanillic acid, 49:1
- 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, 49:1

Epidemiology

- admixture analysis, hebephrenic subtype, 49:199
- admixture analysis, paranoid subtype, 49:199
- admixture analysis, schizophrenia, 49:199
- affective disorder, American Indians, 47:255
- affective disorder, Center for Epidemiologic Studies Depression Scale, 47:255
- affective disorder, cross-cultural assessment, 47:255
- affective disorder, diagnosis, 47:255
- American Indians, affective disorder, 47:255
- American Indians, Center for Epidemiologic Studies Depression Scale, 47:255
- American Indians, cross-cultural assessment, 47:255
- American Indians, diagnosis, 47:255
- cancer patients, caregivers of chronically ill, 49:239
- cancer patients, Center for Epidemiologic Studies Depression Scale, 49:239
- cancer patients, depressed mood, 49:239
- cancer patients, gender differences, 49:239
- caregivers of chronically ill, cancer patients, 49:239
- caregivers of chronically ill, Center for Epidemiologic Studies Depression Scale, 49:239
- caregivers of chronically ill, depressed mood, 49:239
- caregivers of chronically ill, gender differences, 49:239
- Center for Epidemiologic Studies Depression Scale, American Indians, 47:255
- Center for Epidemiologic Studies Depression Scale, cancer patients, 49:239
- Center for Epidemiologic Studies Depression Scale, caregivers of chronically ill, 49:239
- Center for Epidemiologic Studies Depression Scale, cross-cultural assessment, 47:255
- Center for Epidemiologic Studies Depression Scale, diagnosis, 47:255
- Center for Epidemiologic Studies Depression Scale, gender differences, 49:239
- Epidemiology** continued
- cross-cultural assessment, affective disorder, 47:255
- cross-cultural assessment, American Indians, 47:255
- cross-cultural assessment, Center for Epidemiologic Studies Depression Scale, 47:255
- cross-cultural assessment, diagnosis, 47:255
- depressed mood, cancer patients, 49:239
- depressed mood, caregivers of chronically ill, 49:239
- depressed mood, gender differences, 49:239
- diagnosis, affective disorder, 47:255
- diagnosis, American Indians, 47:255
- diagnosis, Center for Epidemiologic Studies Depression Scale, 47:255
- diagnosis, cross-cultural assessment, 47:255
- gender differences, cancer patients, 49:239
- gender differences, caregivers of chronically ill, 49:239
- gender differences, Center for Epidemiologic Studies Depression Scale, 49:239
- gender differences, depressed mood, 49:239
- hebephrenic subtype, admixture analysis, 49:199
- hebephrenic subtype, paranoid subtype, 49:199
- hebephrenic subtype, schizophrenia, 49:199
- paranoid subtype, admixture analysis, 49:199
- paranoid subtype, hebephrenic subtype, 49:199
- paranoid subtype, schizophrenia, 49:199
- schizophrenia, admixture analysis, 49:199
- schizophrenia, hebephrenic subtype, 49:199
- schizophrenia, paranoid subtype, 49:199

Erythrocytes

- Alzheimer's disease, lipids, 46:203
- lipids, Alzheimer's disease, 46:203
- membrane phospholipids, phosphatidyl-ethanolamine, 49:89
- membrane phospholipids, schizophrenia, 49:89
- membrane phospholipids, sphingomyelin, 49:89
- phosphatidylethanolamine, membrane phospholipids, 49:89
- phosphatidylethanolamine, schizophrenia, 49:89
- phosphatidylethanolamine, sphingomyelin, 49:89
- schizophrenia, membrane phospholipids, 49:89
- schizophrenia, phosphatidylethanolamine, 49:89
- schizophrenia, sphingomyelin, 49:89

Erythrocytes continued

 sphingomyelin, membrane phospholipids, 49:89
 sphingomyelin, phosphatidylethanolamine, 49:89
 sphingomyelin, schizophrenia, 49:89

Estradiol

 follicle stimulating hormone, growth hormone, 48:153
 follicle stimulating hormone, luteinizing hormone, 48:153
 follicle stimulating hormone, normal volunteers, 48:153
 follicle stimulating hormone, prolactin, 48:153
 follicle stimulating hormone, sleep deprivation, 48:153
 follicle stimulating hormone, thyroid stimulating hormone, 48:153
 follicle stimulating hormone, thyroxine, 48:153
 follicle stimulating hormone, triiodothyronine, 48:153
 growth hormone, follicle stimulating hormone, 48:153
 growth hormone, luteinizing hormone, 48:153
 growth hormone, normal volunteers, 48:153
 growth hormone, prolactin, 48:153
 growth hormone, sleep deprivation, 48:153
 growth hormone, thyroid stimulating hormone, 48:153
 growth hormone, thyroxine, 48:153
 growth hormone, triiodothyronine, 48:153
 luteinizing hormone, follicle stimulating hormone, 48:153
 luteinizing hormone, growth hormone, 48:153
 luteinizing hormone, normal volunteers, 48:153
 luteinizing hormone, prolactin, 48:153
 luteinizing hormone, sleep deprivation, 48:153
 luteinizing hormone, thyroid stimulating hormone, 48:153
 luteinizing hormone, thyroxine, 48:153
 luteinizing hormone, triiodothyronine, 48:153
 normal volunteers, follicle stimulating hormone, 48:153
 normal volunteers, growth hormone, 48:153
 normal volunteers, luteinizing hormone, 48:153

Estradiol continued

 normal volunteers, prolactin, 48:153
 normal volunteers, sleep deprivation, 48:153
 normal volunteers, thyroid stimulating hormone, 48:153
 normal volunteers, thyroxine, 48:153
 normal volunteers, triiodothyronine, 48:153
 prolactin, follicle stimulating hormone, 48:153
 prolactin, growth hormone, 48:153
 prolactin, luteinizing hormone, 48:153
 prolactin, normal volunteers, 48:153
 prolactin, sleep deprivation, 48:153
 prolactin, thyroid stimulating hormone, 48:153
 prolactin, thyroxine, 48:153
 prolactin, triiodothyronine, 48:153
 sleep deprivation, follicle stimulating hormone, 48:153
 sleep deprivation, growth hormone, 48:153
 sleep deprivation, luteinizing hormone, 48:153
 sleep deprivation, normal volunteers, 48:153
 sleep deprivation, prolactin, 48:153
 sleep deprivation, thyroid stimulating hormone, 48:153
 sleep deprivation, thyroxine, 48:153
 sleep deprivation, triiodothyronine, 48:153
 thyroid stimulating hormone, follicle stimulating hormone, 48:153
 thyroid stimulating hormone, growth hormone, 48:153
 thyroid stimulating hormone, luteinizing hormone, 48:153
 thyroid stimulating hormone, normal volunteers, 48:153
 thyroid stimulating hormone, prolactin, 48:153
 thyroid stimulating hormone, sleep deprivation, 48:153
 thyroid stimulating hormone, thyroxine, 48:153
 thyroid stimulating hormone, triiodothyronine, 48:153
 thyroxine, follicle stimulating hormone, 48:153
 thyroxine, growth hormone, 48:153
 thyroxine, luteinizing hormone, 48:153
 thyroxine, normal volunteers, 48:153
 thyroxine, prolactin, 48:153
 thyroxine, sleep deprivation, 48:153
 thyroxine, thyroid stimulating hormone, 48:153

Estradiol continued

thyroxine, triiodothyronine, 48:153
 triiodothyronine, follicle stimulating hormone, 48:153
 triiodothyronine, growth hormone, 48:153
 triiodothyronine, luteinizing hormone, 48:153
 triiodothyronine, normal volunteers, 48:153
 triiodothyronine, prolactin, 48:153
 triiodothyronine, sleep deprivation, 48:153
 triiodothyronine, thyroid stimulating hormone, 48:153
 triiodothyronine, thyroxine, 48:153

Event related potentials

anxiety disorder, auditory N200, 49:167
 anxiety disorder, laterality, 49:167
 anxiety disorder, neurological soft signs, 49:167
 anxiety disorder, obsessive-compulsive disorder, 49:167
 anxiety disorder, P3 component, 49:167
 auditory evoked potential P3, cortical atrophy, 47:175
 auditory evoked potential P3, human immunodeficiency virus, 47:175
 auditory evoked potential P3, magnetic resonance imaging, 47:175
 auditory evoked potential P3, neuro-psychology, 47:175
 auditory evoked potential P3, substance abuse, 47:175
 auditory N200, anxiety disorder, 49:167
 auditory N200, laterality, 49:167
 auditory N200, neurological soft signs, 49:167
 auditory N200, obsessive-compulsive disorder, 49:167
 auditory N200, P3 component, 49:167
 auditory P50 component, cocaine, 47:243
 auditory P50 component, paranoid subtype, 47:243
 auditory P50 component, schizophrenia, 47:243
 auditory P50 component, substance abuse, 47:243
 auditory sensory gating, P50 component, 49:29
 auditory sensory gating, schizophrenia, 49:29
 auditory sensory gating, sleep, 49:29
 cocaine, auditory P50 component, 47:243
 cocaine, paranoid subtype, 47:243
 cocaine, schizophrenia, 47:243
 cortical atrophy, auditory evoked potential P3, 47:175

Event related potentials continued

cortical atrophy, human immunodeficiency virus, 47:175
 cortical atrophy, magnetic resonance imaging, 47:175
 cortical atrophy, neuropsychology, 47:175
 cortical atrophy, substance abuse, 47:175
 human immunodeficiency virus, auditory evoked potential P3, 47:175
 human immunodeficiency virus, cortical atrophy, 47:175
 human immunodeficiency virus, magnetic resonance imaging, 47:175
 human immunodeficiency virus, neuropsychology, 47:175
 human immunodeficiency virus, substance abuse, 47:175
 laterality, anxiety disorder, 49:167
 laterality, auditory N200, 49:167
 laterality, neurological soft signs, 49:167
 laterality, obsessive-compulsive disorder, 49:167
 laterality, P3 component, 49:167
 magnetic resonance imaging, auditory evoked potential P3, 47:175
 magnetic resonance imaging, cortical atrophy, 47:175
 magnetic resonance imaging, human immunodeficiency virus, 47:175
 magnetic resonance imaging, neuropsychology, 47:175
 magnetic resonance imaging, substance abuse, 47:175
 neurological soft signs, anxiety disorder, 49:167
 neurological soft signs, auditory N200, 49:167
 neurological soft signs, laterality, 49:167
 neurological soft signs, obsessive-compulsive disorder, 49:167
 neurological soft signs, P3 component, 49:167
 neuropsychology, auditory evoked potential P3, 47:175
 neuropsychology, cortical atrophy, 47:175
 neuropsychology, human immunodeficiency virus, 47:175
 neuropsychology, magnetic resonance imaging, 47:175
 neuropsychology, substance abuse, 47:175
 obsessive-compulsive disorder, anxiety disorder, 49:167

Event related potentials continued
 obsessive-compulsive disorder, auditory N200, 49:167
 obsessive-compulsive disorder, laterality, 49:167
 obsessive-compulsive disorder, neurological soft signs, 49:167
 obsessive-compulsive disorder, P3 component, 49:167
 P3 component, anxiety disorder, 49:167
 P3 component, auditory N200, 49:167
 P3 component, laterality, 49:167
 P3 component, neurological soft signs, 49:167
 P3 component, obsessive-compulsive disorder, 49:167
 P50 component, auditory sensory gating, 49:29
 P50 component, schizophrenia, 49:29
 P50 component, sleep, 49:29
 paranoid subtype, auditory P50 component, 47:243
 paranoid subtype, cocaine, 47:243
 paranoid subtype, schizophrenia, 47:243
 paranoid subtype, substance abuse, 47:243
 schizophrenia, auditory P50 component, 47:243
 schizophrenia, auditory sensory gating, 49:29
 schizophrenia, cocaine, 47:243
 schizophrenia, P50 component, 49:29
 schizophrenia, paranoid subtype, 47:243
 schizophrenia, sleep, 49:29
 schizophrenia, substance abuse, 47:243
 sleep, auditory sensory gating, 49:29
 sleep, P50 component, 49:29
 sleep, schizophrenia, 49:29
 substance abuse, auditory evoked potential P3, 47:175
 substance abuse, auditory P50 component, 47:243
 substance abuse, cocaine, 47:243
 substance abuse, cortical atrophy, 47:175
 substance abuse, human immunodeficiency virus, 47:175
 substance abuse, magnetic resonance imaging, 47:175
 substance abuse, neuropsychology, 47:175
 substance abuse, paranoid subtype, 47:243
 substance abuse, schizophrenia, 47:243
Eye blinks
 affective disorder, circannual rhythms, 47:79

Eye blinks continued
 affective disorder, gender differences, 47:79
 affective disorder, phototherapy, 47:79
 affective disorder, seasonal depression, 47:79
 circannual rhythms, affective disorder, 47:79
 circannual rhythms, gender differences, 47:79
 circannual rhythms, phototherapy, 47:79
 circannual rhythms, seasonal depression, 47:79
 gender differences, affective disorder, 47:79
 gender differences, circannual rhythms, 47:79
 gender differences, phototherapy, 47:79
 gender differences, seasonal depression, 47:79
 phototherapy, affective disorder, 47:79
 phototherapy, circannual rhythms, 47:79
 phototherapy, gender differences, 47:79
 phototherapy, seasonal depression, 47:79
 seasonal depression, circannual rhythms, 47:79
 seasonal depression, gender differences, 47:79
 seasonal depression, phototherapy, 47:79
Eye movements. See also *Electrooculography*
 anxiety disorder, diazepam response, 47:151
 anxiety disorder, panic disorder, 47:151
 anxiety disorder, personality, 47:151
 anxiety disorder, saccadic eye movement velocity, 47:151
 anxiety disorder, Tridimensional Personality Questionnaire, 47:151
 diazepam response, anxiety disorder, 47:151
 diazepam response, panic disorder, 47:151
 diazepam response, personality, 47:151
 diazepam response, saccadic eye movement velocity, 47:151
 diazepam response, Tridimensional Personality Questionnaire, 47:151
 frontal lobe, neuropsychology, 48:191
 frontal lobe, obsessive-compulsive disorder, 48:191
 frontal lobe, saccadic, 48:191
 frontal lobe, smooth pursuit, 48:191
 frontal lobe, Wisconsin Card Sorting Test, 48:191
 neuropsychology, frontal lobe, 48:191
 neuropsychology, obsessive-compulsive disorder, 48:191
 neuropsychology, saccadic, 48:191
 neuropsychology, smooth pursuit, 48:191
 neuropsychology, Wisconsin Card Sorting Test, 48:191

Eye movements continued
 obsessive-compulsive disorder, frontal lobe, 48:191
 obsessive-compulsive disorder, neuropsychology, 48:191
 obsessive-compulsive disorder, saccadic, 48:191
 obsessive-compulsive disorder, smooth pursuit, 48:191
 obsessive-compulsive disorder, Wisconsin Card Sorting Test, 48:191
 panic disorder, anxiety disorder, 47:151
 panic disorder, diazepam response, 47:151
 panic disorder, personality, 47:151
 panic disorder, saccadic eye movement velocity, 47:151
 panic disorder, Tridimensional Personality Questionnaire, 47:151
 personality, anxiety disorder, 47:151
 personality, diazepam response, 47:151
 personality, panic disorder, 47:151
 personality, saccadic eye movement velocity, 47:151
 personality, Tridimensional Personality Questionnaire, 47:151
 saccadic eye movement velocity, anxiety disorder, 47:151
 saccadic eye movement velocity, diazepam response, 47:151
 saccadic eye movement velocity, panic disorder, 47:151
 saccadic eye movement velocity, personality, 47:151
 saccadic eye movement velocity, Tridimensional Personality Questionnaire, 47:151
 saccadic, frontal lobe, 48:191
 saccadic, neuropsychology, 48:191
 saccadic, obsessive-compulsive disorder, 48:191
 saccadic, smooth pursuit, 48:191
 saccadic, Wisconsin Card Sorting Test, 48:191
 smooth pursuit, frontal lobe, 48:191
 smooth pursuit, neuropsychology, 48:191
 smooth pursuit, obsessive-compulsive disorder, 48:191
 smooth pursuit, saccadic, 48:191
 smooth pursuit, Wisconsin Card Sorting Test, 48:191
 Tridimensional Personality Questionnaire, anxiety disorder, 47:151
 Tridimensional Personality Questionnaire, diazepam response, 47:151
Eye movements continued
 Tridimensional Personality Questionnaire, panic disorder, 47:151
 Tridimensional Personality Questionnaire, personality, 47:151
 Tridimensional Personality Questionnaire, saccadic eye movement velocity, 47:151
 Wisconsin Card Sorting Test, frontal lobe, 48:191
 Wisconsin Card Sorting Test, neuropsychology, 48:191
 Wisconsin Card Sorting Test, obsessive-compulsive disorder, 48:191
 Wisconsin Card Sorting Test, saccadic, 48:191
 Wisconsin Card Sorting Test, smooth pursuit, 48:191
Fatigue
 sleep disorders, visual analogue scale, 46:207
 visual analogue scale, sleep disorders, 46:207
Fluoxetine
 affective disorder, sleep deprivation, 46:213
 sleep deprivation, affective disorder, 46:213
Fluvoxamine
 anxiety disorder, cortisol, 48:119
 anxiety disorder, 3-methoxy-4-hydroxyphenylglycol, 48:119
 anxiety disorder, norepinephrine, 48:119
 anxiety disorder, panic, 48:119
 anxiety disorder, serotonin, 48:119
 anxiety disorder, yohimbine, 48:119
 behavior therapy, exposure, 49:63
 behavior therapy, obsessive-compulsive disorder, 49:63
 blood pressure, heart rate, 48:119
 blood pressure, panic disorder, 48:119
 blood pressure, yohimbine, 48:119
 cortisol, anxiety disorder, 48:119
 cortisol, 3-methoxy-4-hydroxyphenylglycol, 48:119
 cortisol, norepinephrine, 48:119
 cortisol, panic disorder, 48:119
 cortisol, serotonin, 48:119
 cortisol, yohimbine, 48:119
 exposure therapy, obsessive-compulsive disorder, 49:63
 heart rate, blood pressure, 48:119
 heart rate, panic disorder, 48:119
 heart rate, yohimbine, 48:119
 3-methoxy-4-hydroxyphenylglycol, anxiety disorder, 48:119

Fluvoxamine continued

3-methoxy-4-hydroxyphenylglycol, cortisol, 48:119
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 48:119
 3-methoxy-4-hydroxyphenylglycol, panic disorder, 48:119
 3-methoxy-4-hydroxyphenylglycol, serotonin, 48:119
 3-methoxy-4-hydroxyphenylglycol, yohimbine, 48:119
 norepinephrine, anxiety disorder, 48:119
 norepinephrine, cortisol, 48:119
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 48:119
 norepinephrine, panic disorder, 48:119
 norepinephrine, serotonin, 48:119
 norepinephrine, yohimbine, 48:119
 obsessive-compulsive disorder, behavior therapy, 49:63
 obsessive-compulsive disorder, exposure, 49:63
 panic disorder, blood pressure, 48:119
 panic disorder, heart rate, 48:119
 panic disorder, yohimbine, 48:119
 panic disorder, anxiety disorder, 48:119
 panic disorder, cortisol, 48:119
 panic disorder, 3-methoxy-4-hydroxyphenylglycol, 48:119
 panic disorder, norepinephrine, 48:119
 panic disorder, serotonin, 48:119
 panic disorder, yohimbine, 48:119
 serotonin, anxiety disorder, 48:119
 serotonin, cortisol, 48:119
 serotonin, 3-methoxy-4-hydroxyphenylglycol, 48:119
 serotonin, norepinephrine, 48:119
 serotonin, panic disorder, 48:119
 serotonin, reuptake inhibitor, 48:119
 serotonin, yohimbine, 48:119
 yohimbine, anxiety disorder, 48:119
 yohimbine, blood pressure, 48:119
 yohimbine, cortisol, 48:119
 yohimbine, heart rate, 48:119
 yohimbine, 3-methoxy-4-hydroxyphenylglycol, 48:119
 yohimbine, norepinephrine, 48:119
 yohimbine, panic disorder, 48:119
 yohimbine, serotonin, 48:119

Follicle stimulating hormone

estradiol, growth hormone, 48:153

Follicle stimulating hormone continued

estradiol, luteinizing hormone, 48:153
 estradiol, normal volunteers, 48:153
 estradiol, prolactin, 48:153
 estradiol, sleep deprivation, 48:153
 estradiol, thyroid stimulating hormone, 48:153
 estradiol, thyroxine, 48:153
 estradiol, triiodothyronine, 48:153
 growth hormone, estradiol, 48:153
 growth hormone, luteinizing hormone, 48:153
 growth hormone, normal volunteers, 48:153
 growth hormone, prolactin, 48:153
 growth hormone, sleep deprivation, 48:153
 growth hormone, thyroid stimulating hormone, 48:153
 growth hormone, thyroxine, 48:153
 growth hormone, triiodothyronine, 48:153
 luteinizing hormone, estradiol, 48:153
 luteinizing hormone, growth hormone, 48:153
 luteinizing hormone, normal volunteers, 48:153
 luteinizing hormone, prolactin, 48:153
 luteinizing hormone, sleep deprivation, 48:153
 luteinizing hormone, thyroid stimulating hormone, 48:153
 luteinizing hormone, thyroxine, 48:153
 luteinizing hormone, triiodothyronine, 48:153
 normal volunteers, estradiol, 48:153
 normal volunteers, growth hormone, 48:153
 normal volunteers, luteinizing hormone, 48:153
 normal volunteers, prolactin, 48:153
 normal volunteers, sleep deprivation, 48:153
 normal volunteers, thyroid stimulating hormone, 48:153
 normal volunteers, thyroxine, 48:153
 normal volunteers, triiodothyronine, 48:153
 prolactin, estradiol, 48:153
 prolactin, growth hormone, 48:153
 prolactin, luteinizing hormone, 48:153
 prolactin, normal volunteers, 48:153
 prolactin, sleep deprivation, 48:153
 prolactin, thyroid stimulating hormone, 48:153
 prolactin, thyroxine, 48:153
 prolactin, triiodothyronine, 48:153
 sleep deprivation, estradiol, 48:153

Follicle stimulating hormone continued
 sleep deprivation, growth hormone, 48:153
 sleep deprivation, luteinizing hormone, 48:153
 sleep deprivation, normal volunteers, 48:153
 sleep deprivation, prolactin, 48:153
 sleep deprivation, thyroid stimulating hormone, 48:153
 sleep deprivation, thyroxine, 48:153
 sleep deprivation, triiodothyronine, 48:153
 thyroid stimulating hormone, estradiol, 48:153
 thyroid stimulating hormone, growth hormone, 48:153
 thyroid stimulating hormone, luteinizing hormone, 48:153
 thyroid stimulating hormone, normal volunteers, 48:153
 thyroid stimulating hormone, prolactin, 48:153
 thyroid stimulating hormone, sleep deprivation, 48:153
 thyroid stimulating hormone, thyroxine, 48:153
 thyroid stimulating hormone, triiodothyronine, 48:153
 thyroxine, estradiol, 48:153
 thyroxine, growth hormone, 48:153
 thyroxine, luteinizing hormone, 48:153
 thyroxine, normal volunteers, 48:153
 thyroxine, prolactin, 48:153
 thyroxine, sleep deprivation, 48:153
 thyroxine, thyroid stimulating hormone, 48:153
 triiodothyronine, 48:153
 triiodothyronine, estradiol, 48:153
 triiodothyronine, growth hormone, 48:153
 triiodothyronine, luteinizing hormone, 48:153
 triiodothyronine, normal volunteers, 48:153
 triiodothyronine, prolactin, 48:153
 triiodothyronine, sleep deprivation, 48:153
 triiodothyronine, thyroid stimulating hormone, 48:153
 triiodothyronine, thyroxine, 48:153

Frontal lobe
 alcohol dependence, memory, 46:175
 alcohol dependence, neuropsychology, 46:175
 alcohol dependence, schizophrenia, 46:175
 alcohol dependence, Wisconsin Card Sorting Test, 46:175
 eye movements, neuropsychology, 48:191
 eye movements, obsessive-compulsive disorder, 48:191

Frontal lobe continued
 eye movements, saccadic, 48:191
 eye movements, smooth pursuit, 48:191
 eye movements, Wisconsin Card Sorting Test, 48:191
 memory, alcohol dependence, 46:175
 memory, neuropsychology, 46:175
 memory, schizophrenia, 46:175
 memory, Wisconsin Card Sorting Test, 46:175
 neurodegeneration, post-mortem study, 48:145
 neurodegeneration, schizophrenia, 48:145
 neurodegeneration, ubiquitin, 48:145
 neuropsychology, alcohol dependence, 46:175
 neuropsychology, eye movements, 48:191
 neuropsychology, memory, 46:175
 neuropsychology, obsessive-compulsive disorder, 48:191
 neuropsychology, saccadic, 48:191
 neuropsychology, schizophrenia, 46:175
 neuropsychology, smooth pursuit, 48:191
 neuropsychology, Wisconsin Card Sorting Test, 46:175, 48:191
 obsessive-compulsive disorder, eye movements, 48:191
 obsessive-compulsive disorder, neuro psychology, 48:191
 obsessive-compulsive disorder, saccadic eye movements, 48:191
 obsessive-compulsive disorder, smooth pursuit eye movements, 48:191
 obsessive-compulsive disorder, Wisconsin Card Sorting Test, 48:191
 post-mortem study, ubiquitin, schizophrenia, 48:145
 saccadic eye movements, neuropsychology, 48:191
 saccadic eye movements, obsessive-compulsive disorder, 48:191
 saccadic eye movements, Wisconsin Card Sorting Test, 48:191
 schizophrenia, alcohol dependence, 46:175
 schizophrenia, memory, 46:175
 schizophrenia, neurodegeneration, 48:145
 schizophrenia, neuropsychology, 46:175
 schizophrenia, post-mortem study, 48:145
 schizophrenia, ubiquitin, 48:145
 schizophrenia, Wisconsin Card Sorting Test, 46:175
 smooth pursuit eye movements, neuropsychology, 48:191
 smooth pursuit eye movements, obsessive-compulsive disorder, 48:191

Frontal lobe continued

- smooth pursuit eye movements, Wisconsin Card Sorting Test, 48:191
- ubiquitin, neurodegeneration, 48:145
- ubiquitin, post-mortem study, 48:145
- ubiquitin, schizophrenia, 48:145
- Wisconsin Card Sorting Test, alcohol dependence, 46:175
- Wisconsin Card Sorting Test, eye movements, 48:191
- Wisconsin Card Sorting Test, memory, 46:175
- Wisconsin Card Sorting Test, neuropsychology, 46:175
- Wisconsin Card Sorting Test, neuropsychology, 48:191
- Wisconsin Card Sorting Test, obsessive-compulsive disorder, 48:191
- Wisconsin Card Sorting Test, saccadic eye movements, 48:191
- Wisconsin Card Sorting Test, schizophrenia, 46:175
- Wisconsin Card Sorting Test, smooth pursuit eye movements, 48:191

Genetics

- affective disorder, bipolar subtype, 46:253, 48:37, 48:47
- affective disorder, dopamine D₃ receptor protein, 46:253
- affective disorder, family history of personality disorder, 48:243
- affective disorder, human leukocyte antigen, 48:201
- affective disorder, immune function, 48:201
- affective disorder, lymphocytes, 48:201
- affective disorder, obstetric complications, 48:47
- affective disorder, rapid cycling, 48:37
- affective disorder, schizophrenia, 48:201, 48:243
- affective disorder, serine to glycine substitution on dopamine D₃, 46:253
- affective disorder, substance abuse, 48:37
- aggression, impulsivity, 48:229
- aggression, personality, 48:229
- aggression, twin studies, 48:229
- antisocial personality disorder, children, 46:9
- antisocial personality disorder, conduct disorder, 46:9
- antisocial personality disorder, cortisol in saliva, 46:9
- antisocial personality disorder, sadistic personality, 48:267

Genetics continued

- antisocial personality disorder, substance abuse, 46:9
- autism, c-Harvey-Ras-1 marker, 46:261
- autism, dopamine-beta-hydroxylase, 46:261
- autism, restriction fragment length polymorphism, 46:261
- autism, tryptophan hydroxylase, 46:261
- autism, tyrosine hydroxylase, 46:261
- bipolar subtype, affective disorder, 46:253, 48:37, 48:47
- bipolar subtype, dopamine D₃ receptor protein, 46:253
- bipolar subtype, family history, 48:37, 48:47
- bipolar subtype, obstetric complications, 48:47
- bipolar subtype, rapid cycling, 48:37
- bipolar subtype, serine to glycine substitution on dopamine D₃, 46:253
- bipolar subtype, substance abuse, 48:37
- c-Harvey-Ras-1 marker, autism, 46:261
- c-Harvey-Ras-1 marker, dopamine-beta-hydroxylase, 46:261
- c-Harvey-Ras-1 marker, restriction fragment length polymorphism, 46:261
- c-Harvey-Ras-1 marker, tryptophan hydroxylase, 46:261
- c-Harvey-Ras-1 marker, tyrosine hydroxylase, 46:261
- children, antisocial personality disorder, 46:9
- children, conduct disorder, 46:9
- conduct disorder, antisocial personality disorder, 46:9
- conduct disorder, children, 46:9
- conduct disorder, substance abuse, 46:9
- D₃ receptor gene linkage, dopamine, 46:69
- D₃ receptor gene linkage, Icelandic pedigrees, 46:69
- D₃ receptor gene linkage, schizophrenia, 46:69
- D₃ receptor protein, affective disorder, 46:253
- D₃ receptor protein, bipolar subtype, 46:253
- D₃ receptor protein, dopamine, 46:253
- D₃ receptor protein, serine to glycine substitution on dopamine D₃, 46:253
- discordant monozygotic twins, microsatellite repeats, 48:27
- discordant monozygotic twins, polymorphic markers, 48:27
- discordant monozygotic twins, schizophrenia, 48:27
- dopamine, affective disorder, 46:253
- dopamine, bipolar subtype, 46:253

Genetics continued

dopamine, D₃ receptor gene linkage, 46:69
 dopamine, D₃ receptor protein, 46:253
 dopamine, Icelandic pedigrees, 46:69
 dopamine, linkage of D₃ receptor gene, 46:69
 dopamine, schizophrenia, 46:69
 dopamine, serine to glycine substitution on dopamine D₃, 46:253
 dopamine-beta-hydroxylase, autism, 46:261
 dopamine-beta-hydroxylase, c-Harvey-Ras-1 marker, 46:261
 dopamine-beta-hydroxylase, restriction fragment length polymorphism, 46:261
 dopamine-beta-hydroxylase, tryptophan hydroxylase, 46:261
 dopamine-beta-hydroxylase, tyrosine hydroxylase, 46:261
 family history, affective disorder, 48:37, 48:47, 48:201
 family history, antisocial disorder, 48:267
 family history, bipolar subtype, 48:37, 48:47
 family history, human leukocyte antigen, 48:201
 family history, immune function, 48:201
 family history, lymphocytes, 48:201
 family history, obstetric complications, 48:47
 family history of personality disorder, affective disorder, 48:243
 family history of personality disorder, schizophrenia, 48:243
 family history, personality disorder, 48:267
 family history, rapid cycling bipolar subtype, 48:37
 family history, sadistic personality disorder, 48:267
 family history, schizophrenia, 48:201
 family history, substance abuse, 48:37
 human leukocyte antigen, affective disorder, 48:201
 human leukocyte antigen, immune function, 48:201
 human leukocyte antigen, lymphocytes, 48:201
 human leukocyte antigen, schizophrenia, 48:201
 immune function, affective disorder, 48:201
 immune function, human leukocyte antigen, 48:201
 immune function, lymphocytes, 48:201
 immune function, schizophrenia, 48:201
 impulsivity, aggression, 48:229
 impulsivity, personality, 48:229

Genetics continued

impulsivity, twin studies, 48:229
 linkage of dopamine D₃ receptor gene, Icelandic pedigrees, 46:69
 linkage of dopamine D₃ receptor gene, schizophrenia, 46:69
 lymphocytes, affective disorder, 48:201
 lymphocytes, human leukocyte antigen, 48:201
 lymphocytes, immune function, 48:201
 lymphocytes, schizophrenia, 48:201
 microsatellite repeats, discordant monozygotic twins, 48:27
 microsatellite repeats, polymorphic markers, 48:27
 microsatellite repeats, schizophrenia, 48:27
 microsatellite repeats, twin studies, 48:27
 monoamine oxidase, platelets, 46:239
 monoamine oxidase, twin studies, 46:239
 monoamine oxidase, twins reared together and apart, 46:239
 obstetric complications, affective disorder, 48:47
 obstetric complications, bipolar subtype, 48:47
 obstetric complications, family history, 48:47
 personality, aggression, 48:229
 personality disorder, antisocial disorder, 48:267
 personality disorder, family history, 48:267
 personality disorder, physical anhedonia, 46:47
 personality disorder, psychosis proneness scales, 46:47
 personality disorder, sadistic personality disorder, 48:267
 personality disorder, schizotypy, 46:47
 personality, impulsivity, 48:229
 personality, twin studies, 48:229
 physical anhedonia, personality disorder, 46:47
 physical anhedonia, psychosis proneness scales, 46:47
 physical anhedonia, schizotypy, 46:47
 polymorphic markers, discordant monozygotic twins, 48:27
 polymorphic markers, microsatellite repeats, 48:27
 polymorphic markers, schizophrenia, 48:27
 polymorphic markers, twin studies, 48:27
 psychosis proneness scales, personality disorder, 46:47

Genetics continued

psychosis proneness scales, physical anhedonia, 46:47
 psychosis proneness scales, schizotypy, 46:47
 rapid cycling, affective disorder, 48:37
 rapid cycling, bipolar subtype, 48:37
 restriction fragment length polymorphism, autism, 46:261
 restriction fragment length polymorphism, c-Harvey-Ras-1 marker, 46:261
 restriction fragment length polymorphism, dopamine-beta-hydroxylase, 46:261
 restriction fragment length polymorphism, tryptophan hydroxylase, 46:261
 restriction fragment length polymorphism, tyrosine hydroxylase, 46:261
 sadistic personality disorder, antisocial personality disorder, 48:267
 schizophrenia, affective disorder, 48:201, 48:243
 schizophrenia, discordant monozygotic twins, 48:27
 schizophrenia, dopamine D₃ receptor gene linkage, 46:69
 schizophrenia, family history, 48:201
 schizophrenia, family history of personality disorder, 48:243
 schizophrenia, human leukocyte antigen, 48:201
 schizophrenia, immune function, 48:201
 schizophrenia, linkage of dopamine D₃ receptor gene, 46:69
 schizophrenia, lymphocytes, 48:201
 schizophrenia, microsatellite repeats, 48:27
 schizophrenia, polymorphic markers, 48:27
 schizophrenia, twin studies, 48:27
 schizotypy, personality disorder, 46:47
 schizotypy, physical anhedonia, 46:47
 schizotypy, psychosis proneness scales, 46:47
 serine to glycine substitution on dopamine D₃, affective disorder, 46:253
 serine to glycine substitution on dopamine D₃, bipolar subtype, 46:253
 substance abuse, affective disorder, bipolar subtype, 48:37
 substance abuse, antisocial personality disorder, 46:9
 substance abuse, conduct disorder, 46:9
 substance abuse, family history, 48:37
 tryptophan hydroxylase, autism, 46:261
 tryptophan hydroxylase, c-Harvey-Ras-1 marker, 46:261

Genetics continued

tryptophan hydroxylase, dopamine-beta-hydroxylase, 46:261
 tryptophan hydroxylase, restriction fragment length polymorphism, 46:261
 tryptophan hydroxylase, tyrosine hydroxylase, 46:261
 twin studies, aggression, 48:229
 twin studies, discordant monozygotic twins, 48:27
 twin studies, impulsivity, 48:229
 twin studies, microsatellite repeats, 48:27
 twin studies, monoamine oxidase in platelets, 46:239
 twin studies, personality, 48:229
 twin studies, polymorphic markers, 48:27
 twin studies, schizophrenia, 48:27
 twins reared together and apart, monoamine oxidase in platelets, 46:239
 twins reared together and apart, twin studies, 46:239
 tyrosine hydroxylase, autism, 46:261
 tyrosine hydroxylase, c-Harvey-Ras-1 marker, 46:261
 tyrosine hydroxylase, dopamine-beta-hydroxylase, 46:261
 tyrosine hydroxylase, restriction fragment length polymorphism, 46:261
 tyrosine hydroxylase, tryptophan hydroxylase, 46:261
Glutamyltransferase
 alcohol dependence, depression, 47:57
 alcohol dependence, impulse control disorder, 47:57
 alcohol dependence, serotonin, 47:57
 alcohol dependence, withdrawal, 47:57
 depression, alcohol dependence, 47:57
 depression, impulse control disorder, 47:57
 depression, serotonin, 47:57
 impulse control disorder, alcohol dependence, 47:57
 impulse control disorder, depression, 47:57
 impulse control disorder, serotonin, 47:57
 platelets, serotonin, 47:57
 serotonin, alcohol dependence, 47:57
 serotonin, depression, 47:57
 serotonin, impulse control disorder, 47:57
 serotonin, platelets, 47:57

Growth hormone

affective disorder, circadian rhythms, 47:215
 affective disorder, endogenous subtype, 47:215
 affective disorder, growth hormone releasing hormone, 47:215
 affective disorder, sleep, 47:215
 circadian rhythms, affective disorder, 47:215
 circadian rhythms, endogenous subtype, 47:215
 circadian rhythms, growth hormone releasing hormone, 47:215
 circadian rhythms, sleep, 47:215
 clonidine, diagnostic systems, 48:79
 clonidine, schizophrenia, 48:79
 diagnostic systems, clonidine, 48:79
 diagnostic systems, schizophrenia, 48:79
 endogenous subtype, affective disorder, 47:215
 endogenous subtype, circadian rhythms, 47:215
 endogenous subtype, growth hormone releasing hormone, 47:215
 endogenous subtype, sleep, 47:215
 estradiol, follicle stimulating hormone, 48:153
 estradiol, luteinizing hormone, 48:153
 estradiol, normal volunteers, 48:153
 estradiol, prolactin, 48:153
 estradiol, sleep deprivation, 48:153
 estradiol, thyroid stimulating hormone, 48:153
 estradiol, thyroxine, 48:153
 estradiol, triiodothyronine, 48:153
 follicle stimulating hormone, estradiol, 48:153
 follicle stimulating hormone, luteinizing hormone, 48:153
 follicle stimulating hormone, normal volunteers, 48:153
 follicle stimulating hormone, prolactin, 48:153
 follicle stimulating hormone, sleep deprivation, 48:153
 follicle stimulating hormone, thyroid stimulating hormone, 48:153
 follicle stimulating hormone, thyroxine, 48:153
 follicle stimulating hormone, triiodothyronine, 48:153
 growth hormone releasing hormone, affective disorder, 47:215

Growth hormone continued

growth hormone releasing hormone, circadian rhythms, 47:215
 growth hormone releasing hormone, endogenous subtype, 47:215
 growth hormone releasing hormone, sleep, 47:215
 kappa agonist, motor tics, 47:267
 kappa agonist, opioids, 47:267
 kappa agonist, prolactin, 47:267
 kappa agonist, spiradoline, 47:267
 kappa agonist, Tourette's syndrome, 47:267
 luteinizing hormone, estradiol, 48:153
 luteinizing hormone, follicle stimulating hormone, 48:153
 luteinizing hormone, normal volunteers, 48:153
 luteinizing hormone, prolactin, 48:153
 luteinizing hormone, sleep deprivation, 48:153
 luteinizing hormone, thyroid stimulating hormone, 48:153
 luteinizing hormone, thyroxine, 48:153
 luteinizing hormone, triiodothyronine, 48:153
 motor tics, kappa agonist, 47:267
 motor tics, opioids, 47:267
 motor tics, prolactin, 47:267
 motor tics, spiradoline, 47:267
 motor tics, Tourette's syndrome, 47:267
 normal volunteers, estradiol, 48:153
 normal volunteers, follicle stimulating hormone, 48:153
 normal volunteers, luteinizing hormone, 48:153
 normal volunteers, prolactin, 48:153
 normal volunteers, sleep deprivation, 48:153
 normal volunteers, thyroid stimulating hormone, 48:153
 normal volunteers, thyroxine, 48:153
 normal volunteers, triiodothyronine, 48:153
 opioids, kappa agonist, 47:267
 opioids, motor tics, 47:267
 opioids, prolactin, 47:267
 opioids, spiradoline, 47:267
 opioids, Tourette's syndrome, 47:267
 prolactin, estradiol, 48:153
 prolactin, follicle stimulating hormone, 48:153
 prolactin, kappa agonist, 47:267
 prolactin, luteinizing hormone, 48:153
 prolactin, motor tics, 47:267
 prolactin, normal volunteers, 48:153

Growth hormone continued
 prolactin, opioids, 47:267
 prolactin, sleep deprivation, 48:153
 prolactin, spiradoline, 47:267
 prolactin, thyroid stimulating hormone, 48:153
 prolactin, thyroxine, 48:153
 prolactin, Tourette's syndrome, 47:267
 prolactin, triiodothyronine, 48:153
 schizophrenia, clonidine, 48:79
 schizophrenia, diagnostic systems, 48:79
 sleep, affective disorder, 47:215
 sleep, circadian rhythms, 47:215
 sleep, endogenous subtype, 47:215
 sleep, growth hormone releasing hormone, 47:215
 sleep deprivation, estradiol, 48:153
 sleep deprivation, follicle stimulating hormone, 48:153
 sleep deprivation, luteinizing hormone, 48:153
 sleep deprivation, normal volunteers, 48:153
 sleep deprivation, prolactin, 48:153
 sleep deprivation, thyroid stimulating hormone, 48:153
 sleep deprivation, thyroxine, 48:153
 sleep deprivation, triiodothyronine, 48:153
 spiradoline, motor tics, 47:267
 spiradoline, prolactin, 47:267
 spiradoline, Tourette's syndrome, 47:267
 thyroid stimulating hormone, estradiol, 48:153
 thyroid stimulating hormone, follicle stimulating hormone, 48:153
 thyroid stimulating hormone, luteinizing hormone, 48:153
 thyroid stimulating hormone, normal volunteers, 48:153
 thyroid stimulating hormone, prolactin, 48:153
 thyroid stimulating hormone, sleep deprivation, 48:153
 thyroid stimulating hormone, thyroxine, 48:153
 thyroid stimulating hormone, triiodothyronine, 48:153
 thyroxine, estradiol, 48:153
 thyroxine, follicle stimulating hormone, 48:153
 thyroxine, luteinizing hormone, 48:153
 thyroxine, normal volunteers, 48:153
 thyroxine, prolactin, 48:153

Growth hormone continued
 thyroxine, sleep deprivation, 48:153
 thyroxine, thyroid stimulating hormone, 48:153
 thyroxine, triiodothyronine, 48:153
 Tourette's syndrome, kappa agonist, 47:267
 Tourette's syndrome, motor tics, 47:267
 Tourette's syndrome, opioids, 47:267
 Tourette's syndrome, prolactin, 47:267
 Tourette's syndrome, spiradoline, 47:267
 triiodothyronine, estradiol, 48:153
 triiodothyronine, follicle stimulating hormone, 48:153
 triiodothyronine, luteinizing hormone, 48:153
 triiodothyronine, normal volunteers, 48:153
 triiodothyronine, prolactin, 48:153
 triiodothyronine, sleep deprivation, 48:153
 triiodothyronine, thyroid stimulating hormone, 48:153
 triiodothyronine, thyroxine, 48:153
Haloperidol
 animal models, domperidone, 47:37
 animal models, dysphoria, 47:37
 animal models, locomotor activity, 47:37
 animal models, neuroleptic-induced defecation in rats, 47:37
 circadian rhythms, dopamine, 47:141
 circadian rhythms, homovanillic acid, 47:141
 circadian rhythms, normal subjects, 47:141
 domperidone, animal models, 47:37
 domperidone, dysphoria, 47:37
 domperidone, locomotor activity, 47:37
 domperidone, neuroleptic-induced defecation in rats, 47:37
 dopamine, circadian rhythms, 47:141
 dopamine, homovanillic acid, 47:141
 dopamine, normal subjects, 47:141
 dysphoria, animal models, 47:37
 dysphoria, domperidone, 47:37
 dysphoria, locomotor activity, 47:37
 dysphoria, neuroleptic-induced defecation in rats, 47:37
 homovanillic acid, circadian rhythms, 47:141
 homovanillic acid, dopamine, 47:141
 homovanillic acid, normal subjects, 47:141
 locomotor activity, animal models, 47:37
 locomotor activity, domperidone, 47:37
 locomotor activity, dysphoria, 47:37
 locomotor activity, neuroleptic-induced defecation in rats, 47:37
 neuroleptic-induced defecation in rats, animal models, 47:37

Haloperidol continued

neuroleptic-induced defecation in rats, domperidone, 47:37

neuroleptic-induced defecation in rats, dysphoria, 47:37

neuroleptic-induced defecation in rats, locomotor activity, 47:37

normal subjects, circadian rhythms, 47:141

normal subjects, dopamine, 47:141

normal subjects, homovanillic acid, 47:141

Haptoglobin

affective disorder, amino acids, 49:151

affective disorder, cortisol, 49:11

affective disorder, dexamethasone suppression test, 49:11

affective disorder, immune function, 47:229, 49:11, 49:151

affective disorder, interleukin, 49:11, 49:151

affective disorder, serotonin, 49:151

affective disorder, sleep, 47:229

affective disorder, somatic symptoms, 47:229

affective disorder, transferrin, 49:11, 49:151

affective disorder, tryptophan, 49:151

affective disorder, weight and anorexia, 47:229

amino acids, affective disorder, 49:151

amino acids, immune function, 49:151

amino acids, interleukin, 49:151

amino acids, serotonin, 49:151

amino acids, transferrin, 49:151

amino acids, tryptophan, 49:151

cortisol, affective disorder, 49:11

cortisol, dexamethasone suppression test, 49:11

cortisol, immune function, 49:11

cortisol, interleukins, 49:11

cortisol, transferrin, 49:11

dexamethasone suppression test, affective disorder, 49:11

dexamethasone suppression test, cortisol, 49:11

dexamethasone suppression test, immune function, 49:11

dexamethasone suppression test, interleukins, 49:11

dexamethasone suppression test, transferrin, 49:11

immune function, affective disorder, 47:229, 49:11, 49:151

immune function, amino acids, 49:151

immune function, cortisol, 49:11

immune function, dexamethasone suppression test, 49:11

Haptoglobin continued

immune function, interleukins, 49:11, 49:151

immune function, serotonin, 49:151

immune function, sleep, 47:229

immune function, somatic symptoms, 47:229

immune function, transferrin, 49:11, 49:151

immune function, tryptophan, 49:151

immune function, weight and anorexia, 47:229

interleukins, affective disorder, 49:11, 49:151

interleukins, amino acids, 49:151

interleukins, cortisol, 49:11

interleukins, dexamethasone suppression test, 49:11

interleukins, immune function, 49:11, 49:151

interleukins, serotonin, 49:151

interleukins, transferrin, 49:11, 49:151

interleukins, tryptophan, 49:151

serotonin, affective disorder, 49:151

serotonin, amino acids, 49:151

serotonin, immune function, 49:151

serotonin, interleukins, 49:151

serotonin, transferrin, 49:151

serotonin, tryptophan, 49:151

sleep, affective disorder, 47:229

sleep, immune function, 47:229

sleep, somatic symptoms, 47:229

sleep, weight and anorexia, 47:229

somatic symptoms, affective disorder, 47:229

somatic symptoms, immune function, 47:229

somatic symptoms, sleep, 47:229

somatic symptoms, weight and anorexia, 47:229

transferrin, affective disorder, 49:11, 49:151

transferrin, amino acids, 49:151

transferrin, cortisol, 49:11

transferrin, dexamethasone suppression test, 49:11

transferrin, immune function, 49:11, 49:151

transferrin, interleukins, 49:11, 49:151

transferrin, serotonin, 49:151

tryptophan, affective disorder, 49:151

tryptophan, amino acids, 49:151

tryptophan, immune function, 49:151

tryptophan, interleukins, 49:151

tryptophan, serotonin, 49:151

tryptophan, transferrin, 49:151

weight and anorexia, affective disorder, 47:229

weight and anorexia, immune function, 47:229

Heart rate

anxiety disorder, autonomic nervous system, 46:89

Heart rate continued

anxiety disorder, orthostatic challenge, 46:89
 anxiety disorder, panic, 46:89
 anxiety disorder, power spectral analysis of heart rate, 46:89
 arginine vasopressin, electrodermal response, 48:107
 arginine vasopressin, electromyography, 48:107
 arginine vasopressin, oxytocin, 48:107
 arginine vasopressin, personal combat imagery, 48:107
 arginine vasopressin, posttraumatic stress syndrome, 48:107
 autonomic nervous system, anxiety disorder, 46:89
 autonomic nervous system, orthostatic challenge, 46:89
 autonomic nervous system, panic disorder, 46:89
 autonomic nervous system, power spectral analysis of heart rate, 46:89
 blood pressure, fluvoxamine, 48:119
 blood pressure, panic disorder, 48:119
 blood pressure, yohimbine, 48:119
 desipramine, normal subjects, 46:1
 electrodermal response, arginine vasopressin, 48:107
 electrodermal response, electromyography, 48:107
 electrodermal response, oxytocin, 48:107
 electrodermal response, personal combat imagery, 48:107
 electrodermal response, posttraumatic stress syndrome, 48:107
 electromyography, arginine vasopressin, 48:107
 electromyography, electrodermal response, 48:107
 electromyography, oxytocin, 48:107
 electromyography, personal combat imagery, 48:107
 electromyography, posttraumatic stress syndrome, 48:107
 fluvoxamine, blood pressure, 48:119
 fluvoxamine, panic disorder, 48:119
 fluvoxamine, yohimbine, 48:119
 normal subjects, desipramine, 46:1
 orthostatic challenge, anxiety disorder, 46:89
 orthostatic challenge, autonomic nervous system, 46:89
 orthostatic challenge, panic disorder, 46:89
 orthostatic challenge, power spectral analysis of heart rate, 46:89

Heart rate continued

oxytocin, arginine vasopressin, 48:107
 oxytocin, electrodermal response, 48:107
 oxytocin, electromyography, 48:107
 oxytocin, personal combat imagery, 48:107
 oxytocin, posttraumatic stress syndrome, 48:107
 panic disorder, blood pressure, 48:119
 panic disorder, fluvoxamine, 48:119
 panic disorder, yohimbine, 48:119
 panic disorder, autonomic nervous system, 46:89
 panic disorder, orthostatic challenge, 46:89
 panic disorder, power spectral analysis of heart rate, 46:89
 personal combat imagery, arginine vasopressin, 48:107
 personal combat imagery, electrodermal response, 48:107
 personal combat imagery, electromyography, 48:107
 personal combat imagery, oxytocin, 48:107
 personal combat imagery, posttraumatic stress syndrome, 48:107
 posttraumatic stress syndrome, arginine vasopressin, 48:107
 posttraumatic stress syndrome, electrodermal response, 48:107
 posttraumatic stress syndrome, electromyography, 48:107
 posttraumatic stress syndrome, oxytocin, 48:107
 posttraumatic stress syndrome, personal combat imagery, 48:107
 posttraumatic stress syndrome, Vietnam veterans, 48:107
 power spectral analysis, anxiety disorder, 46:89
 power spectral analysis, autonomic nervous system, 46:89
 power spectral analysis, orthostatic challenge, 46:89
 power spectral analysis, panic disorder, 46:89
 yohimbine, blood pressure, 48:119
 yohimbine, fluvoxamine, 48:119
 yohimbine, panic disorder, 48:119
Hippocampus
 affective disorder, cortisol, 47:163
 affective disorder, dexamethasone suppression test, 47:163
 affective disorder, magnetic resonance imaging, 47:163

Hippocampus continued

Alzheimer's disease, neurofibrillary tangles, 49:41
 Alzheimer's disease, post-mortem, 49:41
 Alzheimer's disease, schizophrenia, 49:41
 Alzheimer's disease, senile plaques, 49:41
 cortisol, affective disorder, 47:163
 cortisol, dexamethasone suppression test, 47:163
 cortisol, magnetic resonance imaging, 47:163
 dexamethasone suppression test, affective disorder, 47:163
 dexamethasone suppression test, cortisol, 47:163
 dexamethasone suppression test, magnetic resonance imaging, 47:163
 magnetic resonance imaging, affective disorder, 47:163
 magnetic resonance imaging, cortisol, 47:163
 magnetic resonance imaging, dexamethasone suppression test, 47:163
 neurofibrillary tangles, Alzheimer's disease, 49:41
 neurofibrillary tangles, post-mortem, 49:41
 neurofibrillary tangles, schizophrenia, 49:41
 neurofibrillary tangles, senile plaques, 49:41
 post-mortem, Alzheimer's disease, 49:41
 post-mortem, neurofibrillary tangles, 49:41
 post-mortem, schizophrenia, 49:41
 post-mortem, senile plaques, 49:41
 schizophrenia, Alzheimer's disease, 49:41
 schizophrenia, neurofibrillary tangles, 49:41
 schizophrenia, post-mortem, 49:41
 schizophrenia, senile plaques, 49:41
 senile plaques, Alzheimer's disease, 49:41
 senile plaques, neurofibrillary tangles, 49:41
 senile plaques, post-mortem, 49:41
 senile plaques, schizophrenia, 49:41

Homovanillic acid

affective disorder, 5-hydroxyindoleacetic acid, 46:19
 affective disorder, 3-methoxy-4-hydroxyphenylglycol, 46:19
 affective disorder, norepinephrine, 46:19
 affective disorder, orthostatic challenge, 46:19
 affective disorder, phototherapy, 46:19
 age of onset, dopamine, 48:93
 age of onset, positive and negative symptoms, 48:93
 age of onset, schizophrenia, 48:93

Homovanillic acid continued

Alzheimer's disease, cognitive impairment, 49:211
 Alzheimer's disease, dihydroxyphenylacetic acid, 49:211
 Alzheimer's disease, dopamine, 49:211
 Alzheimer's disease, post-mortem study, 49:211
 Alzheimer's disease, psychiatric symptoms, 49:211
 circadian rhythms, dopamine, 47:141
 circadian rhythms, haloperidol, 47:141
 circadian rhythms, normal subjects, 47:141
 clozapine, dopamine, 46:139, 46:151
 clozapine, 3-methoxy-4-hydroxyphenylglycol, 46:139
 clozapine, norepinephrine, 46:139, 46:151
 clozapine, schizophrenia, 46:139, 46:151
 clozapine, therapeutic response, 46:139, response, 46:151
 cognitive impairment, Alzheimer's disease, 49:211
 cognitive impairment, dihydroxyphenylacetic acid, 49:211
 cognitive impairment, dopamine, 49:211
 cognitive impairment, psychiatric symptoms, 49:211
 dihydroxyphenylacetic acid, Alzheimer's disease, 49:211
 dihydroxyphenylacetic acid, cognitive impairment, 49:211
 dihydroxyphenylacetic acid, dopamine, 49:211
 dihydroxyphenylacetic acid, post-mortem study, 49:211
 dihydroxyphenylacetic acid, psychiatric symptoms, 49:211
 dissociative phenomena, eating disorder, 49:1
 dissociative phenomena, endorphins, 49:1
 dissociative phenomena, 5-hydroxyindoleacetic acid, 49:1
 dissociative phenomena, 3-methoxy-4-hydroxyphenylglycol, 49:1
 dopamine, age of onset, 48:93
 dopamine, Alzheimer's disease, 49:211
 dopamine, circadian rhythms, 47:141
 dopamine, clozapine, 46:139, 46:151
 dopamine, cognitive impairment, 49:211
 dopamine, dihydroxyphenylacetic acid, 49:211
 dopamine, haloperidol, 47:141
 dopamine, 3-methoxy-4-hydroxyphenylglycol, 46:139
 dopamine, norepinephrine, 46:139, 46:151

Homovanillic acid continued

- dopamine, normal subjects, 47:141
- dopamine, positive and negative symptoms, 48:93
- dopamine, post-mortem study, 49:211
- dopamine, psychiatric symptoms, 49:211
- dopamine, schizophrenia, 46:139, 46:151, 48:93
- dopamine, therapeutic response, 46:139, 46:151
- eating disorder, cerebrospinal fluid, 49:1
- eating disorder, dissociative phenomena, 49:1
- eating disorder, endorphins, 49:1
- eating disorder, 5-hydroxyindoleacetic acid, 49:1
- eating disorder, 3-methoxy-4-hydroxyphenylglycol, 49:1
- endorphins, cerebrospinal fluid, 49:1
- endorphins, dissociative phenomena, 49:1
- endorphins, eating disorder, 49:1
- endorphins, 5-hydroxyindoleacetic acid, 49:1
- endorphins, 3-methoxy-4-hydroxyphenylglycol, 49:1
- haloperidol, circadian rhythms, 47:141
- haloperidol, dopamine, 47:141
- haloperidol, normal subjects, 47:141
- 5-hydroxyindoleacetic acid, affective disorder, 46:19
- 5-hydroxyindoleacetic acid, cerebrospinal fluid, 46:19, 49:1
- 5-hydroxyindoleacetic acid, dissociative phenomena, 49:1
- 5-hydroxyindoleacetic acid, eating disorder, 49:1
- 5-hydroxyindoleacetic acid, endorphins, 49:1
- 5-hydroxyindoleacetic acid, 3-methoxy-4-hydroxyphenylglycol, 46:19, 49:1
- 5-hydroxyindoleacetic acid, norepinephrine, 46:19
- 5-hydroxyindoleacetic acid, orthostatic challenge, 46:19
- 5-hydroxyindoleacetic acid, phototherapy, 46:19
- 5-hydroxyindoleacetic acid, seasonal depression, 46:19
- 3-methoxy-4-hydroxyphenylglycol, affective disorder, 46:19
- 3-methoxy-4-hydroxyphenylglycol, cerebrospinal fluid, 46:19, 49:1
- 3-methoxy-4-hydroxyphenylglycol, clozapine, 46:139
- 3-methoxy-4-hydroxyphenylglycol, dissociative phenomena, 49:1

Homovanillic acid continued

- 3-methoxy-4-hydroxyphenylglycol, dopamine, 46:139
- 3-methoxy-4-hydroxyphenylglycol, eating disorder, 49:1
- 3-methoxy-4-hydroxyphenylglycol, endorphins, 49:1
- 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, 46:19, 49:1
- 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 46:139, 46:19
- 3-methoxy-4-hydroxyphenylglycol, orthostatic challenge, 46:19
- 3-methoxy-4-hydroxyphenylglycol, phototherapy, 46:19
- 3-methoxy-4-hydroxyphenylglycol, schizophrenia, 46:139
- 3-methoxy-4-hydroxyphenylglycol, seasonal depression, 46:19
- 3-methoxy-4-hydroxyphenylglycol, therapeutic response, 46:139
- norepinephrine, affective disorder, 46:19
- norepinephrine, cerebrospinal fluid, 46:19
- norepinephrine, clozapine, 46:139, 46:151
- norepinephrine, dopamine, 46:139, 46:151
- norepinephrine, 5-hydroxyindoleacetic acid, 46:19
- norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 46:19, 46:139
- norepinephrine, orthostatic challenge, 46:19
- norepinephrine, phototherapy, 46:19
- norepinephrine, schizophrenia, 46:139, 46:151
- norepinephrine, seasonal depression, 46:19
- norepinephrine, therapeutic response, 46:139, 46:151
- normal subjects, circadian rhythms, 47:141
- normal subjects, dopamine, 47:141
- normal subjects, haloperidol, 47:141
- orthostatic challenge, affective disorder, 46:19
- orthostatic challenge, 5-hydroxyindoleacetic acid, 46:19
- orthostatic challenge, 3-methoxy-4-hydroxyphenylglycol, 46:19
- orthostatic challenge, norepinephrine, 46:19
- orthostatic challenge, phototherapy, 46:19
- orthostatic challenge, seasonal depression, 46:19
- phototherapy, affective disorder, 46:19
- phototherapy, 5-hydroxyindoleacetic acid, 46:19
- phototherapy, 3-methoxy-4-hydroxyphenylglycol, 46:19

Homovanillic acid continued
 phototherapy, norepinephrine, 46:19
 phototherapy, orthostatic challenge, 46:19
 phototherapy, seasonal depression, 46:19
 positive and negative symptoms, age of onset, 48:93
 positive and negative symptoms, dopamine, 48:93
 positive and negative symptoms, schizophrenia, 48:93
 post-mortem study, Alzheimer's disease, 49:211
 post-mortem study, dihydroxyphenylacetic acid, 49:211
 post-mortem study, dopamine, 49:211
 psychiatric symptoms, Alzheimer's disease, 49:211
 psychiatric symptoms, cognitive impairment, 49:211
 psychiatric symptoms, dihydroxyphenylacetic acid, 49:211
 psychiatric symptoms, dopamine, 49:211
 schizophrenia, age of onset, 48:93
 schizophrenia, clozapine, 46:139, 46:151
 schizophrenia, dopamine, 46:139, 46:151, 48:93
 schizophrenia, 3-methoxy-4-hydroxyphenylglycol, 46:139
 schizophrenia, norepinephrine, 46:139, 46:151
 schizophrenia, positive and negative symptoms, 48:93
 schizophrenia, therapeutic response, 46:139, 46:151
 seasonal depression, 5-hydroxyindoleacetic acid, 46:19
 seasonal depression, 3-methoxy-4-hydroxyphenylglycol, 46:19
 seasonal depression, norepinephrine, 46:19
 seasonal depression, orthostatic challenge, 46:19
 seasonal depression, phototherapy, 46:19
 therapeutic response, clozapine, 46:139, 46:151
 therapeutic response, dopamine, 46:139, 46:151
 therapeutic response, 3-methoxy-4-hydroxyphenylglycol, 46:139
 therapeutic response, norepinephrine, 46:139, 46:151
 therapeutic response, schizophrenia, 46:139, 46:151

Human immunodeficiency virus
 auditory evoked potential P3, cortical atrophy, 47:175
 auditory evoked potential P3, magnetic resonance imaging, 47:175
 auditory evoked potential P3, neuropsychology, 47:175
 auditory evoked potential P3, substance abuse, 47:175
 cortical atrophy, auditory evoked potential P3, 47:175
 cortical atrophy, event related potentials, 47:175
 cortical atrophy, magnetic resonance imaging, 47:175
 cortical atrophy, neuropsychology, 47:175
 cortical atrophy, substance abuse, 47:175
 event related potentials, auditory P3, 47:175
 event related potentials, cortical atrophy, 47:175
 event related potentials, magnetic resonance imaging, 47:175
 event related potentials, neuropsychology, 47:175
 event related potentials, substance abuse, 47:175
 magnetic resonance imaging, auditory evoked potential P3, 47:175
 magnetic resonance imaging, cortical atrophy, 47:175
 magnetic resonance imaging, event related potentials, 47:175
 magnetic resonance imaging, neuropsychology, 47:175
 magnetic resonance imaging, substance abuse, 47:175
 neuropsychology, auditory evoked potential P3, 47:175
 neuropsychology, cortical atrophy, 47:175
 neuropsychology, event related potentials, 47:175
 neuropsychology, magnetic resonance imaging, 47:175
 neuropsychology, substance abuse, 47:175
 substance abuse, auditory evoked potential P3, 47:175
 substance abuse, cortical atrophy, 47:175
 substance abuse, event related potentials, 47:175
 substance abuse, magnetic resonance imaging, 47:175
 substance abuse, neuropsychology, 47:175

Human leukocyte antigen

affective disorder, family history, 48:201
 affective disorder, genetics, 48:201
 affective disorder, immune function, 48:201
 affective disorder, lymphocytes, 48:201
 affective disorder, schizophrenia, 48:201
 family history, affective disorder, 48:201
 family history, immune function, 48:201
 family history, lymphocytes, 48:201
 family history, schizophrenia, 48:201
 genetics, affective disorder, 48:201
 genetics, immune function, 48:201
 genetics, lymphocytes, 48:201
 genetics, schizophrenia, 48:201
 immune function, affective disorder, 48:201
 immune function, family history, 48:201
 immune function, genetics, 48:201
 immune function, lymphocytes, 48:201
 immune function, schizophrenia, 48:201
 lymphocytes, affective disorder, 48:201
 lymphocytes, family history, 48:201
 lymphocytes, genetics, 48:201
 lymphocytes, immune function, 48:201
 lymphocytes, schizophrenia, 48:201
 schizophrenia, affective disorder, 48:201
 schizophrenia, family history, 48:201
 schizophrenia, genetics, 48:201
 schizophrenia, immune function, 48:201
 schizophrenia, lymphocytes, 48:201

5-Hydroxyindoleacetic acid

affective disorder, homovanillic acid, 46:19
 affective disorder, 3-methoxy-4-hydroxy-phenylglycol, 46:19
 affective disorder, norepinephrine, 46:19
 affective disorder, orthostatic challenge, 46:19
 affective disorder, phototherapy, 46:19
 affective disorder, seasonal depression, 46:19
 cerebrospinal fluid, endorphins, 49:1
 cerebrospinal fluid, homovanillic acid, 46:19, 49:1
 cerebrospinal fluid, 3-methoxy-4-hydroxy-phenylglycol, 46:19, 49:1
 cerebrospinal fluid, norepinephrine, 46:19
 cerebrospinal fluid, orthostatic challenge, 46:19
 dissociative phenomena, eating disorder, 49:1
 dissociative phenomena, endorphins, 49:1
 dissociative phenomena, homovanillic acid, 49:1
 dissociative phenomena, 3-methoxy-4-hydroxy-phenylglycol, 49:1

5-Hydroxyindoleacetic acid continued

eating disorder, cerebrospinal fluid, 49:1
 eating disorder, dissociative phenomena, 49:1
 eating disorder, endorphins, 49:1
 eating disorder, homovanillic acid, 49:1
 eating disorder, 3-methoxy-4-hydroxyphenylglycol, 49:1
 endorphins, cerebrospinal fluid, 49:1
 endorphins, dissociative phenomena, 49:1
 endorphins, eating disorder, 49:1
 endorphins, homovanillic acid, 49:1
 endorphins, 3-methoxy-4-hydroxyphenylglycol, 49:1
 homovanillic acid, affective disorder, 46:19
 homovanillic acid, cerebrospinal fluid, 46:19, 49:1
 homovanillic acid, dissociative phenomena, 49:1
 homovanillic acid, eating disorder, 49:1
 homovanillic acid, endorphins, 49:1
 homovanillic acid, 3-methoxy-4-hydroxy-phenylglycol, 46:19, 49:1
 homovanillic acid, norepinephrine, 46:19
 homovanillic acid, orthostatic challenge, 46:19
 homovanillic acid, phototherapy, 46:19
 homovanillic acid, seasonal depression, 46:19
 3-methoxy-4-hydroxyphenylglycol, affective disorder, 46:19
 3-methoxy-4-hydroxyphenylglycol, cerebrospinal fluid, 46:19, 49:1
 3-methoxy-4-hydroxyphenylglycol, dissociative phenomena, 49:1
 3-methoxy-4-hydroxyphenylglycol, eating disorder, 49:1
 3-methoxy-4-hydroxyphenylglycol, endorphins, 49:1
 3-methoxy-4-hydroxyphenylglycol, homovanillic acid, 46:19, 49:1
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 46:19
 3-methoxy-4-hydroxyphenylglycol, orthostatic challenge, 46:19
 3-methoxy-4-hydroxyphenylglycol, phototherapy, 46:19
 3-methoxy-4-hydroxyphenylglycol, seasonal depression, 46:19
 norepinephrine, affective disorder, 46:19
 norepinephrine, cerebrospinal fluid, 46:19
 norepinephrine, homovanillic acid, 46:19
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 46:19

5-Hydroxyindoleacetic acid continued
 norepinephrine, orthostatic challenge, 46:19
 norepinephrine, phototherapy, 46:19
 norepinephrine, seasonal depression, 46:19
 orthostatic challenge, affective disorder, 46:19
 orthostatic challenge, cerebrospinal fluid, 46:19
 orthostatic challenge, homovanillic acid, 46:19
 orthostatic challenge, 3-methoxy-4-hydroxyphenylglycol, 46:19
 orthostatic challenge, norepinephrine, 46:19
 orthostatic challenge, phototherapy, 46:19
 orthostatic challenge, seasonal depression, 46:19
 phototherapy, affective disorder, 46:19
 phototherapy, homovanillic acid, 46:19
 phototherapy, 3-methoxy-4-hydroxyphenylglycol, 46:19
 phototherapy, norepinephrine, 46:19
 phototherapy, orthostatic challenge, 46:19
 phototherapy, seasonal depression, 46:19
 seasonal depression, homovanillic acid, 46:19
 seasonal depression, 3-methoxy-4-hydroxyphenylglycol, 46:19
 seasonal depression, norepinephrine, 46:19
 seasonal depression, orthostatic challenge, 46:19
 seasonal depression, phototherapy, 46:19
Imipramine
 calmodulin affinity chromatography, endogenous serotonin uptake inhibitors, 47:121
 calmodulin affinity chromatography, paroxetine, 47:121
 calmodulin affinity chromatography, serotonin, 47:121
 endogenous serotonin uptake inhibitors, calmodulin affinity chromatography, 47:121
 endogenous serotonin uptake inhibitors, paroxetine, 47:121
 endogenous serotonin uptake inhibitors, serotonin, 47:121
 paroxetine, calmodulin affinity chromatography, 47:121
 paroxetine, endogenous serotonin uptake inhibitors, 47:121
 paroxetine, serotonin, 47:121
 serotonin, calmodulin affinity chromatography, 47:121

Imipramine continued
 serotonin, endogenous serotonin uptake inhibitors, 47:121
 serotonin, paroxetine, 47:121
Immune function
 affective disorder, amino acids, 49:151
 affective disorder, cortisol, 49:11
 affective disorder, dexamethasone suppression test, 49:11
 affective disorder, family history, 48:201
 affective disorder, gender differences, 49:151
 affective disorder, genetics, 48:201
 affective disorder, haptoglobin, 47:229, 49:11, 49:151
 affective disorder, human leukocyte antigen, 48:201
 affective disorder, interleukin, 49:11, 49:151
 affective disorder, lymphocytes, 48:201
 affective disorder, schizophrenia, 48:201
 affective disorder, serotonin, 49:151
 affective disorder, sleep, 47:229
 affective disorder, somatic symptoms, 47:229
 affective disorder, transferrin, 49:11, 49:151
 affective disorder, tryptophan, 49:151
 affective disorder, weight and anorexia, 47:229
 amino acids, affective disorder, 49:151
 amino acids, haptoglobin, 49:151
 amino acids, interleukin, 49:151
 amino acids, serotonin, 49:151
 amino acids, transferrin, 49:151
 amino acids, tryptophan, 49:151
 CD5 positive B lymphocytes, gender differences, 48:69
 CD5 positive B lymphocytes, lymphocytes, 48:69
 CD5 positive B lymphocytes, race differences, 48:69
 CD5 positive B lymphocytes, schizophrenia, 48:69
 cortisol, affective disorder, 49:11
 cortisol, dexamethasone suppression test, 49:11
 cortisol, haptoglobin, 49:11
 cortisol, interleukins, 49:11
 cortisol, transferrin, 49:11
 dexamethasone suppression test, affective disorder, 49:11
 dexamethasone suppression test, cortisol, 49:11
 dexamethasone suppression test, haptoglobin, 49:11

Immune function continued

dexamethasone suppression test, interleukins, 49:11
 dexamethasone suppression test, transferrin, 49:11
 family history, affective disorder, 48:201
 family history, human leukocyte antigen, 48:201
 family history, lymphocytes, 48:201
 family history, schizophrenia, 48:201
 gender differences, affective disorder, 49:151
 gender differences, CD5 positive B lymphocytes, 48:69
 gender differences, lymphocytes, 48:69
 gender differences, race differences, 48:69
 gender differences, schizophrenia, 48:69
 genetics, affective disorder, 48:201
 genetics, family history, 48:201
 genetics, human leukocyte antigen, 48:201
 genetics, lymphocytes, 48:201
 genetics, schizophrenia, 48:201
 haptoglobin, affective disorder, 47:229, 49:11, 49:151
 haptoglobin, amino acids, 49:151
 haptoglobin, cortisol, 49:11
 haptoglobin, dexamethasone suppression test, 49:11
 haptoglobin, interleukin, 49:11, 49:151
 haptoglobin, serotonin, 49:151
 haptoglobin, sleep, 47:229
 haptoglobin, somatic symptoms, 47:229
 haptoglobin, transferrin, 49:11, 49:151
 haptoglobin, tryptophan, 49:151
 haptoglobin, weight and anorexia, 47:229
 human leukocyte antigen, affective disorder, 48:201
 human leukocyte antigen, family history, 48:201
 human leukocyte antigen, genetics, 48:201
 human leukocyte antigen, lymphocytes, 48:201
 human leukocyte antigen, schizophrenia, 48:201
 interleukins, affective disorder, 49:11, 49:151
 interleukins, amino acids, 49:151
 interleukins, cortisol, 49:11
 interleukins, haptoglobin, 49:11, 49:151
 interleukins, serotonin, 49:151
 interleukins, transferrin, 49:11, 49:151
 interleukins, tryptophan, 49:151
 lymphocytes, affective disorder, 48:201
 lymphocytes, CD5 positive B lymphocytes, 48:69

Immune function continued

lymphocytes, family history, 48:201
 lymphocytes, gender differences, 48:69
 lymphocytes, genetics, 48:201
 lymphocytes, human leukocyte antigen, 48:201
 lymphocytes, race differences, 48:69
 lymphocytes, schizophrenia, 48:69, 48:201
 race differences, CD5 positive B lymphocytes, 48:69
 race differences, gender differences, 48:69
 race differences, lymphocytes, 48:69
 race differences, schizophrenia, 48:69
 schizophrenia, affective disorder, 48:201
 schizophrenia, CD5 positive B lymphocytes, 48:69
 schizophrenia, family history, 48:201
 schizophrenia, gender differences, 48:69
 schizophrenia, genetics, 48:201
 schizophrenia, human leukocyte antigen, 48:201
 schizophrenia, lymphocytes, 48:69, 48:201
 schizophrenia, race differences, 48:69
 serotonin, affective disorder, 49:151
 serotonin, amino acids, 49:151
 serotonin, haptoglobin, 49:151
 serotonin, interleukin, 49:151
 serotonin, transferrin, 49:151
 serotonin, tryptophan, 49:151
 sleep, affective disorder, 47:229
 sleep, haptoglobin, 47:229
 sleep, somatic symptoms, 47:229
 sleep, weight and anorexia, 47:229
 somatic symptoms, affective disorder, 47:229
 somatic symptoms, haptoglobin, 47:229
 somatic symptoms, sleep, 47:229
 somatic symptoms, weight and anorexia, 47:229
 transferrin, affective disorder, 49:11, 49:151
 transferrin, amino acids, 49:151
 transferrin, cortisol, 49:11
 transferrin, dexamethasone suppression test, 49:11
 transferrin, haptoglobin, 49:11, 49:151
 transferrin, interleukins, 49:11, 49:151
 transferrin, serotonin, 49:151
 transferrin, tryptophan, 49:151
 tryptophan, affective disorder, 49:151
 tryptophan, amino acids, 49:151
 tryptophan, haptoglobin, 49:151
 tryptophan, interleukins, 49:151
 tryptophan, serotonin, 49:151

Immune function continued

tryptophan, transferrin, 49:151
 weight and anorexia, affective disorder, 47:229
 weight and anorexia, haptoglobin, 47:229
 weight and anorexia, sleep, 47:229
 weight and anorexia, somatic symptoms, 47:229

Impulse control disorder

alcohol dependence, depression, 47:57
 alcohol dependence, glutamyltransferase, 47:57
 alcohol dependence, serotonin, 47:57
 alcohol dependence, withdrawal, 47:57
 depression, alcohol dependence, 47:57
 depression, glutamyltransferase, 47:57
 depression, serotonin, 47:57
 glutamyltransferase, alcohol dependence, 47:57
 glutamyltransferase, depression, 47:57
 glutamyltransferase, serotonin, 47:57
 platelets, serotonin, 47:57
 serotonin, alcohol dependence, 47:57
 serotonin, depression, 47:57
 serotonin, glutamyltransferase, 47:57
 serotonin, platelets, 47:57
 withdrawal, alcohol dependence, 47:57

Joint hypermobility syndrome

affective disorder, mitral valve prolapse, 46:59
 affective disorder, simple phobia, 46:59
 anxiety disorder, panic, 46:59
 mitral valve prolapse, affective disorder, 46:59
 mitral valve prolapse, simple phobia, 46:59
 panic disorder, 46:59
 simple phobia, affective disorder, 46:59
 simple phobia, mitral valve prolapse, 46:59

Lactate

blood pressure, menstrual cycle, 46:79
 blood pressure, panic attacks, 46:79
 blood pressure, premenstrual syndrome, 46:79
 menstrual cycle, blood pressure, 46:79
 menstrual cycle, panic attacks, 46:79
 panic attacks, blood pressure, 46:79
 panic attacks, menstrual cycle, 46:79
 panic attacks, premenstrual syndrome, 46:79
 premenstrual syndrome, blood pressure, 46:79
 premenstrual syndrome, panic attacks, 46:79

Language

affective disorder, laterality, 47:99
 affective disorder, motor performance, 47:99
 affective disorder, phototherapy, 47:99
 laterality, affective disorder, 47:99
 laterality, motor performance, 47:99
 laterality, phototherapy, 47:99
 laterality, seasonal depression, 47:99
 motor performance, affective disorder, 47:99
 motor performance, laterality, 47:99
 motor performance, phototherapy, 47:99
 motor performance, seasonal depression, 47:99
 phototherapy, affective disorder, 47:99
 phototherapy, laterality, 47:99
 phototherapy, motor performance, 47:99
 phototherapy, seasonal depression, 47:99
 seasonal depression, laterality, 47:99
 seasonal depression, motor performance, 47:99
 seasonal depression, phototherapy, 47:99

Light therapy. See **Phototherapy**

Lipids

Alzheimer's disease, erythrocyte membrane, 46:203
 erythrocyte membrane, Alzheimer's disease, 46:203

Lorazepam

alcohol intake, anxiety disorder, 48:135
 alcohol intake, computed tomography, 48:135
 alcohol intake, ventricle-brain ratio, 48:135
 anxiety disorder, alcohol intake, 48:135
 anxiety disorder, computed tomography, 48:135
 anxiety disorder, ventricle-brain ratio, 48:135
 computed tomography, alcohol intake, 48:135
 computed tomography, anxiety disorder, 48:135

computed tomography, ventricle-brain ratio, 48:135

diazepam, alcohol intake, 48:135

diazepam, anxiety disorder, 48:135

ventricle-brain ratio, alcohol intake, 48:135
 ventricle-brain ratio, anxiety disorder, 48:135
 ventricle-brain ratio, benzodiazepines, 48:135
 ventricle-brain ratio, computed tomography, 48:135

Luteinizing hormone

estradiol, follicle stimulating hormone, 48:153
 estradiol, growth hormone, 48:153
 estradiol, normal volunteers, 48:153
 estradiol, prolactin, 48:153
 estradiol, sleep deprivation, 48:153

Luteinizing hormone continued
 estradiol, thyroid stimulating hormone, 48:153
 estradiol, thyroxine, 48:153
 estradiol, triiodothyronine, 48:153
 follicle stimulating hormone, estradiol, 48:153
 follicle stimulating hormone, growth hormone, 48:153
 follicle stimulating hormone, normal volunteers, 48:153
 follicle stimulating hormone, prolactin, 48:153
 follicle stimulating hormone, sleep deprivation, 48:153
 follicle stimulating hormone, thyroid stimulating hormone, 48:153
 follicle stimulating hormone, thyroxine, 48:153
 follicle stimulating hormone, triiodothyronine, 48:153
 growth hormone, estradiol, 48:153
 growth hormone, follicle stimulating hormone, 48:153
 growth hormone, normal volunteers, 48:153
 growth hormone, prolactin, 48:153
 growth hormone, sleep deprivation, 48:153
 growth hormone, thyroid stimulating hormone, 48:153
 growth hormone, thyroxine, 48:153
 growth hormone, triiodothyronine, 48:153
 normal volunteers, estradiol, 48:153
 normal volunteers, follicle stimulating hormone, 48:153
 normal volunteers, growth hormone, 48:153
 normal volunteers, prolactin, 48:153
 normal volunteers, sleep deprivation, 48:153
 normal volunteers, thyroid stimulating hormone, 48:153
 normal volunteers, thyroxine, 48:153
 normal volunteers, triiodothyronine, 48:153
 prolactin, estradiol, 48:153
 prolactin, follicle stimulating hormone, 48:153
 prolactin, growth hormone, 48:153
 prolactin, normal volunteers, 48:153
 prolactin, sleep deprivation, 48:153
 prolactin, thyroid stimulating hormone, 48:153
 prolactin, thyroxine, 48:153
 prolactin, triiodothyronine, 48:153
 sleep deprivation, estradiol, 48:153

Luteinizing hormone continued
 sleep deprivation, follicle stimulating hormone, 48:153
 sleep deprivation, growth hormone, 48:153
 sleep deprivation, normal volunteers, 48:153
 sleep deprivation, prolactin, 48:153
 sleep deprivation, thyroid stimulating hormone, 48:153
 sleep deprivation, thyroxine, 48:153
 sleep deprivation, triiodothyronine, 48:153
 thyroid stimulating hormone, estradiol, 48:153
 thyroid stimulating hormone, follicle stimulating hormone, 48:153
 thyroid stimulating hormone, growth hormone, 48:153
 thyroid stimulating hormone, normal volunteers, 48:153
 thyroid stimulating hormone, prolactin, 48:153
 thyroid stimulating hormone, sleep deprivation, 48:153
 thyroid stimulating hormone, thyroxine, 48:153
 thyroid stimulating hormone, triiodothyronine, 48:153
 thyroxine, estradiol, 48:153
 thyroxine, follicle stimulating hormone, 48:153
 thyroxine, growth hormone, 48:153
 thyroxine, normal volunteers, 48:153
 thyroxine, prolactin, 48:153
 thyroxine, sleep deprivation, 48:153
 thyroxine, thyroid stimulating hormone, 48:153
 triiodothyronine, 48:153
 triiodothyronine, estradiol, 48:153
 triiodothyronine, follicle stimulating hormone, 48:153
 triiodothyronine, growth hormone, 48:153
 triiodothyronine, normal volunteers, 48:153
 triiodothyronine, prolactin, 48:153
 triiodothyronine, sleep deprivation, 48:153
 triiodothyronine, thyroid stimulating hormone, 48:153
 triiodothyronine, thyroxine, 48:153
Lymphocytes
 affective disorder, family history, 48:201
 affective disorder, genetics, 48:201
 affective disorder, human leukocyte antigen, 48:201
 affective disorder, immune function, 48:201

Lymphocytes continued

affective disorder, schizophrenia, 48:201
 CD5 positive B lymphocytes, gender differences, 48:69
 CD5 positive B lymphocytes, immune function, 48:69
 CD5 positive B lymphocytes, race differences, 48:69
 CD5 positive B lymphocytes, schizophrenia, 48:69
 family history, affective disorder, 48:201
 family history, human leukocyte antigen, 48:201
 family history, immune function, 48:201
 family history, schizophrenia, 48:201
 gender differences, CD5 positive B lymphocytes, 48:69
 gender differences, immune function, 48:69
 gender differences, race differences, 48:69
 gender differences, schizophrenia, 48:69
 genetics, affective disorder, 48:201
 genetics, human leukocyte antigen, 48:201
 genetics, immune function, 48:201
 genetics, schizophrenia, 48:201
 human leukocyte antigen, affective disorder, 48:201
 human leukocyte antigen, family history, 48:201
 human leukocyte antigen, genetics, 48:201
 human leukocyte antigen, immune function, 48:201
 human leukocyte antigen, schizophrenia, 48:201
 immune function, affective disorder, 48:201
 immune function, CD5 positive B lymphocytes, 48:69
 immune function, family history, 48:201
 immune function, gender differences, 48:69
 immune function, genetics, 48:201
 immune function, human leukocyte antigen, 48:201
 immune function, race differences, 48:69
 immune function, schizophrenia, 48:69, 48:201
 race differences, CD5 positive B lymphocytes, 48:69
 race differences, gender differences, 48:69
 race differences, immune function, 48:69
 race differences, schizophrenia, 48:69
 schizophrenia, affective disorder, 48:201
 schizophrenia, CD5 positive B lymphocytes, 48:69

Lymphocytes continued

schizophrenia, family history, 48:201
 schizophrenia, gender differences, 48:69
 schizophrenia, genetics, 48:201
 schizophrenia, human leukocyte antigen, 48:201
 schizophrenia, immune function, 48:69, 48:201
 schizophrenia, race differences, 48:69
Magnetic resonance imaging
 affective disorder, cortisol, 47:163
 affective disorder, dexamethasone suppression test, 47:163
 affective disorder, hippocampus, 47:163
 auditory evoked potential P3 wave, cortical atrophy, 47:175
 auditory evoked potential P3 wave, human immunodeficiency virus, 47:175
 auditory evoked potential P3 wave, neuropsychology, 47:175
 auditory evoked potential P3 wave, substance abuse, 47:175
 cortical atrophy, auditory evoked potential P3 wave, 47:175
 cortical atrophy, event related potentials, 47:175
 cortical atrophy, human immunodeficiency virus, 47:175
 cortical atrophy, neuropsychology, 47:175
 cortical atrophy, substance abuse, 47:175
 cortisol, affective disorder, 47:163
 cortisol, dexamethasone suppression test, 47:163
 cortisol, hippocampus, 47:163
 dexamethasone suppression test, affective disorder, 47:163
 dexamethasone suppression test, cortisol, 47:163
 dexamethasone suppression test, hippocampus, 47:163
 event related potentials, auditory P3 wave, 47:175
 event related potentials, cortical atrophy, 47:175
 event related potentials, human immunodeficiency virus, 47:175
 event related potentials, neuropsychology, 47:175
 event related potentials, substance abuse, 47:175
 hippocampus, affective disorder, 47:163
 hippocampus, cortisol, 47:163

Magnetic resonance imaging continued
 hippocampus, dexamethasone suppression test, 47:163
 human immunodeficiency virus, auditory evoked potential P3, 47:175
 human immunodeficiency virus, cortical atrophy, 47:175
 human immunodeficiency virus, event related potentials, 47:175
 human immunodeficiency virus, neuropsychology, 47:175
 human immunodeficiency virus, substance abuse, 47:175
 neuropsychology, auditory evoked potential P3 wave, 47:175
 neuropsychology, cortical atrophy, 47:175
 neuropsychology, event related potentials, 47:175
 neuropsychology, human immunodeficiency virus, 47:175
 neuropsychology, substance abuse, 47:175
 substance abuse, auditory evoked potential P3, 47:175
 substance abuse, cortical atrophy, 47:175
 substance abuse, event related potentials, 47:175
 substance abuse, human immunodeficiency virus, 47:175
 substance abuse, neuropsychology, 47:175
Memory
 affective disorder, antidepressant medication, 46:295
 affective disorder, attention, 46:295
 affective disorder, treatment duration, 46:295
 affective disorder, visual pattern integration, 46:295
 alcohol dependence, frontal lobe, 46:175
 alcohol dependence, neuropsychology, 46:175
 alcohol dependence, schizophrenia, 46:175
 alcohol dependence, Wisconsin Card Sorting Test, 46:175
 antidepressant medication, affective disorder, 46:295
 antidepressant medication, attention, 46:295
 antidepressant medication, treatment duration, 46:295
 antidepressant medication, visual pattern integration, 46:295
 attention, affective disorder, 46:295
 attention, antidepressant medication, 46:295
 attention, treatment duration, 46:295
 attention, visual pattern integration, 46:295

Memory continued
 frontal lobe, alcohol dependence, 46:175
 frontal lobe, neuropsychology, 46:175
 frontal lobe, schizophrenia, 46:175
 frontal lobe, Wisconsin Card Sorting Test, 46:175
 neuropsychology, alcohol dependence, 46:175
 neuropsychology, frontal lobe, 46:175
 neuropsychology, schizophrenia, 46:175
 neuropsychology, Wisconsin Card Sorting Test, 46:175
 schizophrenia, alcohol dependence, 46:175
 schizophrenia, frontal lobe, 46:175
 schizophrenia, neuropsychology, 46:175
 schizophrenia, Wisconsin Card Sorting Test, 46:175
 treatment duration, affective disorder, 46:295
 treatment duration, antidepressant medication, 46:295
 treatment duration, attention, 46:295
 treatment duration, visual pattern integration, 46:295
 visual pattern integration, affective disorder, 46:295
 visual pattern integration, antidepressant medication, 46:295
 visual pattern integration, attention, 46:295
 visual pattern integration, treatment duration, 46:295
 Wisconsin Card Sorting Test, alcohol dependence, 46:175
 Wisconsin Card Sorting Test, frontal lobe, 46:175
 Wisconsin Card Sorting Test, neuropsychology, 46:175
 Wisconsin Card Sorting Test, schizophrenia, 46:175
3-Methoxy-4-hydroxyphenylglycol
 affective disorder, homovanillic acid, 46:19
 affective disorder, 5-hydroxyindoleacetic acid, 46:19
 affective disorder, norepinephrine, 46:19
 affective disorder, orthostatic challenge, 46:19
 anxiety disorder, cortisol, 48:119
 anxiety disorder, fluvoxamine, 48:119
 anxiety disorder, norepinephrine, 48:119
 anxiety disorder, panic, 48:119
 anxiety disorder, serotonin, 48:119
 anxiety disorder, yohimbine, 48:119
 clozapine, dopamine, 46:139
 clozapine, homovanillic acid, 46:139

3-Methoxy-4-hydroxyphenylglycol continued
 clozapine, norepinephrine, 46:139
 clozapine, schizophrenia, 46:139
 clozapine, therapeutic response, 46:139
 cortisol, anxiety disorder, 48:119
 cortisol, fluvoxamine, 48:119
 cortisol, norepinephrine, 48:119
 cortisol, panic disorder, 48:119
 cortisol, serotonin, 48:119
 cortisol, yohimbine, 48:119
 dissociative phenomena, eating disorder, 49:1
 dissociative phenomena, endorphins, 49:1
 dissociative phenomena, homovanillic acid, 49:1
 dissociative phenomena, 5-hydroxyindoleacetic acid, 49:1
 dopamine, clozapine, 46:139
 dopamine, homovanillic acid, 46:139
 dopamine, norepinephrine, 46:139
 dopamine, schizophrenia, 46:139
 dopamine, therapeutic response, 46:139
 eating disorder, dissociative phenomena, 49:1
 eating disorder, endorphins, 49:1
 eating disorder, homovanillic acid, 49:1
 eating disorder, 5-hydroxyindoleacetic acid, 49:1
 endorphins, cerebrospinal fluid, 49:1
 endorphins, dissociative phenomena, 49:1
 endorphins, eating disorder, 49:1
 endorphins, homovanillic acid, 49:1
 endorphins, 5-hydroxyindoleacetic acid, 49:1
 fluvoxamine, anxiety disorder, 48:119
 fluvoxamine, cortisol, 48:119
 fluvoxamine, norepinephrine, 48:119
 fluvoxamine, panic disorder, 48:119
 fluvoxamine, reuptake inhibitor, 48:119
 fluvoxamine, serotonin, 48:119
 fluvoxamine, yohimbine, 48:119
 homovanillic acid, affective disorder, 46:19
 homovanillic acid, cerebrospinal fluid, 46:19, 49:1
 homovanillic acid, clozapine, 46:139
 homovanillic acid, dissociative phenomena, 49:1
 homovanillic acid, dopamine, 46:139
 homovanillic acid, eating disorder, 49:1
 homovanillic acid, endorphins, 49:1
 homovanillic acid, 5-hydroxyindoleacetic acid, 46:19, 49:1
 homovanillic acid, norepinephrine, 46:19, 46:139
 homovanillic acid, orthostatic challenge, 46:19

3-Methoxy-4-hydroxyphenylglycol continued
 homovanillic acid, phototherapy, 46:19
 homovanillic acid, schizophrenia, 46:139
 homovanillic acid, seasonal depression, 46:19
 homovanillic acid, therapeutic response, 46:139
 5-hydroxyindoleacetic acid, affective disorder, 46:19
 5-hydroxyindoleacetic acid, cerebrospinal fluid, 46:19, 49:1
 5-hydroxyindoleacetic acid, dissociative phenomena, 49:1
 5-hydroxyindoleacetic acid, eating disorder, 49:1
 5-hydroxyindoleacetic acid, endorphins, 49:1
 5-hydroxyindoleacetic acid, homovanillic acid, 46:19, 49:1
 5-hydroxyindoleacetic acid, norepinephrine, 46:19
 5-hydroxyindoleacetic acid, orthostatic challenge, 46:19
 5-hydroxyindoleacetic acid, phototherapy, 46:19
 5-hydroxyindoleacetic acid, seasonal depression, 46:19
 norepinephrine, affective disorder, 46:19
 norepinephrine, anxiety disorder, 48:119
 norepinephrine, cerebrospinal fluid, 46:19
 norepinephrine, clozapine, 46:139
 norepinephrine, cortisol, 48:119
 norepinephrine, dopamine, 46:139
 norepinephrine, fluvoxamine, 48:119
 norepinephrine, homovanillic acid, 46:19, 46:139
 norepinephrine, 5-hydroxyindoleacetic acid, 46:19
 norepinephrine, orthostatic challenge, 46:19
 norepinephrine, panic disorder, 48:119
 norepinephrine, phototherapy, 46:19
 norepinephrine, schizophrenia, 46:139
 norepinephrine, seasonal depression, 46:19
 norepinephrine, serotonin, 48:119
 norepinephrine, yohimbine, 48:119
 orthostatic challenge, affective disorder, 46:19
 orthostatic challenge, homovanillic acid, 46:19
 orthostatic challenge, 5-hydroxyindoleacetic acid, 46:19
 orthostatic challenge, norepinephrine, 46:19
 orthostatic challenge, seasonal depression, 46:19

3-Methoxy-4-hydroxyphenylglycol continued
 panic disorder, cortisol, 48:119
 panic disorder, fluvoxamine, 48:119
 panic disorder, norepinephrine, 48:119
 panic disorder, serotonin, 48:119
 panic disorder, yohimbine, 48:119
 phototherapy, affective disorder, 46:19
 phototherapy, homovanillic acid, 46:19
 phototherapy, 5-hydroxyindoleacetic acid, 46:19
 phototherapy, norepinephrine, 46:19
 phototherapy, orthostatic challenge, 46:19
 phototherapy, seasonal depression, 46:19
 reuptake inhibitor, serotonin, 48:119
 schizophrenia, clozapine, 46:139
 schizophrenia, dopamine, 46:139
 schizophrenia, homovanillic acid, 46:139
 schizophrenia, norepinephrine, 46:139
 schizophrenia, therapeutic response, 46:139
 seasonal depression, homovanillic acid, 46:19
 seasonal depression, 5-hydroxyindoleacetic acid, 46:19
 seasonal depression, norepinephrine, 46:19
 seasonal depression, orthostatic challenge, 46:19
 seasonal depression, phototherapy, 46:19
 serotonin, anxiety disorder, 48:119
 serotonin, cortisol, 48:119
 serotonin, fluvoxamine, 48:119
 serotonin, norepinephrine, 48:119
 serotonin, panic disorder, 48:119
 serotonin, reuptake inhibitor, 48:119
 serotonin, yohimbine, 48:119
 therapeutic response, clozapine, 46:139
 therapeutic response, dopamine, 46:139
 therapeutic response, homovanillic acid, 46:139
 therapeutic response, norepinephrine, 46:139
 therapeutic response, schizophrenia, 46:139
 yohimbine, anxiety disorder, 48:119
 yohimbine, cortisol, 48:119
 yohimbine, fluvoxamine, 48:119
 yohimbine, norepinephrine, 48:119
 yohimbine, panic disorder, 48:119
 yohimbine, serotonin, 48:119
Migraine
 bulimia nervosa, 46:201
 eating disorders, 46:201
Motor performance
 affective disorder, language, 47:99
 affective disorder, laterality, 47:99
 affective disorder, phototherapy, 47:99

Motor performance continued
 alcohol dependence, cocaine, 47:69
 alcohol dependence, substance abuse, 47:69
 alcohol dependence, tremor and body sway, 47:69
 cocaine, alcohol dependence, 47:69
 cocaine, tremor and body sway, 47:69
 language, affective disorder, 47:99
 language, laterality, 47:99
 language, phototherapy, 47:99
 language, seasonal depression, 47:99
 laterality, affective disorder, 47:99
 laterality, language, 47:99
 laterality, phototherapy, 47:99
 laterality, seasonal depression, 47:99
 phototherapy, affective disorder, 47:99
 phototherapy, language, 47:99
 phototherapy, laterality, 47:99
 phototherapy, seasonal depression, 47:99
 seasonal depression, language, 47:99
 seasonal depression, laterality, 47:99
 seasonal depression, phototherapy, 47:99
 substance abuse, alcohol dependence, 47:69
 substance abuse, cocaine, 47:69
 substance abuse, tremor and body sway, 47:69
 tremor and body sway, alcohol dependence, 47:69
 tremor and body sway, cocaine, 47:69
 tremor and body sway, substance abuse, 47:69
N-acetyl-beta-glucosaminidase
 affective disorder, bipolar subtype, 47:129
 affective disorder, depressive symptoms, 47:129
 affective disorder, serotonin, 47:129
 bipolar subtype, depressive symptoms, 47:129
 bipolar subtype, serotonin, 47:129
 depressive symptoms, affective disorder, 47:129
 depressive symptoms, bipolar subtype, 47:129
 depressive symptoms, serotonin, 47:129
 serotonin, affective disorder, 47:129
 serotonin, bipolar subtype, 47:129
 serotonin, depressive symptoms, 47:129
Neuroleptics
 amino acids, circadian rhythm, 47:187
 amino acids, dopamine, 47:187
 amino acids, neutral serum amino acids, 47:187

Neuroleptics continued

amino acids, phenylalanine, 47:187
 amino acids, schizophrenia, 47:187
 amino acids, therapeutic response, 47:187
 animal models, domperidone, 47:37
 animal models, dysphoria, 47:37
 animal models, haloperidol, 47:37
 animal models, locomotor activity, 47:37
 animal models, neuroleptic-induced defecation in rats, 47:37
 circadian rhythm, amino acids, 47:187
 circadian rhythm, dopamine, 47:187
 circadian rhythm, neutral serum amino acids, 47:187
 circadian rhythm, phenylalanine, 47:187
 circadian rhythm, schizophrenia, 47:187
 circadian rhythm, therapeutic response, 47:187
 domperidone, animal models, 47:37
 domperidone, dysphoria, 47:37
 domperidone, haloperidol, 47:37
 domperidone, locomotor activity, 47:37
 domperidone, neuroleptic-induced defecation in rats, 47:37
 dopamine, amino acids, 47:187
 dopamine, circadian rhythm, 47:187
 dopamine, neutral serum amino acids, 47:187
 dopamine, phenylalanine, 47:187
 dopamine, schizophrenia, 47:187
 dopamine, therapeutic response, 47:187
 dysphoria, animal models, 47:37
 dysphoria, domperidone, 47:37
 dysphoria, haloperidol, 47:37
 dysphoria, locomotor activity, 47:37
 dysphoria, neuroleptic-induced defecation in rats, 47:37
 haloperidol, animal models, 47:37
 haloperidol, domperidone, 47:37
 haloperidol, dysphoria, 47:37
 haloperidol, locomotor activity, 47:37
 haloperidol, neuroleptic-induced defecation in rats, 47:37
 locomotor activity, animal models, 47:37
 locomotor activity, domperidone, 47:37
 locomotor activity, dysphoria, 47:37
 locomotor activity, haloperidol, 47:37
 locomotor activity, neuroleptic-induced defecation in rats, 47:37
 neuroleptic-induced defecation in rats, animal models, 47:37
 neuroleptic-induced defecation in rats, domperidone, 47:37

Neuroleptics continued

neuroleptic-induced defecation in rats, dysphoria, 47:37
 neuroleptic-induced defecation in rats, haloperidol, 47:37
 neuroleptic-induced defecation in rats, locomotor activity, 47:37
 neutral serum amino acids, circadian rhythm, 47:187
 neutral serum amino acids, dopamine, 47:187
 neutral serum amino acids, phenylalanine, 47:187
 neutral serum amino acids, schizophrenia, 47:187
 neutral serum amino acids, therapeutic response, 47:187
 phenylalanine, amino acids, 47:187
 phenylalanine, circadian rhythm, 47:187
 phenylalanine, dopamine, 47:187
 phenylalanine, neutral serum amino acids, 47:187
 phenylalanine, schizophrenia, 47:187
 phenylalanine, therapeutic response, 47:187
 schizophrenia, amino acids, 47:187
 schizophrenia, circadian rhythm, 47:187
 schizophrenia, dopamine, 47:187
 schizophrenia, neutral serum amino acids, 47:187
 schizophrenia, phenylalanine, 47:187
 schizophrenia, serotonin S2 receptor in platelets, 48:57
 schizophrenia, therapeutic response, 47:187
 serotonin S2 receptor in platelets, schizophrenia, 48:57
 therapeutic response, amino acids, 47:187
 therapeutic response, circadian rhythm, 47:187
 therapeutic response, dopamine, 47:187
 therapeutic response, neutral serum amino acids, 47:187
 therapeutic response, phenylalanine, 47:187
 therapeutic response, schizophrenia, 47:187
Neuropsychology
 alcohol dependence, frontal lobe, 46:175
 alcohol dependence, memory, 46:175
 alcohol dependence, schizophrenia, 46:175
 alcohol dependence, Wisconsin Card Sorting Test, 46:175
 antisocial disorder, borderline disorder, 48:257
 antisocial disorder, impulsivity, 48:257
 antisocial disorder, neurological soft signs, 48:257

Neuropsychology continued

antisocial disorder, personality disorder, 48:257
 auditory evoked potential P3, cortical atrophy, 47:175
 auditory evoked potential P3, human immunodeficiency virus, 47:175
 auditory evoked potential P3, magnetic resonance imaging, 47:175
 auditory evoked potential P3, substance abuse, 47:175
 borderline disorder, antisocial disorder, 48:257
 borderline disorder, impulsivity, 48:257
 borderline disorder, neurological soft signs, 48:257
 cortical atrophy, auditory evoked potential P3, 47:175
 cortical atrophy, event related potentials, 47:175
 cortical atrophy, human immunodeficiency virus, 47:175
 cortical atrophy, magnetic resonance imaging, 47:175
 cortical atrophy, substance abuse, 47:175
 event related potentials, cortical atrophy, 47:175
 event related potentials, human immunodeficiency virus, 47:175
 event related potentials, magnetic resonance imaging, 47:175
 event related potentials, substance abuse, 47:175
 eye movements, frontal lobe, 48:191
 eye movements, obsessive-compulsive disorder, 48:191
 eye movements, saccadic, 48:191
 eye movements, smooth pursuit, 48:191
 eye movements, Wisconsin Card Sorting Test, 48:191
 frontal lobe, alcohol dependence, 46:175
 frontal lobe, eye movements, 48:191
 frontal lobe, memory, 46:175
 frontal lobe, obsessive-compulsive disorder, 48:191
 frontal lobe, schizophrenia, 46:175
 frontal lobe, Wisconsin Card Sorting Test, 46:175, 48:191
 human immunodeficiency virus, auditory evoked potential P3, 47:175
 human immunodeficiency virus, cortical atrophy, 47:175

Neuropsychology continued

human immunodeficiency virus, event related potentials, 47:175
 human immunodeficiency virus, magnetic resonance imaging, 47:175
 human immunodeficiency virus, substance abuse, 47:175
 impulsivity, antisocial disorder, 48:257
 impulsivity, borderline disorder, 48:257
 impulsivity, neurological soft signs, 48:257
 impulsivity, personality disorder, 48:257
 magnetic resonance imaging, auditory evoked potential P3, 47:175
 magnetic resonance imaging, cortical atrophy, 47:175
 magnetic resonance imaging, event related potentials, 47:175
 magnetic resonance imaging, human immunodeficiency virus, 47:175
 magnetic resonance imaging, substance abuse, 47:175
 memory, alcohol dependence, 46:175
 memory, frontal lobe, 46:175
 memory, schizophrenia, 46:175
 memory, Wisconsin Card Sorting Test, 46:175
 neurological soft signs, antisocial disorder, 48:257
 neurological soft signs, borderline disorder, 48:257
 neurological soft signs, impulsivity, 48:257
 neurological soft signs, personality disorder, 48:257
 obsessive-compulsive disorder, eye movements, 48:191
 obsessive-compulsive disorder, frontal lobe, 48:191
 obsessive-compulsive disorder, Wisconsin Card Sorting Test, 48:191
 personality disorder, antisocial, 48:257
 personality disorder, borderline, 48:257
 personality disorder, impulsivity, 48:257
 personality disorder, neurological soft signs, 48:257
 saccadic eye movements, 48:191
 saccadic eye movements, frontal lobe, 48:191
 saccadic eye movements, obsessive-compulsive disorder, 48:191
 saccadic eye movements, Wisconsin Card Sorting Test, 48:191
 schizophrenia, alcohol dependence, 46:175
 schizophrenia, frontal lobe, 46:175

Neuropsychology continued

schizophrenia, memory, 46:175
 schizophrenia, Wisconsin Card Sorting Test, 46:175
 smooth pursuit eye movements, 48:191
 smooth pursuit eye movements, frontal lobe, 48:191
 smooth pursuit eye movements, obsessive-compulsive disorder, 48:191
 smooth pursuit eye movements, Wisconsin Card Sorting Test, 48:191
 substance abuse, auditory evoked potential P3, 47:175
 substance abuse, cortical atrophy, 47:175
 substance abuse, event related potentials, 47:175
 substance abuse, human immunodeficiency virus, 47:175
 substance abuse, magnetic resonance imaging, 47:175
 Wisconsin Card Sorting Test, alcohol dependence, 46:175
 Wisconsin Card Sorting Test, eye movements, 48:191
 Wisconsin Card Sorting Test, frontal lobe, 46:175, 48:191
 Wisconsin Card Sorting Test, memory, 46:175
 Wisconsin Card Sorting Test, obsessive-compulsive disorder, 48:191
 Wisconsin Card Sorting Test, saccadic eye movements, 48:191
 Wisconsin Card Sorting Test, schizophrenia, 46:175
 Wisconsin Card Sorting Test, smooth pursuit eye movements, 48:191

Nimodipine

affective disorder, bipolar subtype, 49:257
 affective disorder, calcium channel blockers, 49:257
 affective disorder, rapid cycling, 49:257
 affective disorder, therapeutic response, 49:257
 bipolar subtype, affective disorder, 49:257
 bipolar subtype, calcium channel blockers, 49:257
 bipolar subtype, rapid cycling, 49:257
 bipolar subtype, therapeutic response, 49:257
 calcium channel blockers, affective disorder, 49:257
 calcium channel blockers, bipolar subtype, 49:257

Nimodipine continued

calcium channel blockers, therapeutic response, 49:257
 rapid cycling, affective disorder, 49:257
 rapid cycling, bipolar subtype, 49:257
 rapid cycling, calcium channel blockers, 49:257
 therapeutic response, affective disorder, 49:257
 therapeutic response, bipolar subtype, 49:257
 therapeutic response, calcium channel blockers, 49:257
 therapeutic response, rapid cycling, 49:257

Obsessive-compulsive disorder
 anxiety disorder, attention, 49:183
 anxiety disorder, auditory N200, 49:167
 anxiety disorder, event related potentials, 49:167
 anxiety disorder, laterality, 49:167
 anxiety disorder, neurological soft signs, 49:167
 anxiety disorder, P3 component, 49:167
 anxiety disorder, Posner task, 49:183
 anxiety disorder, reaction time, 49:183
 anxiety disorder, spatial-linguistic conflict task, 49:183
 attention, anxiety disorder, 49:183
 attention, Posner task, 49:183
 attention, reaction time, 49:183
 attention, spatial-linguistic conflict task, 49:183
 auditory N200, anxiety disorder, 49:167
 auditory N200, event related potentials, 49:167
 auditory N200, laterality, 49:167
 auditory N200, neurological soft signs, 49:167
 auditory N200, P3 component, 49:167
 behavior therapy, exposure, 49:63
 behavior therapy, fluvoxamine, 49:63
 event related potentials, anxiety disorder, 49:167
 event related potentials, auditory N200, 49:167
 event related potentials, laterality, 49:167
 event related potentials, neurological soft signs, 49:167
 event related potentials, P3 component, 49:167
 exposure, behavior therapy, 49:63
 exposure, fluvoxamine, 49:63
 eye movements, frontal lobe, 48:191

Obsessive-compulsive disorder continued
 eye movements, neuropsychology, 48:191
 eye movements, saccadic, 48:191
 eye movements, smooth pursuit, 48:191
 eye movements, Wisconsin Card Sorting Test, 48:191
 fluvoxamine, behavior therapy, 49:63
 fluvoxamine, exposure, 49:63
 frontal lobe, eye movements, 48:191
 frontal lobe, neuropsychology, 48:191
 frontal lobe, saccadic eye movements, 48:191
 frontal lobe, smooth pursuit eye movements, 48:191
 frontal lobe, Wisconsin Card Sorting Test, 48:191
 laterality, anxiety disorder, 49:167
 laterality, auditory N200, 49:167
 laterality, event related potentials, 49:167
 laterality, neurological soft signs, 49:167
 laterality, P3 component, 49:167
 neurological soft signs, anxiety disorder, 49:167
 neurological soft signs, auditory N200, 49:167
 neurological soft signs, event related potentials, 49:167
 neurological soft signs, laterality, 49:167
 neurological soft signs, P3 component, 49:167
 neuropsychology, eye movements, 48:191
 neuropsychology, frontal lobe, 48:191
 neuropsychology, saccadic, 48:191
 neuropsychology, smooth pursuit eye movements, 48:191
 neuropsychology, Wisconsin Card Sorting Test, 48:191
 P3 component, anxiety disorder, 49:167
 P3 component, auditory N200, 49:167
 P3 component, event related potentials, 49:167
 P3 component, laterality, 49:167
 P3 component, neurological soft signs, 49:167
 Posner task, anxiety disorder, 49:183
 Posner task, attention, 49:183
 Posner task, reaction time, 49:183
 Posner task, spatial-linguistic conflict task, 49:183
 reaction time, anxiety disorder, 49:183
 reaction time, attention, 49:183
 reaction time, Posner task, 49:183
 reaction time, spatial-linguistic conflict task, 49:183

Obsessive-compulsive disorder continued
 saccadic eye movements, 48:191
 saccadic eye movements, frontal lobe, 48:191
 saccadic eye movements, neuropsychology, 48:191
 saccadic eye movements, Wisconsin Card Sorting Test, 48:191
 smooth pursuit eye movements, 48:191
 smooth pursuit eye movements, frontal lobe, 48:191
 smooth pursuit eye movements, neuropsychology, 48:191
 smooth pursuit eye movements, Wisconsin Card Sorting Test, 48:191
 spatial-linguistic conflict task, anxiety disorder, 49:183
 spatial-linguistic conflict task, attention, 49:183
 spatial-linguistic conflict task, Posner task, 49:183
 spatial-linguistic conflict task, reaction time, 49:183
 Wisconsin Card Sorting Test, eye movements, 48:191
 Wisconsin Card Sorting Test, frontal lobe, 48:191
 Wisconsin Card Sorting Test, neuropsychology, 48:191
 Wisconsin Card Sorting Test, saccadic eye movements, 48:191
 Wisconsin Card Sorting Test, smooth pursuit eye movements, 48:191
Opioids
 growth hormone, kappa agonist, 47:267
 growth hormone, motor tics, 47:267
 growth hormone, prolactin, 47:267
 growth hormone, spiradoline, 47:267
 growth hormone, Tourette's syndrome, 47:267
 kappa agonist, growth hormone, 47:267
 kappa agonist, motor tics, 47:267
 kappa agonist, prolactin, 47:267
 kappa agonist, spiradoline, 47:267
 kappa agonist, Tourette's syndrome, 47:267
 motor tics, kappa agonist, 47:267
 motor tics, spiradoline, 47:267
 motor tics, Tourette's syndrome, 47:267
 prolactin, growth hormone, 47:267
 prolactin, kappa agonist, 47:267
 prolactin, spiradoline, 47:267
 prolactin, Tourette's syndrome, 47:267
 spiradoline, growth hormone, 47:267

Opioids continued

- spiradoline, motor tics, 47:267
- spiradoline, prolactin, 47:267
- spiradoline, Tourette's syndrome, 47:267
- Tourette's syndrome, growth hormone, 47:267
- Tourette's syndrome, kappa agonist, 47:267
- Tourette's syndrome, motor tics, 47:267
- Tourette's syndrome, prolactin, 47:267
- Tourette's syndrome, spiradoline, 47:267

Oxytocin

- arginine vasopressin, electrodermal response, 48:107
- arginine vasopressin, electromyography, 48:107
- arginine vasopressin, heart rate response, 48:107
- arginine vasopressin, personal combat imagery, 48:107
- arginine vasopressin, posttraumatic stress syndrome, 48:107
- electrodermal response, arginine vasopressin, 48:107
- electrodermal response, electromyography, 48:107
- electrodermal response, heart rate response, 48:107
- electrodermal response, personal combat imagery, 48:107
- electrodermal response, posttraumatic stress syndrome, 48:107
- electromyography, arginine vasopressin, 48:107
- electromyography, electrodermal response, 48:107
- electromyography, heart rate response, 48:107
- electromyography, personal combat imagery, 48:107
- electromyography, posttraumatic stress syndrome, 48:107
- heart rate response, arginine vasopressin, 48:107
- heart rate response, electrodermal response, 48:107
- heart rate response, electromyography, 48:107
- heart rate response, personal combat imagery, 48:107
- heart rate response, posttraumatic stress syndrome, 48:107
- personal combat imagery, arginine vasopressin, 48:107
- personal combat imagery, electrodermal response, 48:107
- personal combat imagery, electromyography, 48:107

Oxytocin continued

- personal combat imagery, heart rate response, 48:107
- personal combat imagery, posttraumatic stress syndrome, 48:107
- posttraumatic stress syndrome, arginine vasopressin, 48:107
- posttraumatic stress syndrome, electrodermal response, 48:107
- posttraumatic stress syndrome, electromyography, 48:107
- posttraumatic stress syndrome, heart rate response, 48:107
- posttraumatic stress syndrome, personal combat imagery, 48:107
- posttraumatic stress syndrome, Vietnam veterans, 48:107

Panic attacks

- blood pressure, lactate infusion, 46:79
- blood pressure, menstrual cycle, 46:79
- blood pressure, premenstrual syndrome, 46:79
- lactate infusion, blood pressure, 46:79
- lactate infusion, menstrual cycle, 46:79
- lactate infusion, premenstrual syndrome, 46:79
- menstrual cycle, blood pressure, 46:79
- menstrual cycle, lactate infusion, 46:79
- premenstrual syndrome, blood pressure, 46:79
- premenstrual syndrome, lactate infusion, 46:79

Panic disorder

- agoraphobia, alcohol dependence, 46:285
- agoraphobia, anxiety disorder, 46:285
- agoraphobia, comorbidity, 46:285
- agoraphobia, substance abuse, 46:285
- alcohol dependence, agoraphobia, 46:285
- alcohol dependence, anxiety disorder, 46:285
- alcohol dependence, comorbidity, 46:285
- alcohol dependence, substance abuse, 46:285
- anxiety disorder, agoraphobia, 46:285
- anxiety disorder, alcohol dependence, 46:285
- anxiety disorder, autonomic nervous system, 46:89
- anxiety disorder, carbon dioxide, 47:1, 47:295
- anxiety disorder, clomipramine, 47:295
- anxiety disorder, comorbidity, 46:285
- anxiety disorder, cortisol, 48:119
- anxiety disorder, diazepam response, 47:151
- anxiety disorder, eye movements, 47:151

Panic disorder continued

anxiety disorder, fluvoxamine, 48:119
 anxiety disorder, HCO₃, 47:1
 anxiety disorder, heart rate, 46:89
 anxiety disorder, hyperventilation, 47:1
 anxiety disorder, joint hypermobility syndrome, 46:59
 anxiety disorder, 3-methoxy-4-hydroxyphenylglycol, 48:119
 anxiety disorder, norepinephrine, 48:119
 anxiety disorder, orthostatic challenge, 46:89
 anxiety disorder, *p*CO₂, 47:1
 anxiety disorder, personality, 47:151
 anxiety disorder, *p*H, 47:1
 anxiety disorder, *p*O₂, 47:1
 anxiety disorder, power spectral analysis of heart rate, 46:89
 anxiety disorder, respiratory alkalosis, 47:1
 anxiety disorder, saccadic eye movement velocity, 47:151
 anxiety disorder, serotonin, 48:119
 anxiety disorder, substance abuse, 46:285
 anxiety disorder, Tridimensional Personality Questionnaire, 47:151
 anxiety disorder, ventilatory response, 47:295
 anxiety disorder, yohimbine, 48:119
 autonomic nervous system, anxiety disorder, 46:89
 autonomic nervous system, heart rate, 46:89
 autonomic nervous system, orthostatic challenge, 46:89
 autonomic nervous system, power spectral analysis of heart rate, 46:89
 carbon dioxide, anxiety disorder, 47:295
 carbon dioxide, clomipramine, 47:295
 carbon dioxide, ventilatory response, 47:295
 carbon dioxide, anxiety disorder, 47:1
 carbon dioxide, HCO₃, 47:1
 carbon dioxide, hyperventilation, 47:1
 carbon dioxide, *p*CO₂, 47:1
 carbon dioxide, *p*H, 47:1
 carbon dioxide, *p*O₂, 47:1
 carbon dioxide, respiratory alkalosis, 47:1
 clomipramine, anxiety disorder, 47:295
 comorbidity, agoraphobia, 46:285
 comorbidity, alcohol dependence, 46:285
 comorbidity, anxiety disorder, 46:285
 comorbidity, substance abuse, 46:285
 cortisol, anxiety disorder, 48:119
 cortisol, fluvoxamine, 48:119
 cortisol, 3-methoxy-4-hydroxyphenylglycol, 48:119

Panic disorder continued

cortisol, norepinephrine, 48:119
 cortisol, serotonin, 48:119
 cortisol, yohimbine, 48:119
 diazepam response, anxiety disorder, 47:151
 diazepam response, eye movements, 47:151
 diazepam response, personality, 47:151
 diazepam response, saccadic eye movement velocity, 47:151
 diazepam response, Tridimensional Personality Questionnaire, 47:151
 eye movements, anxiety disorder, 47:151
 eye movements, diazepam response, 47:151
 eye movements, personality, 47:151
 eye movements, saccadic eye movement velocity, 47:151
 eye movements, Tridimensional Personality Questionnaire, 47:151
 fluvoxamine, anxiety disorder, 48:119
 fluvoxamine, cortisol, 48:119
 fluvoxamine, 3-methoxy-4-hydroxyphenylglycol, 48:119
 fluvoxamine, norepinephrine, 48:119
 fluvoxamine, reuptake inhibitor, 48:119
 fluvoxamine, serotonin, 48:119
 fluvoxamine, yohimbine, 48:119
 HCO₃, anxiety disorder, 47:1
 HCO₃, carbon dioxide, 47:1
 HCO₃, hyperventilation, 47:1
 HCO₃, *p*CO₂, 47:1
 HCO₃, *p*H, 47:1
 HCO₃, *p*O₂, 47:1
 HCO₃, respiratory alkalosis, 47:1
 heart rate, anxiety disorder, 46:89
 heart rate, autonomic nervous system, 46:89
 heart rate, orthostatic challenge, 46:89
 heart rate, power spectral analysis of heart rate, 46:89
 hyperventilation, anxiety disorder, 47:1
 hyperventilation, carbon dioxide, 47:1
 hyperventilation, HCO₃, 47:1
 hyperventilation, *p*CO₂, 47:1
 hyperventilation, *p*H, 47:1
 hyperventilation, *p*O₂, 47:1
 hyperventilation, respiratory alkalosis, 47:1
 joint hypermobility syndrome, anxiety disorder, 46:59
 3-methoxy-4-hydroxyphenylglycol, anxiety disorder, 48:119
 3-methoxy-4-hydroxyphenylglycol, cortisol, 48:119

Panic disorder continued

3-methoxy-4-hydroxyphenylglycol, fluvoxamine, 48:119
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 48:119
 3-methoxy-4-hydroxyphenylglycol, serotonin, 48:119
 3-methoxy-4-hydroxyphenylglycol, yohimbine, 48:119
 norepinephrine, anxiety disorder, 48:119
 norepinephrine, cortisol, 48:119
 norepinephrine, fluvoxamine, 48:119
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 48:119
 norepinephrine, serotonin, 48:119
 norepinephrine, yohimbine, 48:119
 orthostatic challenge, anxiety disorder, 46:89
 orthostatic challenge, autonomic nervous system, 46:89
 orthostatic challenge, heart rate, 46:89
 orthostatic challenge, power spectral analysis of heart rate, 46:89
 $p\text{CO}_2$, anxiety disorder, 47:1
 $p\text{CO}_2$, HCO_3 , 47:1
 $p\text{CO}_2$, hyperventilation, 47:1
 $p\text{CO}_2$, pH , 47:1
 $p\text{CO}_2$, $p\text{O}_2$, 47:1
 $p\text{CO}_2$, respiratory alkalosis, 47:1
 personality, anxiety disorder, 47:151
 personality, diazepam response, 47:151
 personality, eye movements, 47:151
 personality, saccadic eye movement velocity, 47:151
 personality, Tridimensional Personality Questionnaire, 47:151
 pH , anxiety disorder, 47:1
 pH , carbon dioxide, 47:1
 pH , HCO_3 , 47:1
 pH , hyperventilation, 47:1
 pH , $p\text{CO}_2$, 47:1
 pH , $p\text{CO}_2$, 47:1
 pH , respiratory alkalosis, 47:1
 $p\text{CO}_2$, anxiety disorder, 47:1
 $p\text{CO}_2$, carbon dioxide, 47:1
 $p\text{CO}_2$, HCO_3 , 47:1
 $p\text{CO}_2$, hyperventilation, 47:1
 $p\text{O}_2$, $p\text{CO}_2$, 47:1
 $p\text{O}_2$, pH , 47:1
 $p\text{O}_2$, respiratory alkalosis, 47:1
 power spectral analysis of heart rate, anxiety disorder, 46:89

Panic disorder continued

power spectral analysis of heart rate, autonomic nervous system, 46:89
 power spectral analysis of heart rate, orthostatic challenge, 46:89
 respiratory alkalosis, anxiety disorder, 47:1
 respiratory alkalosis, carbon dioxide, 47:1
 respiratory alkalosis, HCO_3 , 47:1
 respiratory alkalosis, hyperventilation, 47:1
 respiratory alkalosis, $p\text{CO}_2$, 47:1
 respiratory alkalosis, pH , 47:1
 respiratory alkalosis, $p\text{O}_2$, 47:1
 reuptake inhibitor, serotonin, 48:119
 saccadic eye movement velocity, anxiety disorder, 47:151
 saccadic eye movement velocity, diazepam response, 47:151
 saccadic eye movement velocity, personality, 47:151
 saccadic eye movement velocity, Tridimensional Personality Questionnaire, 47:151
 serotonin, anxiety disorder, 48:119
 serotonin, cortisol, 48:119
 serotonin, fluvoxamine, 48:119
 serotonin, 3-methoxy-4-hydroxyphenylglycol, 48:119
 serotonin, norepinephrine, 48:119
 serotonin, reuptake inhibitor, 48:119
 serotonin, yohimbine, 48:119
 substance abuse, agoraphobia, 46:285
 substance abuse, alcohol dependence, 46:285
 substance abuse, anxiety disorder, 46:285
 substance abuse, comorbidity, 46:285
 Tridimensional Personality Questionnaire, anxiety disorder, 47:151
 Tridimensional Personality Questionnaire, diazepam response, 47:151
 Tridimensional Personality Questionnaire, eye movements, 47:151
 Tridimensional Personality Questionnaire, saccadic eye movement velocity, 47:151
 ventilatory response, anxiety disorder, 47:295
 ventilatory response, carbon dioxide, 47:295
 ventilatory response, clomipramine, 47:295
 yohimbine, anxiety disorder, 48:119
 yohimbine, cortisol, 48:119
 yohimbine, fluvoxamine, 48:119
 yohimbine, 3-methoxy-4-hydroxyphenylglycol, 48:119
 yohimbine, norepinephrine, 48:119
 yohimbine, serotonin, 48:119

Paroxetine

calmodulin affinity chromatography, endogenous serotonin uptake inhibitors, 47:121
 calmodulin affinity chromatography, imipramine, 47:121
 calmodulin affinity chromatography, serotonin, 47:121
 endogenous serotonin uptake inhibitors, calmodulin affinity chromatography, 47:121
 endogenous serotonin uptake inhibitors, imipramine, 47:121
 endogenous serotonin uptake inhibitors, serotonin, 47:121
 imipramine, calmodulin affinity chromatography, 47:121
 imipramine, endogenous serotonin uptake inhibitors, 47:121
 imipramine, serotonin, 47:121
 serotonin, calmodulin affinity chromatography, 47:121
 serotonin, endogenous serotonin uptake inhibitors, 47:121
 serotonin, imipramine, 47:121

Personality

affective disorder, divorce, 46:165
 affective disorder, dream masochism, 46:165
 affective disorder, gender differences, 46:165
 affective disorder, sex role identification, 46:165
 affective disorder, sleep, 46:165
 aggression, genetics, 48:229
 aggression, impulsivity, 48:229
 aggression, twin studies, 48:229
 anxiety disorders, diazepam response, 47:151
 anxiety disorders, eye movements, 47:151
 anxiety disorders, panic disorder, 47:151
 anxiety disorders, saccadic eye movement velocity, 47:151
 anxiety disorders, Tridimensional Personality Questionnaire, 47:151
 diazepam response, anxiety disorders, 47:151
 diazepam response, eye movements, 47:151
 diazepam response, panic disorder, 47:151
 diazepam response, saccadic eye movement velocity, 47:151
 diazepam response, Tridimensional Personality Questionnaire, 47:151
 divorce, affective disorder, 46:165
 divorce, dream masochism, 46:165
 divorce, gender differences, 46:165
 divorce, sex role identification, 46:165

Personality continued

divorce, sleep, 46:165
 dream masochism, affective disorder, 46:165
 dream masochism, divorce, 46:165
 dream masochism, gender differences, 46:165
 dream masochism, sex role identification, 46:165
 dream masochism, sleep, 46:165
 eye movements, anxiety disorders, 47:151
 eye movements, diazepam response, 47:151
 eye movements, panic disorder, 47:151
 eye movements, saccadic eye movement velocity, 47:151
 eye movements, Tridimensional Personality Questionnaire, 47:151
 gender differences, affective disorder, 46:165
 gender differences, divorce, 46:165
 gender differences, dream masochism, 46:165
 gender differences, sex role identification, 46:165
 gender differences, sleep, 46:165
 genetics, aggression, 48:229
 genetics, impulsivity, 48:229
 genetics, physical anhedonia, 46:47
 genetics, psychosis proneness scales, 46:47
 genetics, schizotypy, 46:47
 genetics, twin studies, 48:229
 impulsivity, aggression, 48:229
 impulsivity, genetics, 48:229
 impulsivity, twin studies, 48:229
 panic disorder, anxiety disorders, 47:151
 panic disorder, diazepam response, 47:151
 panic disorder, eye movements, 47:151
 panic disorder, saccadic eye movement velocity, 47:151
 panic disorder, Tridimensional Personality Questionnaire, 47:151
 physical anhedonia, genetics, 46:47
 physical anhedonia, psychosis proneness scales, 46:47
 physical anhedonia, schizotypy, 46:47
 psychosis proneness scales, genetics, 46:47
 psychosis proneness scales, physical anhedonia, 46:47
 psychosis proneness scales, schizotypy, 46:47
 saccadic eye movement velocity, anxiety disorders, 47:151
 saccadic eye movement velocity, diazepam response, 47:151
 saccadic eye movement velocity, eye movements, 47:151

Personality continued

saccadic eye movement velocity, panic disorder, 47:151
 saccadic eye movement velocity, Tridimensional Personality Questionnaire, 47:151
 schizotypy, genetics, 46:47
 schizotypy, physical anhedonia, 46:47
 schizotypy, psychosis proneness scales, 46:47
 sex role identification, affective disorder, 46:165
 sex role identification, divorce, 46:165
 sex role identification, dream masochism, 46:165
 sex role identification, gender differences, 46:165
 sex role identification, sleep, 46:165
 sleep, affective disorder, 46:165
 sleep, divorce, 46:165
 sleep, dream masochism, 46:165
 sleep, gender differences, 46:165
 sleep, sex role identification, 46:165
 Tridimensional Personality Questionnaire, anxiety disorders, 47:151
 Tridimensional Personality Questionnaire, diazepam response, 47:151
 Tridimensional Personality Questionnaire, eye movements, 47:151
 Tridimensional Personality Questionnaire, panic disorder, 47:151
 Tridimensional Personality Questionnaire, saccadic eye movement velocity, 47:151
 twin studies, aggression, 48:229
 twin studies, genetics, 48:229
 twin studies, impulsivity, 48:229

Personality disorders

affective disorder, family history, 48:243
 affective disorder, schizophrenia, 48:243
 antisocial disorder, borderline disorder, 48:257
 antisocial disorder, family history, 48:267
 antisocial disorder, genetics, 48:267
 antisocial disorder, impulsivity, 48:257
 antisocial disorder, neurological soft signs, 48:257
 antisocial disorder, neuropsychology, 48:257
 antisocial disorder, sadistic disorder, 48:267
 antisocial disorder, veterans, 48:267
 borderline disorder, antisocial disorder, 48:257
 borderline disorder, impulsivity, 48:257
 borderline disorder, neurological soft signs, 48:257

Personality disorders continued

borderline disorder, neuropsychology, 48:257
 family history, affective disorder, 48:243
 family history, antisocial disorder, 48:267
 family history, sadistic disorder, 48:267
 family history, schizophrenia, 48:243
 family history, veterans, 48:267
 genetics, antisocial disorder, 48:267
 genetics, sadistic disorder, 48:267
 genetics, veterans, 48:267
 impulsivity, antisocial disorder, 48:257
 impulsivity, borderline disorder, 48:257
 impulsivity, neurological soft signs, 48:257
 impulsivity, neuropsychology, 48:257
 laterality, neurological soft signs, 48:257
 laterality, Wisconsin Card Sorting Test, 48:257
 neurological soft signs, antisocial disorder, 48:257
 neurological soft signs, borderline disorder, 48:257
 neurological soft signs, impulsivity, 48:257
 neurological soft signs, laterality, 48:257
 neurological soft signs, neuropsychology, 48:257
 neurological soft signs, Wisconsin Card Sorting Test, 48:257
 neuropsychology, antisocial disorder, 48:257
 neuropsychology, borderline disorder, 48:257
 neuropsychology, impulsivity, 48:257
 neuropsychology, neurological soft signs, 48:257
 sadistic disorder, antisocial disorder, 48:267
 sadistic disorder, family history, 48:267
 sadistic disorder, genetics, 48:267
 sadistic disorder, veterans, 48:267
 schizophrenia, affective disorder, 48:243
 schizophrenia, family history, 48:243
 veterans, antisocial disorder, 48:267
 veterans, family history, 48:267
 veterans, sadistic disorder, 48:267
 Wisconsin Card Sorting Test, laterality, 48:257
 Wisconsin Card Sorting Test, neurological soft signs, 48:257

Phenylalanine

amino acids, circadian rhythm, 47:187
 amino acids, dopamine, 47:187
 amino acids, neuroleptics, 47:187
 amino acids, neutral serum amino acids, 47:187
 amino acids, schizophrenia, 47:187

Phenylalanine continued
 amino acids, therapeutic response, 47:187
 circadian rhythm, amino acids, 47:187
 circadian rhythm, dopamine, 47:187
 circadian rhythm, neuroleptics, 47:187
 circadian rhythm, neutral serum amino acids, 47:187
 circadian rhythm, schizophrenia, 47:187
 circadian rhythm, therapeutic response, 47:187
 dopamine, amino acids, 47:187
 dopamine, circadian rhythm, 47:187
 dopamine, neuroleptics, 47:187
 dopamine, neutral serum amino acids, 47:187
 dopamine, schizophrenia, 47:187
 dopamine, therapeutic response, 47:187
 neuroleptics, amino acids, 47:187
 neuroleptics, circadian rhythm, 47:187
 neuroleptics, dopamine, 47:187
 neuroleptics, neutral serum amino acids, 47:187
 neuroleptics, schizophrenia, 47:187
 neuroleptics, therapeutic response, 47:187
 neutral serum amino acids, circadian rhythm, 47:187
 neutral serum amino acids, dopamine, 47:187
 neutral serum amino acids, neuroleptics, 47:187
 neutral serum amino acids, schizophrenia, 47:187
 neutral serum amino acids, therapeutic response, 47:187
 schizophrenia, amino acids, 47:187
 schizophrenia, circadian rhythm, 47:187
 schizophrenia, dopamine, 47:187
 schizophrenia, neuroleptics, 47:187
 schizophrenia, neutral serum amino acids, 47:187
 schizophrenia, therapeutic response, 47:187
 therapeutic response, amino acids, 47:187
 therapeutic response, circadian rhythm, 47:187
 therapeutic response, dopamine, 47:187
 therapeutic response, neuroleptics, 47:187
 therapeutic response, neutral serum amino acids, 47:187
 therapeutic response, schizophrenia, 47:187

Phosphatidylethanolamine
 erythrocytes, membrane phospholipids, 49:89
 erythrocytes, schizophrenia, 49:89
 erythrocytes, sphingomyelin, 49:89
 membrane phospholipids, erythrocytes, 49:89

Phosphatidylethanolamine continued
 membrane phospholipids, schizophrenia, 49:89
 membrane phospholipids, sphingomyelin, 49:89
 schizophrenia, erythrocytes, 49:89
 schizophrenia, membrane phospholipids, 49:89
 schizophrenia, sphingomyelin, 49:89
 sphingomyelin, erythrocytes, 49:89
 sphingomyelin, membrane phospholipids, 49:89
 sphingomyelin, schizophrenia, 49:89
Phototherapy
 affective disorder, carbohydrate craving, 46:107
 affective disorder, circadian rhythms, 46:107
 affective disorder, circannual rhythm, 46:29, 47:79
 affective disorder, diet, 46:107
 affective disorder, eating sweets, 46:107
 affective disorder, electrooculography, 49:99
 affective disorder, eye blink rate, 47:79
 affective disorder, gender differences, 47:79
 affective disorder, homovanillic acid, 46:19
 affective disorder, 5-hydroxyindoleacetic acid, 46:19
 affective disorder, language, 47:99
 affective disorder, laterality, 47:99
 affective disorder, light visor treatment, 46:29
 affective disorder, 3-methoxy-4-hydroxyphenylglycol, 46:19
 affective disorder, motor performance, 47:99
 affective disorder, norepinephrine, 46:19
 affective disorder, orthostatic challenge, 46:19
 aging, depressed mood in elderly women, 47:87
 aging, sleep, 47:87
 carbohydrate craving, affective disorder, 46:107
 carbohydrate craving, circadian rhythms, 46:107
 carbohydrate craving, seasonal affective disorder, 46:107
 cerebrospinal fluid, homovanillic acid, 46:19
 cerebrospinal fluid, 5-hydroxyindoleacetic acid, 46:19
 cerebrospinal fluid, 3-methoxy-4-hydroxyphenylglycol, 46:19
 cerebrospinal fluid, norepinephrine, 46:19
 circadian rhythms, affective disorder, 46:107
 circadian rhythms, carbohydrate craving, 46:107
 circadian rhythms, diet, 46:107

Phototherapy continued

circadian rhythms, eating sweets, 46:107
 circadian rhythms, seasonal affective disorder, 46:107
 circannual rhythms, affective disorder, 46:29, 47:79
 circannual rhythms, eye blink rate, 47:79
 circannual rhythms, gender differences, 47:79
 circannual rhythms, light visor treatment, 46:29
 circannual rhythms, seasonal affective disorder, 46:29, 47:79
 depressed mood in elderly women, aging, 47:87
 depressed mood in elderly women, sleep, 47:87
 diet, affective disorder, 46:107
 diet, circadian rhythms, 46:107
 diet, eating sweets, 46:107
 diet, seasonal affective disorder, 46:107
 eating sweets, affective disorder, 46:107
 eating sweets, carbohydrate craving, 46:107
 eating sweets, circadian rhythms, 46:107
 eating sweets, seasonal affective disorder, 46:107
 electrooculography, affective disorder, 49:99
 electrooculography, seasonal affective disorder, 49:99
 eye blink rate, affective disorder, 47:79
 eye blink rate, circannual rhythms, 47:79
 eye blink rate, gender differences, 47:79
 eye blink rate, seasonal affective disorder, 47:79
 gender differences, affective disorder, 47:79
 gender differences, circannual rhythms, 47:79
 gender differences, eye blink rate, 47:79
 gender differences, seasonal affective disorder, 47:79
 homovanillic acid, affective disorder, 46:19
 homovanillic acid, cerebrospinal fluid, 46:19
 homovanillic acid, 5-hydroxyindoleacetic acid, 46:19
 homovanillic acid, 3-methoxy-4-hydroxyphenylglycol, 46:19
 homovanillic acid, norepinephrine, 46:19
 homovanillic acid, orthostatic challenge, 46:19
 homovanillic acid, seasonal affective disorder, 46:19
 5-hydroxyindoleacetic acid, affective disorder, 46:19
 5-hydroxyindoleacetic acid, cerebrospinal fluid, 46:19

Phototherapy continued

5-hydroxyindoleacetic acid, homovanillic acid, 46:19
 5-hydroxyindoleacetic acid, 3-methoxy-4-hydroxyphenylglycol, 46:19
 5-hydroxyindoleacetic acid, norepinephrine, 46:19
 5-hydroxyindoleacetic acid, orthostatic challenge, 46:19
 5-hydroxyindoleacetic acid, seasonal affective disorder, 46:19
 language, affective disorder, 47:99
 language, laterality, 47:99
 language, motor performance, 47:99
 language, seasonal affective disorder, 47:99
 laterality, affective disorder, 47:99
 laterality, language, 47:99
 laterality, motor performance, 47:99
 laterality, seasonal affective disorder, 47:99
 light visor treatment, affective disorder, 46:29
 light visor treatment, circannual rhythm, 46:29
 light visor treatment, seasonal affective disorder, 46:29
 3-methoxy-4-hydroxyphenylglycol, affective disorder, 46:19
 3-methoxy-4-hydroxyphenylglycol, cerebrospinal fluid, 46:19
 3-methoxy-4-hydroxyphenylglycol, homovanillic acid, 46:19
 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, 46:19
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 46:19
 3-methoxy-4-hydroxyphenylglycol, orthostatic challenge, 46:19
 3-methoxy-4-hydroxyphenylglycol, seasonal affective disorder, 46:19
 motor performance, affective disorder, 47:99
 motor performance, language, 47:99
 motor performance, laterality, 47:99
 motor performance, seasonal affective disorder, 47:99
 norepinephrine, affective disorder, 46:19
 norepinephrine, cerebrospinal fluid, 46:19
 norepinephrine, homovanillic acid, 46:19
 norepinephrine, 5-hydroxyindoleacetic acid, 46:19
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 46:19
 norepinephrine, orthostatic challenge, 46:19

Phototherapy continued

- norepinephrine, seasonal affective disorder, 46:19
- orthostatic challenge, affective disorder, 46:19
- orthostatic challenge, homovanillic acid, 46:19
- orthostatic challenge, 5-hydroxyindoleacetic acid, 46:19
- orthostatic challenge, 3-methoxy-4-hydroxyphenylglycol, 46:19
- orthostatic challenge, norepinephrine, 46:19
- orthostatic challenge, seasonal affective disorder, 46:19
- seasonal affective disorder, carbohydrate craving, 46:107
- seasonal affective disorder, circadian rhythms, 46:107
- seasonal affective disorder, circannual rhythms, 46:29, 47:79
- seasonal affective disorder, diet, 46:107
- seasonal affective disorder, eating sweets, 46:107
- seasonal affective disorder, electrooculography, 49:99
- seasonal affective disorder, eye blink rate, 47:79
- seasonal affective disorder, gender differences, 47:79
- seasonal affective disorder, homovanillic acid, 46:19
- seasonal affective disorder, 5-hydroxyindoleacetic acid, 46:19
- seasonal affective disorder, language, 47:99
- seasonal affective disorder, laterality, 47:99
- seasonal affective disorder, light visor treatment, 46:29
- seasonal affective disorder, 3-methoxy-4-hydroxyphenylglycol, 46:19
- seasonal affective disorder, motor performance, 47:99
- seasonal affective disorder, norepinephrine, 46:19
- seasonal affective disorder, orthostatic challenge, 46:19
- sleep, aging, 47:87
- sleep, depressed mood in elderly women, 47:87

Positron emission tomography continued

- aging, dopamine D₂ receptor density, 49:219
- aging, gender differences, 49:219
- aging, illness duration, 49:219
- aging, methylspiperone, 49:219
- aging, schizophrenia, 49:219
- aging, striatum, 49:219
- dopamine D₂ receptor density, aging, 49:219
- dopamine D₂ receptor density, gender differences, 49:219
- dopamine D₂ receptor density, illness duration, 49:219
- dopamine D₂ receptor density, methylspiperone, 49:219
- dopamine D₂ receptor density, schizophrenia, 49:219
- dopamine D₂ receptor density, striatum, 49:219
- gender differences, aging, 49:219
- gender differences, dopamine D₂ receptor density, 49:219
- gender differences, illness duration, 49:219
- gender differences, methylspiperone, 49:219
- gender differences, schizophrenia, 49:219
- gender differences, striatum, 49:219
- illness duration, aging, 49:219
- illness duration, dopamine D₂ receptor density, 49:219
- illness duration, gender differences, 49:219
- illness duration, methylspiperone, 49:219
- illness duration, schizophrenia, 49:219
- illness duration, striatum, 49:219
- methylspiperone, aging, 49:219
- methylspiperone, dopamine D₂ receptor density, 49:219
- methylspiperone, gender differences, 49:219
- methylspiperone, illness duration, 49:219
- methylspiperone, schizophrenia, 49:219
- methylspiperone, striatum, 49:219
- schizophrenia, aging, 49:219
- schizophrenia, dopamine D₂ receptor density, 49:219
- schizophrenia, gender differences, 49:219
- schizophrenia, illness duration, 49:219
- schizophrenia, methylspiperone, 49:219
- schizophrenia, striatum, 49:219
- striatum, aging, 49:219
- striatum, dopamine D₂ receptor density, 49:219
- striatum, gender differences, 49:219
- striatum, illness duration, 49:219
- striatum, methylspiperone, 49:219
- striatum, schizophrenia, 49:219

Posttraumatic stress disorder

- arginine vasopressin, electrodermal response, 48:107

Posttraumatic stress disorder continued
 arginine vasopressin, electromyography, 48:107
 arginine vasopressin, heart rate response, 48:107
 arginine vasopressin, oxytocin, 48:107
 arginine vasopressin, personal combat imagery, 48:107
 arginine vasopressin, Vietnam veterans, 48:107
 electrodermal response, arginine vasopressin, 48:107
 electrodermal response, electromyography, 48:107
 electrodermal response, heart rate response, 48:107
 electrodermal response, oxytocin, 48:107
 electrodermal response, personal combat imagery, 48:107
 electrodermal response, Vietnam veterans, 48:107
 electromyography, arginine vasopressin, 48:107
 electromyography, electrodermal response, 48:107
 electromyography, heart rate response, 48:107
 electromyography, oxytocin, 48:107
 electromyography, personal combat imagery, 48:107
 electromyography, Vietnam veterans, 48:107
 heart rate response, arginine vasopressin, 48:107
 heart rate response, electrodermal response, 48:107
 heart rate response, electromyography, 48:107
 heart rate response, oxytocin, 48:107
 heart rate response, personal combat imagery, 48:107
 heart rate response, Vietnam veterans, 48:107
 oxytocin, arginine vasopressin, 48:107
 oxytocin, electrodermal response, 48:107
 oxytocin, electromyography, 48:107
 oxytocin, heart rate response, 48:107
 oxytocin, personal combat imagery, 48:107
 oxytocin, Vietnam veterans, 48:107
 personal combat imagery, arginine vasopressin, 48:107
 personal combat imagery, electrodermal response, 48:107
 personal combat imagery, electromyography, 48:107
 personal combat imagery, heart rate response, 48:107

Posttraumatic stress disorder continued
 personal combat imagery, oxytocin, 48:107
 personal combat imagery, Vietnam veterans, 48:107
 Vietnam veterans, arginine vasopressin, 48:107
 Vietnam veterans, electrodermal response, 48:107
 Vietnam veterans, electromyography, 48:107
 Vietnam veterans, heart rate response, 48:107
 Vietnam veterans, oxytocin, 48:107
 Vietnam veterans, personal combat imagery, 48:107
Premenstrual syndrome
 blood pressure, lactate infusion, 46:79
 blood pressure, menstrual cycle, 46:79
 blood pressure, panic attacks, 46:79
 lactate infusion, blood pressure, 46:79
 lactate infusion, menstrual cycle, 46:79
 lactate infusion, panic attacks, 46:79
 menstrual cycle, blood pressure, 46:79
 menstrual cycle, lactate infusion, 46:79
 menstrual cycle, panic attacks, 46:79
 panic attacks, blood pressure, 46:79
 panic attacks, lactate infusion, 46:79
 panic attacks, menstrual cycle, 46:79
Prolactin
 affective disorder, antidepressant medication, 46:213
 affective disorder, cortisol, 46:213
 affective disorder, sleep deprivation, 46:213
 affective disorder, thyroid stimulating hormone, 46:213
 affective disorder, triiodothyronine, 46:213
 antidepressant medication, affective disorder, 46:213
 antidepressant medication, cortisol, 46:213
 antidepressant medication, sleep deprivation, 46:213
 antidepressant medication, thyroid stimulating hormone, 46:213
 antidepressant medication, triiodothyronine, 46:213
 circadian rhythm, schizophrenia, 47:187
 circadian rhythm, tyrosine, 47:187
 cortisol, affective disorder, 46:213
 cortisol, antidepressant medication, 46:213
 cortisol, sleep deprivation, 46:213
 cortisol, thyroid stimulating hormone, 46:213
 cortisol, triiodothyronine, 46:213
 estradiol, follicle stimulating hormone, 48:153

Prolactin continued

estradiol, growth hormone, 48:153
 estradiol, luteinizing hormone, 48:153
 estradiol, normal volunteers, 48:153
 estradiol, sleep deprivation, 48:153
 estradiol, thyroid stimulating hormone, 48:153
 estradiol, thyroxine, 48:153
 estradiol, triiodothyronine, 48:153
 follicle stimulating hormone, estradiol, 48:153
 follicle stimulating hormone, growth hormone, 48:153
 follicle stimulating hormone, luteinizing hormone, 48:153
 follicle stimulating hormone, normal volunteers, 48:153
 follicle stimulating hormone, sleep deprivation, 48:153
 follicle stimulating hormone, thyroid stimulating hormone, 48:153
 follicle stimulating hormone, thyroxine, 48:153
 follicle stimulating hormone, triiodothyronine, 48:153
 growth hormone, estradiol, 48:153
 growth hormone, follicle stimulating hormone, 48:153
 growth hormone, kappa agonist, 47:267
 growth hormone, luteinizing hormone, 48:153
 growth hormone, motor tics, 47:267
 growth hormone, normal volunteers, 48:153
 growth hormone, opioids, 47:267
 growth hormone, sleep deprivation, 48:153
 growth hormone, spiradoline, 47:267
 growth hormone, thyroid stimulating hormone, 48:153
 growth hormone, thyroxine, 48:153
 growth hormone, Tourette's syndrome, 47:267
 growth hormone, triiodothyronine, 48:153
 kappa agonist, growth hormone, 47:267
 kappa agonist, motor tics, 47:267
 kappa agonist, opioids, 47:267
 kappa agonist, spiradoline, 47:267
 kappa agonist, Tourette's syndrome, 47:267
 luteinizing hormone, estradiol, 48:153
 luteinizing hormone, follicle stimulating hormone, 48:153
 luteinizing hormone, growth hormone, 48:153

Prolactin continued

luteinizing hormone, normal volunteers, 48:153
 luteinizing hormone, sleep deprivation, 48:153
 luteinizing hormone, thyroid stimulating hormone, 48:153
 luteinizing hormone, thyroxine, 48:153
 luteinizing hormone, triiodothyronine, 48:153
 motor tics, growth hormone, 47:267
 motor tics, kappa agonist, 47:267
 motor tics, opioids, 47:267
 motor tics, spiradoline, 47:267
 motor tics, Tourette's syndrome, 47:267
 normal volunteers, estradiol, 48:153
 normal volunteers, follicle stimulating hormone, 48:153
 normal volunteers, growth hormone, 48:153
 normal volunteers, luteinizing hormone, 48:153
 normal volunteers, sleep deprivation, 48:153
 normal volunteers, thyroid stimulating hormone, 48:153
 normal volunteers, thyroxine, 48:153
 normal volunteers, triiodothyronine, 48:153
 opioids, growth hormone, 47:267
 opioids, kappa agonist, 47:267
 opioids, motor tics, 47:267
 opioids, spiradoline, 47:267
 opioids, Tourette's syndrome, 47:267
 schizophrenia, circadian rhythm, 47:187
 schizophrenia, tyrosine, 47:187
 sleep deprivation, affective disorder, 46:213
 sleep deprivation, antidepressant medication, 46:213
 sleep deprivation, cortisol, 46:213
 sleep deprivation, estradiol, 48:153
 sleep deprivation, follicle stimulating hormone, 48:153
 sleep deprivation, growth hormone, 48:153
 sleep deprivation, luteinizing hormone, 48:153
 sleep deprivation, normal volunteers, 48:153
 sleep deprivation, thyroid stimulating hormone, 46:213, 48:153
 sleep deprivation, thyroxine, 48:153
 sleep deprivation, triiodothyronine, 46:213, 48:153
 spiradoline, growth hormone, 47:267
 spiradoline, motor tics, 47:267
 spiradoline, opioids, 47:267
 spiradoline, Tourette's syndrome, 47:267

Prolactin continued

thyroid stimulating hormone, affective disorder, 46:213
 thyroid stimulating hormone, antidepressant medication, 46:213
 thyroid stimulating hormone, cortisol, 46:213
 thyroid stimulating hormone, estradiol, 48:153
 thyroid stimulating hormone, follicle stimulating hormone, 48:153
 thyroid stimulating hormone, growth hormone, 48:153
 thyroid stimulating hormone, luteinizing hormone, 48:153
 thyroid stimulating hormone, normal volunteers, 48:153
 thyroid stimulating hormone, sleep deprivation, 46:213, 48:153
 thyroid stimulating hormone, thyroxine, 48:153
 thyroid stimulating hormone, triiodothyronine, 46:213, 48:153
 thyroxine, estradiol, 48:153
 thyroxine, follicle stimulating hormone, 48:153
 thyroxine, growth hormone, 48:153
 thyroxine, luteinizing hormone, 48:153
 thyroxine, normal volunteers, 48:153
 thyroxine, sleep deprivation, 48:153
 thyroxine, thyroid stimulating hormone, 48:153
 thyroxine, triiodothyronine, 48:153
 Tourette's syndrome, growth hormone, 47:267
 Tourette's syndrome, kappa agonist, 47:267
 Tourette's syndrome, motor tics, 47:267
 Tourette's syndrome, opioids, 47:267
 Tourette's syndrome, spiradoline, 47:267
 triiodothyronine, affective disorder, 46:213
 triiodothyronine, antidepressant medication, 46:213
 triiodothyronine, cortisol, 46:213
 triiodothyronine, estradiol, 48:153
 triiodothyronine, follicle stimulating hormone, 48:153
 triiodothyronine, growth hormone, 48:153
 triiodothyronine, luteinizing hormone, 48:153
 triiodothyronine, normal volunteers, 48:153
 triiodothyronine, sleep deprivation, 46:213, 48:153
 triiodothyronine, thyroid stimulating hormone, 46:213, 48:153

Prolactin continued

triiodothyronine, thyroxine, 48:153
 tyrosine, circadian rhythms, 47:187
 tyrosine, schizophrenia, 47:187
Reaction time
 alcohol dependence, attention, 46:202
 alcohol dependence, cocaine, 46:202
 alcohol dependence, substance abuse, 46:202
 alcohol dependence, visual and auditory suppression tasks, 46:202
 alcohol dependence, withdrawal, 46:202
 anxiety disorder, attention, 49:183
 anxiety disorder, obsessive-compulsive disorder, 49:183
 anxiety disorder, Posner task, 49:183
 anxiety disorder, spatial-linguistic conflict task, 49:183
 attention, alcohol dependence, 46:202
 attention, anxiety disorder, 49:183
 attention, cocaine, 46:202
 attention, obsessive-compulsive disorder, 49:183
 attention, Posner task, 49:183
 attention, spatial-linguistic conflict task, 49:183
 attention, substance abuse, 46:202
 attention, visual and auditory suppression tasks, 46:202
 cocaine, alcohol dependence, 46:202
 cocaine, attention, 46:202
 cocaine, visual and auditory suppression tasks, 46:202
 cocaine, withdrawal, 46:202
 obsessive-compulsive disorder, anxiety disorder, 49:183
 obsessive-compulsive disorder, attention, 49:183
 obsessive-compulsive disorder, Posner task, 49:183
 obsessive-compulsive disorder, spatial-linguistic conflict task, 49:183
 Posner task, anxiety disorder, 49:183
 Posner task, attention, 49:183
 Posner task, obsessive-compulsive disorder, 49:183
 Posner task, spatial-linguistic conflict task, 49:183
 spatial-linguistic conflict task, anxiety disorder, 49:183
 spatial-linguistic conflict task, attention, 49:183

Reaction time continued

- spatial-linguistic conflict task, obsessive-compulsive disorder, 49:183
- spatial-linguistic conflict task, Posner task, 49:183
- substance abuse, alcohol dependence, 46:202
- substance abuse, attention, 46:202
- substance abuse, cocaine, 46:202
- substance abuse, visual and auditory suppression tasks, 46:202
- substance abuse, withdrawal, 46:202
- visual and auditory suppression tasks, alcohol dependence, 46:202
- visual and auditory suppression tasks, attention, 46:202
- visual and auditory suppression tasks, cocaine, 46:202
- visual and auditory suppression tasks, substance abuse, 46:202
- withdrawal, alcohol dependence, 46:202
- withdrawal, cocaine, 46:202
- withdrawal, substance abuse, 46:202

Schizophrenia

- admixture analysis, epidemiology, 49:199
- admixture analysis, hebephrenic subtype, 49:199
- admixture analysis, paranoid subtype, 49:199
- affective disorder, family history, 48:201
- affective disorder, family history of personality disorder, 48:243
- affective disorder, genetics, 48:243, 48:201
- affective disorder, human leukocyte antigen, 48:201
- affective disorder, immune function, 48:201
- affective disorder, lymphocytes, 48:201
- age of onset, dopamine, 48:93
- age of onset, homovanillic acid, 48:93
- age of onset, positive and negative symptoms, 48:93
- aging, dopamine D₂ receptor density, 49:219
- aging, gender differences, 49:219
- aging, illness duration, 49:219
- aging, methylspiperone, 49:219
- aging, positron emission tomography, 49:219
- aging, striatum, 49:219
- alcohol dependence, frontal lobe, 46:175
- alcohol dependence, memory, 46:175
- alcohol dependence, neuropsychology, 46:175
- alcohol dependence, Wisconsin Card Sorting Test, 46:175
- alogia, dyadic interaction, 48:181
- alogia, speech, 48:181

Schizophrenia continued

- alogia, vocal acoustic scale, 48:181
- Alzheimer's disease, hippocampus, 49:41
- Alzheimer's disease, neurofibrillary tangles, 49:41
- Alzheimer's disease, post-mortem, 49:41
- Alzheimer's disease, senile plaques, 49:41
- amino acids, circadian rhythm, 47:187
- amino acids, dopamine, 47:187
- amino acids, neuroleptics, 47:187
- asymmetry, auditory acuity, 46:127
- attention, continuous performance test, 47:205
- attention, paranoid subtype, 48:17
- attention, positive and negative symptoms, 47:205
- attention, span of apprehension, 47:205
- attention, Stroop task, 48:17
- attention, thought disorder, 47:205
- attention, undifferentiated subtype, 48:17
- audiograms, hallucinations, 46:127
- audiograms, laterality, 46:127
- audiograms, positive and negative symptoms, 46:127
- auditory acuity, asymmetry, 46:127
- auditory P50 component, cocaine, 47:243
- auditory P50 component, paranoid subtype, 47:243
- auditory P50 component, substance abuse, 47:243
- auditory sensory gating, P50 component, 49:29
- auditory sensory gating, sleep, 49:29
- Brief Psychiatric Rating Scale, deficit syndrome diagnosis, 47:47
- CD5 positive B lymphocytes, gender differences, 48:69
- CD5 positive B lymphocytes, immune function, 48:69
- CD5 positive B lymphocytes, lymphocytes, 48:69
- CD5 positive B lymphocytes, race differences, 48:69
- circadian rhythms, amino acids, 47:187
- circadian rhythms, dopamine, 47:187
- circadian rhythms, neuroleptics, 47:187
- circadian rhythms, neutral serum amino acids, 47:187
- circadian rhythms, phenylalanine, 47:187
- circadian rhythms, prolactin, 47:187
- circadian rhythms, therapeutic response, 47:187

Schizophrenia continued

- circadian rhythms, tyrosine, 47:187
- clonidine, diagnostic systems, 48:79
- clonidine, growth hormone, 48:79
- clozapine, dopamine, 46:139, 46:151
- clozapine, homovanillic acid, 46:139
- clozapine, homovanillic acid, 46:151
- clozapine, 3-methoxy-4-hydroxyphenylglycol, 46:139
- clozapine, norepinephrine, 46:139, 46:151
- clozapine, therapeutic response, 46:139, 46:151
- cocaine, auditory P50 component, 47:243
- cocaine, event related potentials, 47:243
- cocaine, paranoid subtype, 47:243
- cocaine, substance abuse, 47:243
- continuous performance test, attention, 47:205
- continuous performance test, positive and negative symptoms, 47:205
- continuous performance test, span of apprehension, 47:205
- continuous performance test, thought disorder, 47:205
- D₂ receptor density, aging, 49:219
- D₂ receptor density, gender differences, 49:219
- D₂ receptor density, illness duration, 49:219
- D₂ receptor density, methylspiperone, 49:219
- D₂ receptor density, positron emission tomography, 49:219
- D₂ receptor density, striatum, 49:219
- D₃ receptor gene linkage, Icelandic pedigrees, 46:69
- deficit syndrome, demographic features, 47:47
- deficit syndrome diagnosis, Brief Psychiatric Rating Scale, 47:47
- deficit syndrome, epidemiology, 47:47
- deficit syndrome, negative symptoms, 47:47
- demographic features, deficit syndrome, 47:47
- demographic features, negative symptoms, 47:47
- diagnostic systems, clonidine, 48:79
- diagnostic systems, growth hormone, 48:79
- discordant monozygotic twins, genetics, 48:27
- discordant monozygotic twins, microsatellite repeats, 48:27
- discordant monozygotic twins, polymorphic markers, 48:27
- dopamine, age of onset, 48:93

Schizophrenia continued

- dopamine, aging, 49:219
- dopamine, amino acids, 47:187
- dopamine, circadian rhythms, 47:187
- dopamine, clozapine, 46:139, 46:151
- dopamine, D₂ receptor density, 49:219
- dopamine, D₃ receptor gene linkage, 46:69
- dopamine, gender differences, 49:219
- dopamine, genetics, 46:69
- dopamine, homovanillic acid, 46:139, 46:151, 48:93
- dopamine, Icelandic pedigrees, 46:69
- dopamine, illness duration, 49:219
- dopamine, linkage of D₃ receptor gene, 46:69
- dopamine, 3-methoxy-4-hydroxyphenylglycol, 46:139
- dopamine, methylspiperone, 49:219
- dopamine, neuroleptics, 47:187
- dopamine, neutral serum amino acids, 47:187
- dopamine, norepinephrine, 46:139, 46:151
- dopamine, phenylalanine, 47:187
- dopamine, positive and negative symptoms, 48:93
- dopamine, positron emission tomography, 49:219
- dopamine, striatum, 49:219
- dopamine, therapeutic response, 46:139, 46:151, 47:187
- dyadic interaction, alogia, 48:181
- dyadic interaction, speech, 48:181
- dyadic interaction, vocal acoustic scale, 48:181
- epidemiology, admixture analysis, 49:199
- epidemiology, deficit syndrome, 47:47
- epidemiology, hebephrenic subtype, 49:199
- epidemiology, negative symptoms, 47:47
- epidemiology, paranoid subtype, 49:199
- erythrocytes, membrane phospholipids, 49:89
- erythrocytes, phosphatidylethanolamine, 49:89
- erythrocytes, sphingomyelin, 49:89
- event related potential, auditory sensory gating, 49:29
- event related potential, P50 component, 49:29
- event related potential, sleep, 49:29
- event related potentials, auditory P50 component, 47:243
- event related potentials, cocaine, 47:243
- event related potentials, paranoid subtype, 47:243
- event related potentials, substance abuse, 47:243

Schizophrenia continued

family history, affective disorder, 48:201
 family history, immune function, 48:201
 family history, lymphocytes, 48:201
 family history of personality disorder,
 affective disorder, 48:243
 frontal lobe, alcohol dependence, 46:175
 frontal lobe, memory, 46:175
 frontal lobe, neurodegeneration, 48:145
 frontal lobe, neuropsychology, 46:175
 frontal lobe, post-mortem study, 48:145
 frontal lobe, ubiquitin, 48:145
 frontal lobe, Wisconsin Card Sorting Test,
 46:175
 gender differences, aging, 49:219
 gender differences, CD5 positive B
 lymphocytes, 48:69
 gender differences, D_2 receptor density,
 49:219
 gender differences, dopamine, 49:219
 gender differences, illness duration, 49:219
 gender differences, immune function, 48:69
 gender differences, lymphocytes, 48:69
 gender differences, methylspiperone, 49:219
 gender differences, positron emission
 tomography, 49:219
 gender differences, race differences, 48:69
 gender differences, striatum, 49:219
 genetics, affective disorder, 48:201, 48:243
 genetics, D_3 receptor gene linkage, 46:69
 genetics, discordant monozygotic twins,
 48:27
 genetics, dopamine, 46:69
 genetics, family history of personality
 disorder, 48:243
 genetics, human leukocyte antigen, 48:201
 genetics, immune function, 48:201
 genetics, linkage of D_3 receptor gene, 46:69
 genetics, lymphocytes, 48:201
 genetics, microsatellite repeats, 48:27
 genetics, polymorphic markers, 48:27
 genetics, twin studies, 48:27
 growth hormone, clonidine, 48:79
 growth hormone, diagnostic systems,
 48:79
 hallucinations, audiograms, 46:127
 hallucinations, laterality, 46:127
 hallucinations, positive and negative
 symptoms, 46:127
 hebephrenic subtype, admixture analysis,
 49:199
 hebephrenic subtype, epidemiology, 49:199

Schizophrenia continued

hebephrenic subtype, paranoid subtype,
 49:199
 hippocampus, Alzheimer's disease, 49:41
 hippocampus, neurofibrillary tangles, 49:41
 hippocampus, post-mortem, 49:41
 hippocampus, senile plaques, 49:41
 homovanillic acid, age of onset, 48:93
 homovanillic acid, clozapine, 46:139, 46:151
 homovanillic acid, dopamine, 46:139, 46:151,
 48:93
 homovanillic acid, 3-methoxy-4-hydroxy-
 phenylglycol, 46:139
 homovanillic acid, norepinephrine, 46:139,
 46:151
 homovanillic acid, positive and negative
 symptoms, 48:93
 homovanillic acid, therapeutic response,
 46:139, 46:151
 human leukocyte antigen, affective disorder,
 48:201
 human leukocyte antigen, family history,
 48:201
 human leukocyte antigen, genetics, 48:201
 human leukocyte antigen, immune function,
 48:201
 human leukocyte antigen, lymphocytes, 48:201
 illness duration, aging, 49:219
 illness duration, D_2 receptor density, 49:219
 illness duration, dopamine, 49:219
 illness duration, gender differences, 49:219
 illness duration, methylspiperone, 49:219
 illness duration, positron emission tomography,
 49:219
 illness duration, striatum, 49:219
 immune function, affective disorder, 48:201
 immune function, CD5 positive B lymphocytes,
 48:69
 immune function, family history, 48:201
 immune function, gender differences, 48:69
 immune function, genetics, 48:201
 immune function, human leukocyte antigen,
 48:201
 immune function, lymphocytes, 48:69, 48:201
 immune function, race differences, 48:69
 infectious disease, negative symptoms, 47:297
 laterality, audiograms, 46:127
 laterality, hallucinations, 46:127
 laterality, positive and negative symptoms,
 46:127
 linkage of D_3 receptor gene, Icelandic
 pedigrees, 46:69

Schizophrenia continued

lymphocytes, affective disorder, 48:201
 lymphocytes, CD5 positive B lymphocytes, 48:69
 lymphocytes, family history, 48:201
 lymphocytes, gender differences, 48:69
 lymphocytes, genetics, 48:201
 lymphocytes, human leukocyte antigen, 48:201
 lymphocytes, immune function, 48:69, 48:201
 lymphocytes, race differences, 48:69
 membrane phospholipids, erythrocytes, 49:89
 membrane phospholipids, phosphatidylethanolamine, 49:89
 membrane phospholipids, sphingomyelin, 49:89
 memory, alcohol dependence, 46:175
 memory, frontal lobe, 46:175
 memory, neuropsychology, 46:175
 memory, Wisconsin Card Sorting Test, 46:175
 3-methoxy-4-hydroxyphenylglycol, clozapine, 46:139
 3-methoxy-4-hydroxyphenylglycol, dopamine, 46:139
 3-methoxy-4-hydroxyphenylglycol, homovanillic acid, 46:139
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 46:139
 3-methoxy-4-hydroxyphenylglycol, therapeutic response, 46:139
 methylspiperone, aging, 49:219
 methylspiperone, D₂ receptor density, 49:219
 methylspiperone, dopamine, 49:219
 methylspiperone, gender differences, 49:219
 methylspiperone, illness duration, 49:219
 methylspiperone, positron emission tomography, 49:219
 methylspiperone, striatum, 49:219
 microsatellite repeats, discordant monozygotic twins, 48:27
 microsatellite repeats, genetics, 48:27
 microsatellite repeats, polymorphic markers, 48:27
 microsatellite repeats, twin studies, 48:27
 negative symptoms, deficit syndrome, 47:47
 negative symptoms, demographic features, 47:47
 negative symptoms, epidemiology, 47:47
 negative symptoms, infectious disease, 47:297
 neurodegeneration, frontal lobe, 48:145
 neurodegeneration, post-mortem study, 48:145

Schizophrenia continued

neurodegeneration, ubiquitin, 48:145
 neurofibrillary tangles, Alzheimer's disease, 49:41
 neurofibrillary tangles, hippocampus, 49:41
 neurofibrillary tangles, senile plaques, 49:41
 neuroleptics, amino acids, 47:187
 neuroleptics, circadian rhythms, 47:187
 neuroleptics, dopamine, 47:187
 neuroleptics, neutral serum amino acids, 47:187
 neuroleptics, phenylalanine, 47:187
 neuroleptics, S2 receptor in platelets, 48:57
 neuroleptics, serotonin, 48:57
 neuroleptics, therapeutic response, 47:187
 neuropsychology, alcohol dependence, 46:175
 neuropsychology, frontal lobe, 46:175
 neuropsychology, memory, 46:175
 neuropsychology, Wisconsin Card Sorting Test, 46:175
 neutral serum amino acids, circadian rhythms, 47:187
 neutral serum amino acids, dopamine, 47:187
 neutral serum amino acids, neuroleptics, 47:187
 neutral serum amino acids, phenylalanine, 47:187
 neutral serum amino acids, therapeutic response, 47:187
 norepinephrine, clozapine, 46:139, 46:151
 norepinephrine, dopamine, 46:139, 46:151
 norepinephrine, homovanillic acid, 46:139, 46:151
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 46:139
 norepinephrine, therapeutic response, 46:139, 46:151
 P50 component, auditory sensory gating, 49:29
 P50 component, sleep, 49:29
 paranoid subtype, admixture analysis, 49:199
 paranoid subtype, attention, 48:17
 paranoid subtype, auditory P50 component, 47:243
 paranoid subtype, cocaine, 47:243
 paranoid subtype, epidemiology, 49:199
 paranoid subtype, event related potentials, 47:243
 paranoid subtype, hebephrenic subtype, 49:199
 paranoid subtype, Stroop task, 48:17
 paranoid subtype, substance abuse, 47:243

Schizophrenia continued
 paranoid subtype, undifferentiated subtype, 48:17
 phenylalanine, amino acids, 47:187
 phenylalanine, circadian rhythms, 47:187
 phenylalanine, dopamine, 47:187
 phenylalanine, neuroleptics, 47:187
 phenylalanine, neutral serum amino acids, 47:187
 phenylalanine, therapeutic response, 47:187
 phosphatidylethanolamine, erythrocytes, 49:89
 phosphatidylethanolamine, membrane phospholipids, 49:89
 phosphatidylethanolamine, sphingomyelin, 49:89
 polymorphic markers, discordant monozygotic twins, 48:27
 polymorphic markers, genetics, 48:27
 polymorphic markers, microsatellite repeats, 48:27
 polymorphic markers, twin studies, 48:27
 positive and negative symptoms, age of onset, 48:93
 positive and negative symptoms, attention, 47:205
 positive and negative symptoms, audiograms, 46:127
 positive and negative symptoms, continuous performance test, 47:205
 positive and negative symptoms, dopamine, 48:93
 positive and negative symptoms, hallucinations, 46:127
 positive and negative symptoms, homovanillic acid, 48:93
 positive and negative symptoms, laterality, 46:127
 positive and negative symptoms, span of apprehension, 47:205
 positive and negative symptoms, thought disorder, 47:205
 positron emission tomography, aging, 49:219
 positron emission tomography, D₂ receptor density, 49:219
 positron emission tomography, dopamine, 49:219
 positron emission tomography, gender differences, 49:219
 positron emission tomography, illness duration, 49:219
 positron emission tomography, methylspiperone, 49:219

Schizophrenia continued
 positron emission tomography, striatum, 49:219
 post-mortem study, Alzheimer's disease, 49:41
 post-mortem study, frontal lobe, 48:145
 post-mortem study, hippocampus, 49:41
 post-mortem study, neurodegeneration, 48:145
 post mortem study, neurofibrillary tangles, 49:41
 post-mortem study, senile plaques, 49:41
 post-mortem study, ubiquitin, 48:145
 prolactin, circadian rhythm, 47:187
 prolactin, tyrosine, 47:187
 race differences, CD5 positive B lymphocytes, 48:69
 race differences, gender differences, 48:69
 race differences, immune function, 48:69
 race differences, lymphocytes, 48:69
 S₂ receptor binding in platelets, suicide, 47:111
 S₂ receptor in platelets, neuroleptics, 48:57
 senile plaques, Alzheimer's disease, 49:41
 senile plaques, hippocampus, 49:41
 senile plaques, neurofibrillary tangles, 49:41
 serotonin, neuroleptics, 48:57
 serotonin, S₂ receptor binding in platelets, 47:111, 48:57
 serotonin, suicide, 47:111
 sleep, auditory sensory gating, 49:29
 sleep, event related potential, 49:29
 sleep, P50 component, 49:29
 span of apprehension, attention, 47:205
 span of apprehension, continuous performance test, 47:205
 span of apprehension, positive and negative symptoms, 47:205
 span of apprehension, thought disorder, 47:205
 speech, alogia, 48:181
 speech, dyadic interaction, 48:181
 speech, vocal acoustic scale, 48:181
 sphingomyelin, erythrocytes, 49:89
 sphingomyelin, membrane phospholipids, 49:89
 sphingomyelin, phosphatidylethanolamine, 49:89
 striatum, aging, 49:219
 striatum, D₂ receptor density, 49:219
 striatum, dopamine, 49:219
 striatum, gender differences, 49:219
 striatum, illness duration, 49:219

Schizophrenia continued

striatum, methylspiperone, 49:219
 striatum, positron emission tomography, 49:219
 Stroop task, attention, 48:17
 Stroop task, paranoid subtype, 48:17
 Stroop task, undifferentiated subtype, 48:17
 substance abuse, auditory P50 component, 47:243
 substance abuse, cocaine, 47:243
 substance abuse, event related potentials, 47:243
 substance abuse, paranoid subtype, 47:243
 suicide, S_2 receptor binding in platelets, 47:111
 suicide, serotonin, 47:111
 therapeutic response, amino acids, 47:187
 therapeutic response, circadian rhythms, 47:187
 therapeutic response, clozapine, 46:139, 46:151
 therapeutic response, dopamine, 46:139, 46:151, 47:187
 therapeutic response, homovanillic acid, 46:139, 46:151
 therapeutic response, 3-methoxy-4-hydroxy-phenylglycol, 46:139
 therapeutic response, neuroleptics, 47:187
 therapeutic response, neutral serum amino acids, 47:187
 therapeutic response, norepinephrine, 46:139, 46:151
 therapeutic response, phenylalanine, 47:187
 thought disorder, attention, 47:205
 thought disorder, continuous performance test, 47:205
 thought disorder, positive and negative symptoms, 47:205
 thought disorder, span of apprehension, 47:205
 twin studies, discordant monozygotic twins, 48:27
 twin studies, microsatellite repeats, 48:27
 twin studies, polymorphic markers, 48:27
 tyrosine, circadian rhythms, 47:187
 tyrosine, prolactin, 47:187
 ubiquitin, frontal lobe, 48:145
 ubiquitin, neurodegeneration, 48:145
 ubiquitin, post-mortem study, 48:145
 undifferentiated subtype, attention, 48:17
 undifferentiated subtype, paranoid subtype, 48:17

Schizophrenia continued

undifferentiated subtype, Stroop task, 48:17
 vocal acoustic scale, alogia, 48:181
 vocal acoustic scale, dyadic interaction, 48:181
 vocal acoustic scale, speech, 48:181
 Wisconsin Card Sorting Test, alcohol dependence, 46:175
 Wisconsin Card Sorting Test, frontal lobe, 46:175
 Wisconsin Card Sorting Test, memory, 46:175
 Wisconsin Card Sorting Test, neuropsychology, 46:175
Schizotypy
 genetics, personality disorder, 46:47
 genetics, physical anhedonia, 46:47
 genetics, psychosis proneness scales, 46:47
 personality disorder, genetics, 46:47
 personality disorder, physical anhedonia, 46:47
 personality disorder, psychosis proneness scales, 46:47
 physical anhedonia, genetics, 46:47
 physical anhedonia, personality disorder, 46:47
 physical anhedonia, psychosis proneness scales, 46:47
 psychosis proneness scales, genetics, 46:47
 psychosis proneness scales, personality disorder, 46:47
 psychosis proneness scales, physical anhedonia, 46:47
Seasonal affective disorder. See **Affective disorder, seasonal depression**
Serotonin
 affective disorder, amino acids, 49:151
 affective disorder, bipolar subtype, 47:129
 affective disorder, depressive symptoms, 47:129
 affective disorder, haptoglobin, 49:151
 affective disorder, immune function, 49:151
 affective disorder, interleukin, 49:151
 affective disorder, *N*-acetyl-beta-glucosaminidase, 47:129
 affective disorder, transferrin, 49:151
 affective disorder, tryptophan, 49:151
 alcohol dependence, depression, 47:57
 alcohol dependence, glutamyltransferase, 47:57
 alcohol dependence, impulse control disorder, 47:57
 alcohol dependence, withdrawal, 47:57

Serotonin continued

amino acids, affective disorder, 49:151
 amino acids, haptoglobin, 49:151
 amino acids, immune function, 49:151
 amino acids, interleukin, 49:151
 amino acids, transferrin, 49:151
 amino acids, tryptophan, 49:151
 anxiety disorder, cortisol, 48:119
 anxiety disorder, fluvoxamine, 48:119
 anxiety disorder, 3-methoxy-4-hydroxyphenylglycol, 48:119
 anxiety disorder, norepinephrine, 48:119
 anxiety disorder, panic disorder, 48:119
 anxiety disorder, yohimbine, 48:119
 bipolar subtype, affective disorder, 47:129
 bipolar subtype, depressive symptoms, 47:129
 bipolar subtype, *N*-acetyl-beta-glucosaminidase, 47:129
 bulimia, novelty seeking, 48:9
 bulimia, Tridimensional Personality Questionnaire, 48:9
 bulimia, whole blood levels, 48:9
 calmodulin affinity chromatography, endogenous uptake inhibitors, 47:121
 calmodulin affinity chromatography, imipramine, 47:121
 calmodulin affinity chromatography, paroxetine, 47:121
 cortisol, anxiety disorder, 48:119
 cortisol, fluvoxamine, 48:119
 cortisol, 3-methoxy-4-hydroxyphenylglycol, 48:119
 cortisol, norepinephrine, 48:119
 cortisol, panic disorder, 48:119
 cortisol, yohimbine, 48:119
 depression, alcohol dependence, 47:57
 depression, glutamyltransferase, 47:57
 depression, impulse control disorder, 47:57
 depression, withdrawal, 47:57
 depressive symptoms, bipolar subtype, 47:129
 depressive symptoms, *N*-acetyl-beta-glucosaminidase, 47:129
 eating disorder, bulimia, 48:9
 eating disorder, novelty seeking, 48:9
 eating disorder, Tridimensional Personality Questionnaire, 48:9
 endogenous uptake inhibitors, calmodulin affinity chromatography, 47:121
 endogenous uptake inhibitors, imipramine, 47:121

Serotonin continued

endogenous uptake inhibitors, paroxetine, 47:121
 fluvoxamine, anxiety disorder, 48:119
 fluvoxamine, cortisol, 48:119
 fluvoxamine, 3-methoxy-4-hydroxyphenylglycol, 48:119
 fluvoxamine, norepinephrine, 48:119
 fluvoxamine, panic disorder, 48:119
 fluvoxamine, yohimbine, 48:119
 glutamyltransferase, alcohol dependence, 47:57
 glutamyltransferase, depression, 47:57
 glutamyltransferase, impulse control disorder, 47:57
 glutamyltransferase, withdrawal, 47:57
 haptoglobin, affective disorder, 49:151
 haptoglobin, amino acids, 49:151
 haptoglobin, immune function, 49:151
 haptoglobin, interleukin, 49:151
 haptoglobin, transferrin, 49:151
 haptoglobin, tryptophan, 49:151
 imipramine, calmodulin affinity chromatography, 47:121
 imipramine, endogenous serotonin uptake inhibitors, 47:121
 imipramine, paroxetine, 47:121
 immune function, affective disorder, 49:151
 immune function, amino acids, 49:151
 immune function, haptoglobin, 49:151
 immune function, interleukin, 49:151
 immune function, transferrin, 49:151
 immune function, tryptophan, 49:151
 impulse control disorder, alcohol dependence, 47:57
 impulse control disorder, depression, 47:57
 impulse control disorder, glutamyltransferase, 47:57
 impulse control disorder, withdrawal, 47:57
 interleukin, affective disorder, 49:151
 interleukin, amino acids, 49:151
 interleukin, haptoglobin, 49:151
 interleukin, immune function, 49:151
 interleukin, transferrin, 49:151
 interleukin, tryptophan, 49:151
 3-methoxy-4-hydroxyphenylglycol, anxiety disorder, 48:119
 3-methoxy-4-hydroxyphenylglycol, cortisol, 48:119
 3-methoxy-4-hydroxyphenylglycol, fluvoxamine, 48:119
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 48:119

Serotonin continued

3-methoxy-4-hydroxyphenylglycol, panic disorder, 48:119
 3-methoxy-4-hydroxyphenylglycol, yohimbine, 48:119
N-acetyl-beta-glucosaminidase, affective disorder, 47:129
N-acetyl-beta-glucosaminidase, bipolar subtype, 47:129
N-acetyl-beta-glucosaminidase, depressive symptoms, 47:129
 neuroleptics, *S*₂ receptor in platelets, 48:57
 neuroleptics, schizophrenia, 48:57
 norepinephrine, anxiety disorder, 48:119
 norepinephrine, cortisol, 48:119
 norepinephrine, fluvoxamine, 48:119
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 48:119
 norepinephrine, panic disorder, 48:119
 norepinephrine, yohimbine, 48:119
 novelty seeking, bulimia, 48:9
 novelty seeking, eating disorder, 48:9
 novelty seeking, Tridimensional Personality Questionnaire, 48:9
 panic disorder, cortisol, 48:119
 panic disorder, fluvoxamine, 48:119
 panic disorder, 3-methoxy-4-hydroxyphenylglycol, 48:119
 panic disorder, norepinephrine, 48:119
 panic disorder, yohimbine, 48:119
 paroxetine, calmodulin affinity chromatography, 47:121
 paroxetine, endogenous serotonin uptake inhibitors, 47:121
 paroxetine, imipramine, 47:121
 platelets, alcohol dependence, 47:57
 platelets, depression, 47:57
 platelets, impulse control disorder, 47:57
 reuptake inhibitor, anxiety disorder, 48:119
 reuptake inhibitor, cortisol, 48:119
 reuptake inhibitor, fluvoxamine, 48:119
 reuptake inhibitor, 3-methoxy-4-hydroxyphenylglycol, 48:119
 reuptake inhibitor, norepinephrine, 48:119
 reuptake inhibitor, panic disorder, 48:119
 reuptake inhibitor, yohimbine, 48:119
*S*₂ receptor binding in platelets, schizophrenia, 47:111, 48:57
*S*₂ receptor binding in platelets, suicide, 47:111
 schizophrenia, neuroleptics, 48:57
 schizophrenia, *S*₂ receptor binding in platelets, 47:111, 48:57

Serotonin continued

schizophrenia, suicide, 47:111
*S*₂ receptor binding in platelets, 47:111
 suicide, schizophrenia, 47:111
 transferrin, affective disorder, 49:151
 transferrin, amino acids, 49:151
 transferrin, haptoglobin, 49:151
 transferrin, immune function, 49:151
 transferrin, interleukin, 49:151
 transferrin, tryptophan, 49:151
 Tridimensional Personality Questionnaire, bulimia, 48:9
 Tridimensional Personality Questionnaire, eating disorder, 48:9
 Tridimensional Personality Questionnaire, novelty seeking, 48:9
 tryptophan, affective disorder, 49:151
 tryptophan, amino acids, 49:151
 tryptophan, haptoglobin, 49:151
 tryptophan, immune function, 49:151
 tryptophan, interleukin, 49:151
 tryptophan, transferrin, 49:151
 whole blood levels, bulimia, 48:9
 whole blood levels, eating disorder, 48:9
 whole blood levels, novelty seeking, 48:9
 whole blood levels, Tridimensional Personality Questionnaire, 48:9
 withdrawal, alcohol dependence, 47:57
 withdrawal, depression, 47:57
 withdrawal, glutamyltransferase, 47:57
 withdrawal, impulse control disorder, 47:57
 yohimbine, anxiety disorder, 48:119
 yohimbine, cortisol, 48:119
 yohimbine, fluvoxamine, 48:119
 yohimbine, 3-methoxy-4-hydroxyphenylglycol, 48:119
 yohimbine, norepinephrine, 48:119
 yohimbine, panic disorder, 48:119
Sleep
 affective disorder, circadian rhythms, 47:215, 49:139
 affective disorder, daytime affect, 49:139
 affective disorder, depressed mood, 49:109
 affective disorder, divorce, 46:165
 affective disorder, dream masochism, 46:165
 affective disorder, endogenous subtype, 47:215
 affective disorder, gender differences, 46:165
 affective disorder, growth hormone, 47:215
 affective disorder, growth hormone releasing hormone, 47:215

Sleep continued

affective disorder, haptoglobin, 47:229
 affective disorder, immune function, 47:229
 affective disorder, interpersonal psychotherapy, 49:121
 affective disorder, naps, 49:109
 affective disorder, nocturnal penile tumescence, 49:139
 affective disorder, personality, 46:165
 affective disorder, rapid eye movement latency, 46:269, 49:121
 affective disorder, remission, 46:269, 49:121
 affective disorder, sex role identification, 46:165
 affective disorder, sexual function, 49:139
 affective disorder, sleep deprivation, 49:109
 affective disorder, somatic symptoms, 47:229
 affective disorder, weight and anorexia, 47:229
 aging, agitation, 48:277
 aging, circadian rhythms, 48:277
 aging, circannual rhythms, 48:277
 aging, dementia, 48:277
 aging, depressed mood in elderly women, 47:87
 aging, phototherapy, 47:87
 aging, sundowning, 48:277
 agitation, aging, 48:277
 agitation, circadian rhythms, 48:277
 agitation, circannual rhythms, 48:277
 agitation, dementia, 48:277
 agitation, sundowning, 48:277
 anxiety disorder, depressive mood, 49:251
 anxiety disorder, insomnia, 49:251
 anxiety disorder, phobia, 49:251
 anxiety disorder, quality of sleep, 49:251
 auditory sensory gating, event related potential, 49:29
 auditory sensory gating, P50 component, 49:29
 auditory sensory gating, schizophrenia, 49:29
 circadian rhythms, affective disorder, 47:215, 49:139
 circadian rhythms, aging, 48:277
 circadian rhythms, agitation, 48:277
 circadian rhythms, circannual rhythms, 48:277
 circadian rhythms, daytime affect, 49:139
 circadian rhythms, dementia, 48:277
 circadian rhythms, endogenous subtype, 47:215
 circadian rhythms, growth hormone, 47:215

Sleep continued

circadian rhythms, growth hormone releasing hormone, 47:215
 circadian rhythms, nocturnal penile tumescence, 49:139
 circadian rhythms, sexual function, 49:139
 circadian rhythms, sundowning, 48:277
 circannual rhythms, aging, 48:277
 circannual rhythms, agitation, 48:277
 circannual rhythms, circadian rhythms, 48:277
 circannual rhythms, dementia, 48:277
 circannual rhythms, sundowning, 48:277
 daytime affect, affective disorder, 49:139
 daytime affect, circadian rhythms, 49:139
 daytime affect, nocturnal penile tumescence, 49:139
 daytime affect, sexual function, 49:139
 dementia, aging, 48:277
 dementia, agitation, 48:277
 dementia, circadian rhythms, 48:277
 dementia, circannual rhythms, 48:277
 dementia, sundowning, 48:277
 depressed mood, affective disorder, 49:109
 depressed mood in elderly women, aging, 47:87
 depressed mood in elderly women, phototherapy, 47:87
 depressed mood, naps, 49:109
 depressed mood, sleep deprivation, 49:109
 depressive mood, anxiety disorder, 49:251
 depressive mood, insomnia, 49:251
 depressive mood, phobia, 49:251
 depressive mood, quality of sleep, 49:251
 divorce, affective disorder, 46:165
 divorce, dream masochism, 46:165
 divorce, gender differences, 46:165
 divorce, personality, 46:165
 divorce, sex role identification, 46:165
 dream masochism, affective disorder, 46:165
 dream masochism, divorce, 46:165
 dream masochism, gender differences, 46:165
 dream masochism, personality, 46:165
 dream masochism, sex role identification, 46:165
 endogenous subtype, circadian rhythms, 47:215
 endogenous subtype, growth hormone, 47:215
 endogenous subtype, growth hormone releasing hormone, 47:215
 event related potential, auditory sensory gating, 49:29

Sleep continued

event related potential, P50 component, 49:29
 event related potential, schizophrenia, 49:29
 gender differences, affective disorder, 46:165
 gender differences, divorce, 46:165
 gender differences, dream masochism, 46:165
 gender differences, personality, 46:165
 gender differences, sex role identification, 46:165
 growth hormone, affective disorder, 47:215
 growth hormone, circadian rhythms, 47:215
 growth hormone, endogenous subtype, 47:215
 growth hormone, growth hormone releasing hormone, 47:215
 growth hormone releasing hormone, affective disorder, 47:215
 growth hormone releasing hormone, circadian rhythms, 47:215
 growth hormone releasing hormone, endogenous subtype, 47:215
 growth hormone releasing hormone, growth hormone, 47:215
 haptoglobin, affective disorder, 47:229
 haptoglobin, immune function, 47:229
 haptoglobin, somatic symptoms, 47:229
 haptoglobin, weight and anorexia, 47:229
 immune function, affective disorder, 47:229
 immune function, haptoglobin, 47:229
 immune function, somatic symptoms, 47:229
 immune function, weight and anorexia, 47:229
 insomnia, anxiety disorder, 49:251
 insomnia, depressive mood, 49:251
 insomnia, phobia, 49:251
 insomnia, quality of sleep, 49:251
 interpersonal psychotherapy, affective disorder, 49:121
 interpersonal psychotherapy, rapid eye movement latency, 49:121
 interpersonal psychotherapy, recovery, 49:121
 naps, affective disorder, 49:109
 naps, depressed mood, 49:109
 naps, sleep deprivation, 49:109
 nocturnal penile tumescence, affective disorder, 49:139
 nocturnal penile tumescence, circadian rhythms, 49:139
 nocturnal penile tumescence, daytime affect, 49:139
 nocturnal penile tumescence, sexual function, 49:139

Sleep continued

P50 component, auditory sensory gating, 49:29
 P50 component, schizophrenia, 49:29
 personality, affective disorder, 46:165
 personality, divorce, 46:165
 personality, dream masochism, 46:165
 personality, gender differences, 46:165
 personality, sex role identification, 46:165
 phobia, anxiety disorder, 49:251
 phobia, depressive mood, 49:251
 phobia, insomnia, 49:251
 phobia, quality of sleep, 49:251
 phototherapy, aging, 47:87
 phototherapy, depressed mood in elderly women, 47:87
 quality of sleep, anxiety disorder, 49:251
 quality of sleep, depressive mood, 49:251
 quality of sleep, insomnia, 49:251
 quality of sleep, phobia, 49:251
 rapid eye movement latency, affective disorder, 46:269, 49:121
 rapid eye movement latency, interpersonal psychotherapy, 49:121
 rapid eye movement latency, remission, 46:269, 49:121
 recovery, affective disorder, 49:121
 recovery, interpersonal psychotherapy, 49:121
 recovery, rapid eye movement latency, 49:121
 remission, affective disorder, 46:269
 remission, rapid eye movement latency, 46:269
 schizophrenia, auditory sensory gating, 49:29
 schizophrenia, event related potential, 49:29
 schizophrenia, P50 component, 49:29
 sex role identification, affective disorder, 46:165
 sex role identification, divorce, 46:165
 sex role identification, dream masochism, 46:165
 sex role identification, gender differences, 46:165
 sex role identification, personality, 46:165
 sexual function, affective disorder, 49:139
 sexual function, circadian rhythms, 49:139
 sexual function, daytime affect, 49:139
 sexual function, nocturnal penile tumescence, 49:139
 sleep deprivation, affective disorder, 49:109
 sleep deprivation, depressed mood, 49:109
 sleep deprivation, naps, 49:109
 somatic symptoms, affective disorder, 47:229

Sleep continued

somatic symptoms, haptoglobin, 47:229
 somatic symptoms, immune function, 47:229
 somatic symptoms, weight and anorexia, 47:229
 sundowning, aging, 48:277
 sundowning, agitation, 48:277
 sundowning, circadian rhythms, 48:277
 sundowning, circannual rhythms, 48:277
 sundowning, dementia, 48:277
 weight and anorexia, affective disorder, 47:229
 weight and anorexia, haptoglobin, 47:229
 weight and anorexia, immune function, 47:229
 weight and anorexia, somatic symptoms, 47:229

Sleep deprivation

affective disorder, antidepressant medication, 46:213
 affective disorder, cortisol, 46:213
 affective disorder, depressed mood, 49:109
 affective disorder, fluoxetine, 46:213
 affective disorder, naps, 49:109
 affective disorder, prolactin, 46:213
 affective disorder, sleep, 49:109
 affective disorder, thyroid stimulating hormone, 46:213
 affective disorder, triiodothyronine, 46:213
 antidepressant medication, affective disorder, 46:213
 antidepressant medication, cortisol, 46:213
 antidepressant medication, prolactin, 46:213
 antidepressant medication, thyroid stimulating hormone, 46:213
 antidepressant medication, triiodothyronine, 46:213
 cortisol, affective disorder, 46:213
 cortisol, antidepressant medication, 46:213
 cortisol, prolactin, 46:213
 cortisol, thyroid stimulating hormone, 46:213
 cortisol, triiodothyronine, 46:213
 depressed mood, affective disorder, 49:109
 depressed mood, naps, 49:109
 depressed mood, sleep, 49:109
 estradiol, follicle stimulating hormone, 48:153
 estradiol, growth hormone, 48:153
 estradiol, luteinizing hormone, 48:153
 estradiol, normal volunteers, 48:153
 estradiol, prolactin, 48:153
 estradiol, thyroid stimulating hormone, 48:153
 estradiol, thyroxine, 48:153

Sleep deprivation continued

estradiol, triiodothyronine, 48:153
 fluoxetine, affective disorder, 46:213
 follicle stimulating hormone, estradiol, 48:153
 follicle stimulating hormone, growth hormone, 48:153
 follicle stimulating hormone, luteinizing hormone, 48:153
 follicle stimulating hormone, normal volunteers, 48:153
 follicle stimulating hormone, prolactin, 48:153
 follicle stimulating hormone, thyroid stimulating hormone, 48:153
 follicle stimulating hormone, thyroxine, 48:153
 follicle stimulating hormone, triiodothyronine, 48:153
 growth hormone, estradiol, 48:153
 growth hormone, follicle stimulating hormone, 48:153
 growth hormone, luteinizing hormone, 48:153
 growth hormone, normal volunteers, 48:153
 growth hormone, prolactin, 48:153
 growth hormone, thyroid stimulating hormone, 48:153
 growth hormone, thyroxine, 48:153
 growth hormone, triiodothyronine, 48:153
 luteinizing hormone, estradiol, 48:153
 luteinizing hormone, follicle stimulating hormone, 48:153
 luteinizing hormone, growth hormone, 48:153
 luteinizing hormone, normal volunteers, 48:153
 luteinizing hormone, prolactin, 48:153
 luteinizing hormone, thyroid stimulating hormone, 48:153
 luteinizing hormone, thyroxine, 48:153
 luteinizing hormone, triiodothyronine, 48:153
 naps, affective disorder, 49:109
 naps, depressed mood, 49:109
 naps, sleep, 49:109
 normal volunteers, estradiol, 48:153
 normal volunteers, follicle stimulating hormone, 48:153
 normal volunteers, growth hormone, 48:153
 normal volunteers, luteinizing hormone, 48:153
 normal volunteers, prolactin, 48:153

Sleep deprivation continued

normal volunteers, thyroid stimulating hormone, 48:153
 normal volunteers, thyroxine, 48:153
 normal volunteers, triiodothyronine, 48:153
 prolactin, affective disorder, 46:213
 prolactin, antidepressant medication, 46:213
 prolactin, cortisol, 46:213
 prolactin, estradiol, 48:153
 prolactin, follicle stimulating hormone, 48:153
 prolactin, growth hormone, 48:153
 prolactin, luteinizing hormone, 48:153
 prolactin, normal volunteers, 48:153
 prolactin, thyroid stimulating hormone, 46:213, 48:153
 prolactin, thyroxine, 48:153
 prolactin, triiodothyronine, 46:213, 48:153
 sleep, affective disorder, 49:109
 sleep, depressed mood, 49:109
 sleep, naps, 49:109
 thyroid stimulating hormone, affective disorder, 46:213
 thyroid stimulating hormone, antidepressant medication, 46:213
 thyroid stimulating hormone, cortisol, 46:213
 thyroid stimulating hormone, estradiol, 48:153
 thyroid stimulating hormone, follicle stimulating hormone, 48:153
 thyroid stimulating hormone, growth hormone, 48:153
 thyroid stimulating hormone, luteinizing hormone, 48:153
 thyroid stimulating hormone, normal volunteers, 48:153
 thyroid stimulating hormone, prolactin, 46:213, 48:153
 thyroid stimulating hormone, thyroxine, 48:153
 thyroid stimulating hormone, triiodothyronine, 46:213, 48:153
 thyroxine, estradiol, 48:153
 thyroxine, follicle stimulating hormone, 48:153
 thyroxine, growth hormone, 48:153
 thyroxine, luteinizing hormone, 48:153
 thyroxine, normal volunteers, 48:153
 thyroxine, prolactin, 48:153
 thyroxine, thyroid stimulating hormone, 48:153
 thyroxine, triiodothyronine, 48:153
 triiodothyronine, affective disorder, 46:213
 triiodothyronine, antidepressant medication, 46:213

Sleep deprivation continued

triiodothyronine, cortisol, 46:213
 triiodothyronine, estradiol, 48:153
 triiodothyronine, follicle stimulating hormone, 48:153
 triiodothyronine, growth hormone, 48:153
 triiodothyronine, luteinizing hormone, 48:153
 triiodothyronine, normal volunteers, 48:153
 triiodothyronine, prolactin, 46:213, 48:153
 triiodothyronine, thyroid stimulating hormone, 46:213, 48:153
 triiodothyronine, thyroxine, 48:153

Sleep disorders

fatigue, visual analogue scale, 46:207
 visual analogue scale, fatigue, 46:207

Speech

alogia, dyadic interaction, 48:181
 alogia, schizophrenia, 48:181
 alogia, vocal acoustic scale, 48:181
 dyadic interaction, alogia, 48:181
 dyadic interaction, schizophrenia, 48:181
 dyadic interaction, vocal acoustic scale, 48:181
 schizophrenia, alogia, 48:181
 schizophrenia, dyadic interaction, 48:181
 schizophrenia, vocal acoustic scale, 48:181
 vocal acoustic scale, alogia, 48:181
 vocal acoustic scale, dyadic interaction, 48:181
 vocal acoustic scale, schizophrenia, 48:181

Sphingomyelin

erythrocytes, membrane phospholipids, 49:89
 erythrocytes, phosphatidylethanolamine, 49:89
 erythrocytes, schizophrenia, 49:89
 membrane phospholipids, erythrocytes, 49:89
 membrane phospholipids, phosphatidyl-ethanolamine, 49:89

membrane phospholipids, schizophrenia, 49:89
 phosphatidylethanolamine, erythrocytes, 49:89
 phosphatidylethanolamine, membrane phospholipids, 49:89

phosphatidylethanolamine, schizophrenia, 49:89
 schizophrenia, erythrocytes, 49:89

schizophrenia, membrane phospholipids, 49:89
 schizophrenia, phosphatidylethanolamine, 49:89

schizophrenia, phosphatidylethanolamine, 49:89
 phosphatidylethanolamine, schizophrenia, 49:89

Spiradoline

growth hormone, motor tics, 47:267
 growth hormone, opioids, 47:267
 growth hormone, prolactin, 47:267

Spiradoline continued

growth hormone, Tourette's syndrome, 47:267

motor tics, growth hormone, 47:267

motor tics, prolactin, 47:267

prolactin, growth hormone, 47:267

prolactin, motor tics, 47:267

prolactin, Tourette's syndrome, 47:267

Tourette's syndrome, growth hormone, 47:267

Tourette's syndrome, motor tics, 47:267

Tourette's syndrome, prolactin, 47:267

Statistics

bootstrap resampling, kappa coefficient, 49:97

kappa coefficient, bootstrap resampling, 49:97

Striatum

aging, dopamine D₂ receptor density, 49:219

aging, positron emission tomography, 49:219

aging, schizophrenia, 49:219

dopamine D₂ receptor density, aging, 49:219

dopamine D₂ receptor density, gender differences, 49:219

dopamine D₂ receptor density, illness duration, 49:219

dopamine D₂ receptor density, methylspiperone, 49:219

dopamine D₂ receptor density, positron emission tomography, 49:219

dopamine D₂ receptor density, schizophrenia, 49:219

gender differences, dopamine D₂ receptor density, 49:219

gender differences, positron emission tomography, 49:219

gender differences, schizophrenia, 49:219

illness duration, dopamine D₂ receptor density, 49:219

methylspiperone, dopamine D₂ receptor density, 49:219

positron emission tomography, dopamine D₂ receptor density, 49:219

schizophrenia, dopamine D₂ receptor density, 49:219

Suicide

impulsivity, inpatient sample, 47:281

impulsivity, risk assessment, 47:281

impulsivity, violence, 47:281

risk assessment, impulsivity, 47:281

risk assessment, inpatient sample, 47:281

risk assessment, social support, 47:281

Suicide continued

risk assessment, violence, 47:281

schizophrenia, serotonin S₂ receptor binding in platelets, 47:111

serotonin S₂ receptor binding in platelets, 47:111

serotonin, schizophrenia, 47:111

social support, impulsivity, 47:281

social support, risk assessment, 47:281

social support, violence, 47:281

violence, impulsivity, 47:281

violence, inpatient sample, 47:281

violence, risk assessment, 47:281

violence, social support, 47:281

Thyroid

affective disorder, cortisol, 47:7, 47:23

affective disorder, dexamethasone suppression test, 47:7, 47:23

affective disorder, dysthymic disorder, 47:7

affective disorder, electrodermal activity, 47:23

affective disorder, hypothalamic-pituitary-adrenal axis, 47:7

affective disorder, thyroid stimulating hormone, 47:7, 47:23

affective disorder, thyroxine, 47:7, 47:23

affective disorder, triiodothyronine, 47:7, 47:23

cortisol, affective disorder, 47:7, 47:23

cortisol, dexamethasone suppression test, 49:77

circannual rhythms, Vitamin D, 49:77

cortisol, affective disorder, 46:213, 47:7, 47:23

cortisol, antidepressant medication, 46:213

cortisol, dexamethasone suppression test, 47:7, 47:23

cortisol, dysthymic disorder, 47:7

cortisol, electrodermal activity, 47:23

cortisol, prolactin, 46:213

cortisol, sleep deprivation, 46:213

cortisol, thyroxine, 47:7, 47:23

cortisol, triiodothyronine, 46:213, 47:7, 47:23

depressed mood, circannual rhythms, 49:77

depressed mood, normal women, 49:77

depressed mood, Profile of Mood States, 49:77

depressed mood, thyroxine, 49:77

depressed mood, triiodothyronine, 49:77

depressed mood, Vitamin D, 49:77

dexamethasone suppression test, affective disorder, 47:7, 47:23

Thyroid continued

dexamethasone suppression test, cortisol, 47:7, 47:23
 dexamethasone suppression test, dysthymic disorder, 47:7
 dexamethasone suppression test, electrodermal activity, 47:23
 dexamethasone suppression test, thyroxine, 47:7, 47:23
 dexamethasone suppression test, triiodothyronine, 47:7, 47:23
 dysthymic disorder, affective disorder, 47:7
 dysthymic disorder, cortisol, 47:7
 dysthymic disorder, dexamethasone suppression test, 47:7
 dysthymic disorder, thyroxine, 47:7
 dysthymic disorder, triiodothyronine, 47:7
 electrodermal activity, affective disorder, 47:23
 electrodermal activity, cortisol, 47:23
 electrodermal activity, dexamethasone suppression test, 47:23
 electrodermal activity, thyroxine, 47:23
 electrodermal activity, triiodothyronine, 47:23
 estradiol, follicle stimulating hormone, 48:153
 estradiol, growth hormone, 48:153
 estradiol, luteinizing hormone, 48:153
 estradiol, normal volunteers, 48:153
 estradiol, prolactin, 48:153
 estradiol, sleep deprivation, 48:153
 estradiol, thyroxine, 48:153
 estradiol, triiodothyronine, 48:153
 follicle stimulating hormone, estradiol, 48:153
 follicle stimulating hormone, growth hormone, 48:153
 follicle stimulating hormone, luteinizing hormone, 48:153
 follicle stimulating hormone, normal volunteers, 48:153
 follicle stimulating hormone, prolactin, 48:153
 follicle stimulating hormone, sleep deprivation, 48:153
 follicle stimulating hormone, thyroxine, 48:153
 follicle stimulating hormone, triiodothyronine, 48:153
 growth hormone, estradiol, 48:153
 growth hormone, follicle stimulating hormone, 48:153

Thyroid continued

growth hormone, luteinizing hormone, 48:153
 growth hormone, normal volunteers, 48:153
 growth hormone, prolactin, 48:153
 growth hormone, sleep deprivation, 48:153
 growth hormone, thyroxine, 48:153
 growth hormone, triiodothyronine, 48:153
 luteinizing hormone, estradiol, 48:153
 luteinizing hormone, follicle stimulating hormone, 48:153
 luteinizing hormone, growth hormone, 48:153
 luteinizing hormone, normal volunteers, 48:153
 luteinizing hormone, prolactin, 48:153
 thyroid stimulating hormone, affective disorder, 47:23
 thyroid stimulating hormone, affective disorder, 47:7
 thyroid stimulating hormone, cortisol, 47:7, 47:23
 thyroid stimulating hormone, dexamethasone suppression test, 47:7, 47:23
 thyroid stimulating hormone, dysthymic disorder, 47:7
 thyroid stimulating hormone, electrodermal activity, 47:23
 thyroid stimulating hormone, hypothalamic-pituitary-adrenal axis, 47:7
 thyroid stimulating hormone, thyroxine, 47:7, 47:23
 thyroid stimulating hormone, triiodothyronine, 47:7, 47:23
 thyroxine, affective disorder, 47:7, 47:23
 thyroxine, cortisol, 47:7, 47:23
 thyroxine, dexamethasone suppression test, 47:7, 47:23
 thyroxine, dysthymic disorder, 47:7
 thyroxine, electrodermal activity, 47:23
 thyroxine, hypothalamic-pituitary-adrenal axis, 47:7
 thyroxine, thyroid stimulating hormone, 47:7, 47:23
 thyroxine, triiodothyronine, 47:7, 47:23
 triiodothyronine, affective disorder, 47:7, 47:23
 triiodothyronine, cortisol, 47:7, 47:23
 triiodothyronine, dexamethasone suppression test, 47:7, 47:23
 triiodothyronine, dysthymic disorder, 47:7
 triiodothyronine, electrodermal activity, 47:23

Thyroid continued

triiodothyronine, hypothalamic-pituitary-adrenal axis, 47:7
 triiodothyronine, thyroid stimulating hormone, 47:7, 47:23
 triiodothyronine, thyroxine, 47:7, 47:23

Thyroid stimulating hormone
 affective disorder, antidepressant medication, 46:213
 affective disorder, cortisol, 46:213, 47:7, 47:23
 affective disorder, dexamethasone suppression test, 47:7, 47:23
 affective disorder, dysthymic disorder, 47:7
 affective disorder, electrodermal activity, 47:23
 affective disorder, prolactin, 46:213
 affective disorder, sleep deprivation, 46:213
 affective disorder, thyroxine, 47:7, 47:23
 affective disorder, triiodothyronine, 46:213, 47:7, 47:23
 antidepressant medication, affective disorder, 46:213
 antidepressant medication, cortisol, 46:213
 antidepressant medication, prolactin, 46:213
 antidepressant medication, sleep deprivation, 46:213
 antidepressant medication, triiodothyronine, 46:213
 circannual rhythms, depressed mood, 49:77
 circannual rhythms, normal women, 49:77
 circannual rhythms, Profile of Mood States, 49:77
 thyroxine, 49:77
 luteinizing hormone, thyroxine, 48:153
 luteinizing hormone, triiodothyronine, 48:153
 normal volunteers, estradiol, 48:153
 normal volunteers, follicle stimulating hormone, 48:153
 normal volunteers, growth hormone, 48:153
 normal volunteers, luteinizing hormone, 48:153
 normal volunteers, prolactin, 48:153
 normal volunteers, sleep deprivation, 48:153
 normal volunteers, thyroxine, 48:153
 normal volunteers, triiodothyronine, 48:153
 normal women, circannual rhythms, 49:77
 normal women, depressed mood, 49:77
 normal women, Profile of Mood States, 49:77
 normal women, thyroxine, 49:77
 normal women, triiodothyronine, 49:77
 normal women, Vitamin D, 49:77

Thyroid stimulating hormone continued

Profile of Mood States, circannual rhythms, 49:77
 Profile of Mood States, depressed mood, 49:77
 Profile of Mood States, normal women, 49:77
 Profile of Mood States, thyroxine, 49:77
 Profile of Mood States, triiodothyronine, 49:77
 Profile of Mood States, Vitamin D, 49:77
 prolactin, affective disorder, 46:213
 prolactin, antidepressant medication, 46:213
 prolactin, cortisol, 46:213
 prolactin, estradiol, 48:153
 prolactin, follicle stimulating hormone, 48:153
 prolactin, growth hormone, 48:153
 prolactin, luteinizing hormone, 48:153
 prolactin, normal volunteers, 48:153
 prolactin, sleep deprivation, 46:213, 48:153
 prolactin, thyroxine, 48:153
 prolactin, triiodothyronine, 46:213, 48:153
 sleep deprivation, 48:153
 sleep deprivation, affective disorder, 46:213
 sleep deprivation, antidepressant medication, 46:213
 sleep deprivation, cortisol, 46:213
 sleep deprivation, estradiol, 48:153
 sleep deprivation, follicle stimulating hormone, 48:153
 sleep deprivation, growth hormone, 48:153
 sleep deprivation, luteinizing hormone, 48:153
 sleep deprivation, normal volunteers, 48:153
 sleep deprivation, prolactin, 46:213, 48:153
 sleep deprivation, thyroxine, 48:153
 sleep deprivation, triiodothyronine, 46:213, 48:153
 thyroxine, affective disorder, 47:7, 47:23
 thyroxine, circannual rhythms, 49:77
 thyroxine, cortisol, 47:7, 47:23
 thyroxine, depressed mood, 49:77
 thyroxine, dexamethasone suppression test, 47:7, 47:23
 thyroxine, dysthymic disorder, 47:7
 thyroxine, electrodermal activity, 47:23
 thyroxine, estradiol, 48:153
 thyroxine, follicle stimulating hormone, 48:153
 thyroxine, growth hormone, 48:153
 thyroxine, luteinizing hormone, 48:153
 thyroxine, normal volunteers, 48:153
 thyroxine, normal women, 49:77

Thyroid stimulating hormone continued
thyroxine, Profile of Mood States, 49:77
thyroxine, prolactin, 48:153
thyroxine, sleep deprivation, 48:153
thyroxine, triiodothyronine, 47:7, 47:23,
48:153, 49:77
thyroxine, Vitamin D, 49:77
triiodothyronine, affective disorder, 46:213,
47:7, 47:23
triiodothyronine, antidepressant medication,
46:213
triiodothyronine, circannual rhythms, 49:77
triiodothyronine, cortisol, 46:213, 47:7, 47:23
triiodothyronine, depressed mood, 49:77
triiodothyronine, dexamethasone suppression
test, 47:7, 47:23
triiodothyronine, dysthymic disorder, 47:7
triiodothyronine, electrodermal activity, 47:23
triiodothyronine, estradiol, 48:153
triiodothyronine, follicle stimulating hormone,
48:153
triiodothyronine, growth hormone, 48:153
triiodothyronine, luteinizing hormone, 48:153
triiodothyronine, normal volunteers, 48:153
triiodothyronine, normal women, 49:77
triiodothyronine, Profile of Mood States,
49:77
triiodothyronine, prolactin, 46:213, 48:153
triiodothyronine, sleep deprivation, 46:213,
48:153
triiodothyronine, thyroxine, 47:7, 47:23,
48:153, 49:77
triiodothyronine, Vitamin D, 49:77
Vitamin D, circannual rhythms, 49:77
Vitamin D, depressed mood, 49:77
Vitamin D, normal women, 49:77
Vitamin D, Profile of Mood States, 49:77
Vitamin D, thyroxine, 49:77
Vitamin D, triiodothyronine, 49:77
Tourette's syndrome
growth hormone, kappa agonist, 47:267
growth hormone, motor tics, 47:267
growth hormone, opioids, 47:267
growth hormone, prolactin, 47:267
growth hormone, spiradoline, 47:267
kappa agonist, growth hormone, 47:267
kappa agonist, motor tics, 47:267
kappa agonist, opioids, 47:267
kappa agonist, prolactin, 47:267
kappa agonist, spiradoline, 47:267
motor tics, growth hormone, 47:267
motor tics, kappa agonist, 47:267
motor tics, opioids, 47:267
motor tics, prolactin, 47:267

Tourette's syndrome continued
motor tics, spiradoline, 47:267
opioids, growth hormone, 47:267
opioids, kappa agonist, 47:267
opioids, motor tics, 47:267
opioids, prolactin, 47:267
opioids, spiradoline, 47:267
prolactin, growth hormone, 47:267
prolactin, kappa agonist, 47:267
prolactin, motor tics, 47:267
prolactin, opioids, 47:267
prolactin, spiradoline, 47:267
spiradoline, growth hormone, 47:267
spiradoline, motor tics, 47:267
spiradoline, opioids, 47:267
spiradoline, prolactin, 47:267
Transferrin
affective disorder, amino acids, 49:151
affective disorder, cortisol, 49:11
affective disorder, dexamethasone suppression
test, 49:11
affective disorder, haptoglobin, 49:11, 49:151
affective disorder, immune function, 49:11,
49:151
affective disorder, interleukins, 49:11, 49:151
affective disorder, serotonin, 49:151
affective disorder, tryptophan, 49:151
amino acids, affective disorder, 49:151
amino acids, haptoglobin, 49:151
amino acids, immune function, 49:151
amino acids, interleukins, 49:151
amino acids, serotonin, 49:151
amino acids, tryptophan, 49:151
cortisol, affective disorder, 49:11
cortisol, dexamethasone suppression test,
49:11
cortisol, haptoglobin, 49:11
cortisol, immune function, 49:11
cortisol, interleukins, 49:11
dexamethasone suppression test, affective
disorder, 49:11
dexamethasone suppression test, cortisol, 49:11
dexamethasone suppression test, haptoglobin,
49:11
dexamethasone suppression test, immune
function, 49:11
dexamethasone suppression test, interleukins,
49:11
haptoglobin, affective disorder, 49:11, 49:151
haptoglobin, amino acids, 49:151
haptoglobin, cortisol, 49:11
haptoglobin, dexamethasone suppression
test, 49:11
haptoglobin, immune function, 49:11, 49:151

Transferrin continued

haptoglobin, interleukins, 49:11, 49:151
 haptoglobin, serotonin, 49:151
 haptoglobin, tryptophan, 49:151
 immune function, affective disorder, 49:11, 49:151
 immune function, amino acids, 49:151
 immune function, cortisol, 49:11
 immune function, dexamethasone suppression test, 49:11
 immune function, haptoglobin, 49:11, 49:151
 immune function, interleukins, 49:11, 49:151
 immune function, serotonin, 49:151
 immune function, tryptophan, 49:151
 interleukins, affective disorder, 49:11, 49:151
 interleukins, amino acids, 49:151
 interleukins, cortisol 49:11
 interleukins, haptoglobin, 49:11, 49:151
 interleukins, immune function, 49:11, 49:151
 interleukins, serotonin, 49:151
 interleukins, tryptophan, 49:151
 serotonin, affective disorder, 49:151
 serotonin, amino acids, 49:151
 serotonin, haptoglobin, 49:151
 serotonin, immune function, 49:151
 serotonin, interleukins, 49:151
 serotonin, tryptophan, 49:151
 tryptophan, affective disorder, 49:151
 tryptophan, amino acids, 49:151
 tryptophan, haptoglobin, 49:151
 tryptophan, immune function, 49:151
 tryptophan, interleukins, 49:151
 tryptophan, serotonin, 49:151

Tryptophan

affective disorder, aging, 49:151
 affective disorder, amino acids, 49:151
 affective disorder, haptoglobin, 49:151
 affective disorder, immune function, 49:151
 affective disorder, interleukin, 49:151
 affective disorder, serotonin, 49:151
 affective disorder, transferrin, 49:151
 aging, affective disorder, 49:151
 amino acids, affective disorder, 49:151
 amino acids, haptoglobin, 49:151
 amino acids, immune function, 49:151
 amino acids, interleukin, 49:151
 amino acids, serotonin, 49:151
 amino acids, transferrin, 49:151
 autism, c-Harvey-Ras-1 marker, 46:261
 autism, dopamine-beta-hydroxylase, 46:261
 autism, genetics, 46:261
 autism, restriction fragment length polymorphism, 46:261
 autism, tyrosine hydroxylase, 46:261

Tryptophan continued

c-Harvey-Ras-1 marker, autism, 46:261
 c-Harvey-Ras-1 marker, dopamine-beta-hydroxylase, 46:261
 c-Harvey-Ras-1 marker, genetics, 46:261
 c-Harvey-Ras-1 marker, restriction fragment length polymorphism, 46:261
 c-Harvey-Ras-1 marker, tyrosine hydroxylase, 46:261
 dopamine-beta-hydroxylase, autism, 46:261
 dopamine-beta-hydroxylase, c-Harvey-Ras-1 marker, 46:261
 dopamine-beta-hydroxylase, genetics, 46:261
 dopamine-beta-hydroxylase, restriction fragment length polymorphism, 46:261
 dopamine-beta-hydroxylase, tyrosine hydroxylase, 46:261
 genetics, autism, 46:261
 genetics, c-Harvey-Ras-1 marker, 46:261
 genetics, dopamine-beta-hydroxylase, 46:261
 genetics, restriction fragment length polymorphism, 46:261
 genetics, tyrosine hydroxylase, 46:261
 haptoglobin, affective disorder, 49:151
 haptoglobin, amino acids, 49:151
 haptoglobin, immune function, 49:151
 haptoglobin, interleukin, 49:151
 haptoglobin, serotonin, 49:151
 haptoglobin, transferrin, 49:151
 immune function, affective disorder, 49:151
 immune function, amino acids, 49:151
 immune function, haptoglobin, 49:151
 immune function, interleukin, 49:151
 immune function, serotonin, 49:151
 immune function, transferrin, 49:151
 interleukin, affective disorder, 49:151
 interleukins, amino acids, 49:151
 interleukins, haptoglobin, 49:151
 interleukins, immune function, 49:151
 interleukins, serotonin, 49:151
 interleukins, transferrin, 49:151
 restriction fragment length polymorphism, autism, 46:261
 restriction fragment length polymorphism, c-Harvey-Ras-1 marker, 46:261
 restriction fragment length polymorphism, dopamine-beta-hydroxylase, 46:261
 restriction fragment length polymorphism, genetics, 46:261
 restriction fragment length polymorphism, tyrosine hydroxylase, 46:261
 serotonin, affective disorder, 49:151
 serotonin, amino acids, 49:151

Tryptophan continued

- serotonin, haptoglobin, 49:151
- serotonin, immune function, 49:151
- serotonin, interleukins, 49:151
- serotonin, transferrin, 49:151
- transferrin, affective disorder, 49:151
- transferrin, amino acids, 49:151
- transferrin, haptoglobin, 49:151
- transferrin, immune function, 49:151
- transferrin, interleukins, 49:151
- transferrin, serotonin, 49:151
- tyrosine hydroxylase, autism, 46:261
- tyrosine hydroxylase, c-Harvey-Ras-1 marker, 46:261
- tyrosine hydroxylase, dopamine-beta-hydroxylase, 46:261
- tyrosine hydroxylase, genetics, 46:261
- tyrosine hydroxylase, restriction fragment length polymorphism, 46:261

Twin studies. See *Genetics*.**Tyrosine hydroxylase**

- autism, c-Harvey-Ras-1 marker, 46:261
- autism, dopamine-beta-hydroxylase, 46:261
- autism, genetics, 46:261
- autism, restriction fragment length polymorphism, 46:261
- autism, tryptophan hydroxylase, 46:261
- c-Harvey-Ras-1 marker, autism, 46:261
- c-Harvey-Ras-1 marker, dopamine-beta-hydroxylase, 46:261
- c-Harvey-Ras-1 marker, genetics, 46:261
- c-Harvey-Ras-1 marker, restriction fragment length polymorphism, 46:261
- c-Harvey-Ras-1 marker, tryptophan hydroxylase, 46:261
- circadian rhythm, prolactin, 47:187
- circadian rhythm, schizophrenia, 47:187
- dopamine-beta-hydroxylase, autism, 46:261
- dopamine-beta-hydroxylase, c-Harvey-Ras-1 marker, 46:261
- dopamine-beta-hydroxylase, genetics, 46:261
- dopamine-beta-hydroxylase, restriction fragment length polymorphism, 46:261
- dopamine-beta-hydroxylase, tryptophan hydroxylase, 46:261
- genetics, autism, 46:261
- genetics, c-Harvey-Ras-1 marker, 46:261
- genetics, dopamine-beta-hydroxylase, 46:261
- genetics, restriction fragment length polymorphism, 46:261
- genetics, tryptophan hydroxylase, 46:261
- prolactin, circadian rhythm, 47:187
- prolactin, schizophrenia, 47:187

Tyrosine hydroxylase continued

- restriction fragment length polymorphism, autism, 46:261
- restriction fragment length polymorphism, c-Harvey-Ras-1 marker, 46:261
- restriction fragment length polymorphism, dopamine-beta-hydroxylase, 46:261
- restriction fragment length polymorphism, genetics, 46:261
- restriction fragment length polymorphism, tryptophan hydroxylase, 46:261
- schizophrenia, circadian rhythm, 47:187
- schizophrenia, prolactin, 47:187
- tryptophan hydroxylase, autism, 46:261
- tryptophan hydroxylase, c-Harvey-Ras-1 marker, 46:261
- tryptophan hydroxylase, dopamine-beta-hydroxylase, 46:261
- tryptophan hydroxylase, genetics, 46:261
- tryptophan hydroxylase, restriction fragment length polymorphism, 46:261

Ubiquitin

- frontal lobe, neurodegeneration, 48:145
- frontal lobe, post-mortem study, 48:145
- frontal lobe, schizophrenia, 48:145
- neurodegeneration, frontal lobe, 48:145
- neurodegeneration, post-mortem study, 48:145
- neurodegeneration, schizophrenia, 48:145
- post-mortem study, frontal lobe, 48:145
- post-mortem study, neurodegeneration, 48:145
- post-mortem study, schizophrenia, 48:145
- schizophrenia, frontal lobe, 48:145
- schizophrenia, neurodegeneration, 48:145
- schizophrenia, post-mortem study, 48:145

Ventricle-brain ratio

- alcohol intake, anxiety disorder, 48:135
- alcohol intake, benzodiazepines, 48:135
- alcohol intake, computed tomography, 48:135
- alcohol intake, diazepam, 48:135
- alcohol intake, lorazepam, 48:135
- anxiety disorder, alcohol intake, 48:135
- anxiety disorder, benzodiazepines, 48:135
- anxiety disorder, computed tomography, 48:135
- anxiety disorder, diazepam, 48:135
- anxiety disorder, lorazepam, 48:135
- benzodiazepines, alcohol intake, 48:135
- benzodiazepines, anxiety disorder, 48:135
- benzodiazepines, computed tomography, 48:135
- benzodiazepines, diazepam, 48:135
- benzodiazepines, lorazepam, 48:135
- computed tomography, alcohol intake, 48:135

Venticle-brain ratio continued
 computed tomography, anxiety disorder, 48:135
 computed tomography, benzodiazepines, 48:135
 computed tomography, diazepam, 48:135
 computed tomography, lorazepam, 48:135
 diazepam, alcohol intake, 48:135
 diazepam, anxiety disorder, 48:135
 diazepam, benzodiazepines, 48:135
 diazepam, computed tomography, 48:135
 diazepam, lorazepam, 48:135
 lorazepam, alcohol intake, 48:135
 lorazepam, anxiety disorder, 48:135
 lorazepam, benzodiazepines, 48:135
 lorazepam, computed tomography, 48:135
 lorazepam, diazepam, 48:135

Violence
 impulsivity, inpatient sample, 47:281
 impulsivity, risk assessment, 47:281
 impulsivity, social support, 47:281
 impulsivity, suicide, 47:281
 risk assessment, impulsivity, 47:281
 risk assessment, inpatient sample, 47:281
 risk assessment, social support, 47:281
 risk assessment, suicide, 47:281
 social support, impulsivity, 47:281
 social support, inpatient sample, 47:281
 social support, risk assessment, 47:281
 social support, suicide, 47:281
 suicide, impulsivity, 47:281
 suicide, inpatient sample, 47:281
 suicide, risk assessment, 47:281
 suicide, social support, 47:281

Wisconsin Card Sorting Test. See *Frontal lobe; Neuropsychology*.

Yohimbine
 anxiety disorder, cortisol, 48:119
 anxiety disorder, fluvoxamine, 48:119
 anxiety disorder, 3-methoxy-4-hydroxyphenylglycol, 48:119
 anxiety disorder, norepinephrine, 48:119
 anxiety disorder, panic, 48:119
 anxiety disorder, serotonin, 48:119
 blood pressure, fluvoxamine, 48:119
 blood pressure, heart rate, 48:119
 blood pressure, panic disorder, 48:119
 cortisol, anxiety disorder, 48:119
 cortisol, fluvoxamine, 48:119
 cortisol, 3-methoxy-4-hydroxyphenylglycol, 48:119
 cortisol, norepinephrine, 48:119

Yohimbine continued
 cortisol, panic disorder, 48:119
 cortisol, serotonin, 48:119
 fluvoxamine, anxiety disorder, 48:119
 fluvoxamine, blood pressure, 48:119
 fluvoxamine, cortisol, 48:119
 fluvoxamine, heart rate, 48:119
 fluvoxamine, 3-methoxy-4-hydroxyphenylglycol, 48:119
 fluvoxamine, norepinephrine, 48:119
 fluvoxamine, panic disorder, 48:119
 fluvoxamine, serotonin, 48:119
 heart rate, blood pressure, 48:119
 heart rate, fluvoxamine, 48:119
 heart rate, panic disorder, 48:119
 3-methoxy-4-hydroxyphenylglycol, anxiety disorder, 48:119
 3-methoxy-4-hydroxyphenylglycol, cortisol, 48:119
 3-methoxy-4-hydroxyphenylglycol, fluvoxamine, 48:119
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 48:119
 3-methoxy-4-hydroxyphenylglycol, panic disorder, 48:119
 3-methoxy-4-hydroxyphenylglycol, serotonin, 48:119
 norepinephrine, anxiety disorder, 48:119
 norepinephrine, cortisol, 48:119
 norepinephrine, fluvoxamine, 48:119
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 48:119
 norepinephrine, panic disorder, 48:119
 norepinephrine, serotonin, 48:119
 panic disorder, blood pressure, 48:119
 panic disorder, fluvoxamine, 48:119
 panic disorder, heart rate, 48:119
 panic disorder, cortisol, 48:119
 panic disorder, fluvoxamine, 48:119
 panic disorder, 3-methoxy-4-hydroxyphenylglycol, 48:119
 panic disorder, norepinephrine, 48:119
 panic disorder, reuptake inhibitor, 48:119
 panic disorder, serotonin, 48:119
 serotonin, anxiety disorder, 48:119
 serotonin, cortisol, 48:119
 serotonin, fluvoxamine, 48:119
 serotonin, 3-methoxy-4-hydroxyphenylglycol, 48:119
 serotonin, norepinephrine, 48:119
 serotonin, panic disorder, 48:119
 serotonin, reuptake inhibitor, 48:119